<SEC-DOCUMENT>0001628280-18-006417.txt : 20180509
<SEC-HEADER>0001628280-18-006417.hdr.sgml : 20180509
<ACCEPTANCE-DATETIME>20180509171301
ACCESSION NUMBER:		0001628280-18-006417
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		46
CONFORMED PERIOD OF REPORT:	20180331
FILED AS OF DATE:		20180509
DATE AS OF CHANGE:		20180509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		18819413

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cpix-20180331.htm
<DESCRIPTION>10-Q Q1 2018
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2017 Workiva--><!--r:6f9d426d-7cdf-4d24-852c-1304a591467b,g:9b882308-6c8b-47b4-823c-512a5c520540--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cpix="http://cumberlandpharma.com/20180331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26"><head><meta http-equiv="Content-Type" content="text/html"></meta>


<title>Document</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGFibGU6NDRmODBmMGRhMWRjNGUwMzljZWM3MTI1Yjc3ZDRmYmQvdGFibGVyYW5nZTo0NGY4MGYwZGExZGM0ZTAzOWNlYzcxMjViNzdkNGZiZF8wMjExQUFBQUJBQUFBQVFBQUFBQkFBQUFBUUFBQUFBQUFCU1dBQUElM0Q_23f9fbef-a9e2-4367-bf69-ebb39464c70e" escape="true">Non-accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" format="ixt:datemonthdayyear" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGFibGU6NDRmODBmMGRhMWRjNGUwMzljZWM3MTI1Yjc3ZDRmYmQvdGFibGVyYW5nZTo0NGY4MGYwZGExZGM0ZTAzOWNlYzcxMjViNzdkNGZiZF8wMjE3QUFBQUJnQUFBQVlBQUFBQkFBQUFBUUFBQUFBQUFCT3NBQUElM0Q_2beb0383-0a8d-4dbf-bf86-d57c0927b03c">3/31/2018</ix:nonNumeric><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGFibGU6NDRmODBmMGRhMWRjNGUwMzljZWM3MTI1Yjc3ZDRmYmQvdGFibGVyYW5nZTo0NGY4MGYwZGExZGM0ZTAzOWNlYzcxMjViNzdkNGZiZF8wMjE2QUFBQUJ3QUFBQWNBQUFBQkFBQUFBUUFBQUFBQUFCT3RBQUElM0Q_14d92678-eb3c-49f7-8e76-44e426f8dd88">2018</ix:nonNumeric><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGFibGU6NDRmODBmMGRhMWRjNGUwMzljZWM3MTI1Yjc3ZDRmYmQvdGFibGVyYW5nZTo0NGY4MGYwZGExZGM0ZTAzOWNlYzcxMjViNzdkNGZiZF8wMmU5QUFBQUNBQUFBQWdBQUFBQkFBQUFBUUFBQUFBQUFCT3VBQUElM0Q_f50ee0f8-2087-471f-9b4e-38a91e79ad32">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGFibGU6NDRmODBmMGRhMWRjNGUwMzljZWM3MTI1Yjc3ZDRmYmQvdGFibGVyYW5nZTo0NGY4MGYwZGExZGM0ZTAzOWNlYzcxMjViNzdkNGZiZF8wMmU4QUFBQUNRQUFBQWtBQUFBQkFBQUFBUUFBQUFBQUFCT3ZBQUElM0Q_64fe1dff-1f50-4e1c-87ef-da006dc90e48">FALSE</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="i56a7cfadcc3c4eee8a5d550fa4eb8f26_I20180504" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGFibGU6NDRmODBmMGRhMWRjNGUwMzljZWM3MTI1Yjc3ZDRmYmQvdGFibGVyYW5nZTo0NGY4MGYwZGExZGM0ZTAzOWNlYzcxMjViNzdkNGZiZF8wMmUyQUFBQUNnQUFBQW9BQUFBQ0FBQUFBZ0FBQUFBQUFCaiUyRkFBQSUzRA_f0ade8d3-2c2e-47ee-9ae8-7f8cd4e05519">15,710,953</ix:nonFraction><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGV4dHJlZ2lvbjpjMGRjYTk1MGFjMGQ1ODdmYTU4YmE1ZGZhOGYwNTRhN18xMDk5NTExNjI3ODYz_99cf5869-85b3-412c-a643-dd1dcf7f6b6e">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGV4dHJlZ2lvbjpjMGRjYTk1MGFjMGQ1ODdmYTU4YmE1ZGZhOGYwNTRhN18xMDk5NTExNjI3ODYy_963b0e87-cea7-4a84-be1d-31c02e08bcf6">--12-31</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockNoParValue" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMTJBQUFBQVFBQUFBRUFBQUFCQUFBQUFRQUFBQUFBQUJPMUFBQSUzRA_c358da0d-7bdd-4267-a286-6dcd572a8078">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockNoParValue" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMTdBQUFBQVFBQUFBRUFBQUFDQUFBQUFnQUFBQUFBQUJPNUFBQSUzRA_774a6cfc-cec1-4807-a47d-e07753742ac9">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMWRBQUFBQWdBQUFBSUFBQUFCQUFBQUFRQUFBQUFBQUJPMkFBQSUzRA_380eac0e-f879-4159-9336-550f5dd8c6cd">100,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMThBQUFBQWdBQUFBSUFBQUFDQUFBQUFnQUFBQUFBQUJPNkFBQSUzRA_01a19461-238c-471b-8bd2-d79b4685cf9e">100,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMWNBQUFBQXdBQUFBTUFBQUFCQUFBQUFRQUFBQUFBQUJPM0FBQSUzRA_baa80b31-0d2d-469f-a57c-97f5f835b0d9">15,727,250</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMWJBQUFBQXdBQUFBTUFBQUFDQUFBQUFnQUFBQUFBQUJPN0FBQSUzRA_eb70433b-a3f6-487f-9db6-06a820f02fc5">15,723,075</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMjExQUFBQUJBQUFBQVFBQUFBQkFBQUFBUUFBQUFBQUFCTzRBQUElM0Q_e4814efb-47ff-4fc8-9d99-eec7cbf59f0c">15,727,250</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMjFlQUFBQUJBQUFBQVFBQUFBQ0FBQUFBZ0FBQUFBQUFCTzhBQUElM0Q_3c470d2b-573f-406e-bd7b-0f035c4decc8">15,723,075</ix:nonFraction><ix:nonNumeric contextRef="id15e3d5e3e57462dba32d88ff64f623d_D20180101-20180331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyNjE_3db38b5b-b57e-4753-bab2-0401c4da4aa8">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ifb8bca4936ff40e2b30ed5d20dc32c4f_D20170731-20170731" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzNDI_faa1036d-aac4-495e-970e-7d7605ba1f7c">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cpix-20180331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i56a7cfadcc3c4eee8a5d550fa4eb8f26_I20180504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66977d80365d404296229eb847d696f2_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bf8f59dc7274cd6980319cc241a28f2_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd9dd6ff2ca40c88619dd5d86f0eafb_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i097d668a5f1047f0be37d4b8f2dd8771_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fd3da4e3c75411aa04652f12b8f13df_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0420ad95a0194945bfcbfd1dbc3b688f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied2c88c7a3e94ca69560e97f372df5eb_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i895db0703de048cb8eb76978269e35a6_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic602d02dff724990b5feb87e55fbb783_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26a1fb7ff6bd4d2085da7c1c604620e1_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5909472559854a45a161ee9683451710_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:segment</xbrli:measure></xbrli:unit><xbrli:context id="i91ee759fede74a44afc15799417026fc_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4184f63683bf45109fe4a49c88baafbc_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4572e5a71c344688b9efe5e38ee4a0e8_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac05f8bde425448ea4955ae4d2988a48_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43d4a46326a24d6caca1fac6793144ce_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51f8d7b7f57f4d7388487c437f5ab518_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c6551d700a840f38a0908ea87bf44cf_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d63d8a95b20480d99100f9855f3f288_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aea36d855cf456e880b35e2dc2c0505_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i740c45d85a2942c196e262b2964e237b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i996d7d1b56cb43219465772f1f7597fe_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie54bf1c8e2d14928a9a06a734dfd7c6c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i439c1bc3ca8e4e5b9ea4d7bdb13d6991_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01938b90ab854812b8ec66565464d607_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5149372296b940a2aa525db6faa8f3c4_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5a2b34ed5004b8fa2acfe953a3cc3c4_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2830ebd535c84a6496a304acfc539e9a_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4dd4eb6277e4ca19f808c8a63b5fd3e_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18a7c5c9ec3446ddad8bd6afcd563cf6_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aae0fc592af4b14936eced6617fdc55_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d02d8434f0641b9a2539c9d2707cf7b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863ba3e77c42420dbba1bfa4d84f2196_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia15f718fd7ee4613bd4f49589b3d8fdc_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe82cbc40bcb489390a75fce71b8b80f_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8ae969ed44e419f8fc0f2099a9510cd_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ed094dbab104669b5bce32fe7460a28_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84d27aa248d24ab8b554e59624c79428_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed830091dab43ba8375cdfb0f7f2a8c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idde5b053a5b6476bb846c88390de0bc5_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id98aa82685604140986e94a71f9d1936_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c8ca872cb5c4f4596ce2fd08ca9aa5e_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5c0c160863d4cceb26f484a2325fb1d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i381dc586d9494541bcf340e8bda4d8d0_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0982f8386a84f56bf35e403d479f381_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb29255b0cce4beabad9c0ef7e86504e_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffcc23dd7a9944139daf9824e5b8eac5_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6809c3be77f6432d9076c460384fbb07_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2cf28a7f39c448f96b2e5671107943f_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d8502d751864f05a59b40ecc159972b_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic700e54bd9e84fe38825f0e668b5fc38_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c5e9f1b87044a0da9566dff708f6520_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf73e673b6164c78ab232ce6f110e7d1_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i088036779adb405fb051b2f6ea583979_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i302d2057998b42f88bce95c8b68a0dca_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc0d050afaf4677960684f8f326d0a1_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i666c2dae486e4b1eac47ec35b708938f_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib034705aa5544216b55c469279e3eaba_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17303c3256e5493faf87462aef420fab_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d39aea30fbc46889b6cfa872b2b6fb7_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id74555dabd6a4ff2ad0bdc7e28c863bc_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i654f0cb0d52e49d39635e4e808fc2055_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73e54bcae66640ebbb1fffa211e276c6_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:GenericAcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eb22c1d61c749ddac462523b2b31161_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:GenericAcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fd8c1a5a34842988819ab52812dc1e7_I20100513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib436aa4112784a5bb575f9ce9fe4fb53_I20120430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2012-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a9e1ab5b93d4567815cacdf06859be8_I20130131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2013-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47407fdc5afa40749b77a0412daf8956_I20110131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2011-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebdcd0b9547b443b8727649905bdb07b_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5236a3131db4202b5eaec29f686e679_I20150131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2015-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6b3a2fc1ae64e68a3298edf95187fcd_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61a9610b573b4e75a7c8f0f35d1cb4d8_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i653bf892b8c94a22be15b4bc51db3a05_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id15e3d5e3e57462dba32d88ff64f623d_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b744dac368c4c3eb91bc9bb77c5cf97_I20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb8bca4936ff40e2b30ed5d20dc32c4f_D20170731-20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-31</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i55c284425d4448d79d408df2a3a756f9_I20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i288af4ef515f4257be46413b7b9d94ee_I20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e981a44ed99406590f2ed76af33aa59_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:SunTrustBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;text-align:center;margin-top:3pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:16pt;font-weight:700;line-height:120%;vertical-align:bottom;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:16pt;font-weight:700;line-height:120%;vertical-align:bottom;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:700;line-height:120%;vertical-align:bottom;">WASHINGTON, DC 20549</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</span></div><div style="line-height:120%;text-align:center;margin-top:3pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:16pt;font-weight:700;line-height:120%;vertical-align:bottom;">FORM <ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xL2ZyYWc6OWE1ODVhZGNhZWMxNGFjNzg1MTJlYzgzNTQ0NTU4N2MvdGV4dHJlZ2lvbjo5YTU4NWFkY2FlYzE0YWM3ODUxMmVjODM1NDQ1NTg3Y18xMDk5NTExNjMxODAz_ee75a1cc-8425-4e23-a6a9-4749ef9f1551" escape="true">10-Q</ix:nonNumeric></span></div><div style="line-height:120%;margin-top:5pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(Mark One)</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:12pt;font-weight:400;font-family:Wingdings;color:000000;background-color:rgb(255,255,255, 0.0);">&#253;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:11pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934&#160;</span></td></tr></table></div><div style="line-height:120%;text-align:center;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">For the quarterly period ended March&#160;31, 2018&#160;</span></div><div style="line-height:120%;text-align:center;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">OR</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:12pt;font-weight:400;font-family:Wingdings;color:000000;background-color:rgb(255,255,255, 0.0);">&#168;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:11pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934&#160;</span></td></tr></table></div><div style="line-height:120%;text-align:center;margin-top:5pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="line-height:120%;text-align:center;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Commission file number: 001-33637</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</span></div><div style="line-height:120%;text-align:center;margin-top:5pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:20pt;font-weight:700;line-height:120%;vertical-align:bottom;"><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xL2ZyYWc6OWE1ODVhZGNhZWMxNGFjNzg1MTJlYzgzNTQ0NTU4N2MvdGV4dHJlZ2lvbjo5YTU4NWFkY2FlYzE0YWM3ODUxMmVjODM1NDQ1NTg3Y18xMDk5NTExNjMxODA0_f7a9993b-c85a-41b3-90c5-2772ac0fbc3d">Cumberland Pharmaceuticals Inc.</ix:nonNumeric></span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(Exact Name of Registrant as Specified In Its Charter)</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:47.632893%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.443172%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.723935%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Tennessee&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">62-1765329&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">(State or Other Jurisdiction of</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Incorporation or Organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">(I.R.S. Employer</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Identification No.)</span></div></td></tr><tr><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;vertical-align:bottom;">2525 West End Avenue, Suite 950,</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;vertical-align:bottom;">Nashville, Tennessee</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">37203&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(Address of Principal Executive Offices)&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(Zip Code)&#160;</span></td></tr></table></div><div style="line-height:120%;text-align:center;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(615) 255-0068</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:120%;vertical-align:bottom;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="line-height:120%;text-align:justify;margin-top:5pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9pt;line-height:120%;vertical-align:bottom;">&#253;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9pt;line-height:120%;vertical-align:bottom;">&#168;</span></div><div style="line-height:120%;text-align:justify;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.) Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9pt;line-height:120%;vertical-align:bottom;">&#253;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9pt;line-height:120%;vertical-align:bottom;">&#168;</span></div><div style="line-height:120%;text-align:justify;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:21.529412%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.300000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:41.088235%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.447059%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.941176%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.447059%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.447059%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:9pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Large&#160;accelerated&#160;filer&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:9pt;font-weight:400;font-family:Wingdings;color:000000;background-color:rgb(255,255,255, 0.0);">&#168;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:9pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Accelerated&#160;filer&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:9pt;font-weight:400;font-family:Wingdings;color:000000;background-color:rgb(255,255,255, 0.0);">&#168;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:9pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9pt;font-weight:400;line-height:100%;vertical-align:bottom;">&#253; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;font-weight:400;line-height:100%;vertical-align:bottom;">(Do not check if a smaller reporting company)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:9pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:9pt;font-weight:400;font-family:Wingdings;color:000000;background-color:rgb(255,255,255, 0.0);">&#168;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:9pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9pt;font-weight:400;line-height:100%;vertical-align:bottom;">&#168;</span></div><div style="line-height:120%;"><span><br/></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="line-height:120%;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to&#160;Section 13(a) of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9pt;line-height:120%;vertical-align:bottom;">&#168;</span></div><div style="line-height:120%;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9pt;line-height:120%;vertical-align:bottom;">&#168;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9pt;line-height:120%;vertical-align:bottom;">&#253;</span></div><div style="line-height:120%;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:45.067449%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.260997%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:29.671554%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Class&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Outstanding at May 4, 2018&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Common stock, no par value&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i56a7cfadcc3c4eee8a5d550fa4eb8f26_I20180504" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xL2ZyYWc6OWE1ODVhZGNhZWMxNGFjNzg1MTJlYzgzNTQ0NTU4N2MvdGFibGU6ZDc3MWIyZGRjNzNjNDdhYzlkMTA3NjYwMTA4MTllYTgvdGFibGVyYW5nZTpkNzcxYjJkZGM3M2M0N2FjOWQxMDc2NjAxMDgxOWVhOF8wMTdBQUFBQVFBQUFBRUFBQUFDQUFBQUFnQUFBQUFBQUJSRUFBQSUzRA_c50198af-26a6-4a3c-961d-649e54b52c46">15,710,953</ix:nonFraction>&#160;</span></td></tr></table></div><div id="i_0_11"></div><div style="line-height:120%;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;"></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CUMBERLAND PHARMACEUTICALS INC.</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">INDEX</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:81.431085%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.568915%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_21">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_21">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_33">Item&#160;1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_33">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_44">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_44">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_54">Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_54">2</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_66">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_66">3</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_78">Condensed Consolidated Statement of Equity</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_78">4</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_90">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_90">5</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_232">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_232">12</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_298">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_298">19</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_309">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_309">20</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_321">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_321">21</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_332">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_332">21</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_343">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_343">21</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_354">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_354">21</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_366">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_366">22</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;vertical-align:bottom;" href="#i_0_378">SIGNATURES</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;" href="#i_0_378">23</a></span></div></td></tr></table></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span><br/></span></div><div id="i_0_21"></div><div style="line-height:120%;text-align:center;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;"></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="i_0_33"></div><div style="line-height:120%;margin-top:14pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Item&#160;1. Financial Statements (Unaudited)</span></div><div id="i_0_44"></div><div style="line-height:120%;text-align:center;margin-top:18pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Condensed Consolidated Balance Sheets</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(Unaudited)</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:70.368421%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.450292%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.450292%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">ASSETS&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Current assets:&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMy0xLTEtMS0yMw_f4891eef-48fb-4cc3-915f-8417f823ef1d">35,262,976</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMy0zLTEtMS0yMw_ffa0c0c3-74ea-4a52-a8e8-f0fee11bb598">45,412,868</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Marketable securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNC0xLTEtMS0yMw_3cbf7f49-4c46-41a1-b65b-4e341406f954">15,610,105</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNC0zLTEtMS0yMw_ff60a054-59ec-44d8-86b5-835953b0fb0b">4,672,476</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net of allowances&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNS0xLTEtMS0yMw_0c53f282-a1cf-488b-89e9-90fb2d6e9adb">6,301,162</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNS0zLTEtMS0yMw_ce687acf-d6fb-4fef-8871-ed000770395c">8,395,112</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Inventories, net&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNi0xLTEtMS0yMw_601ecf43-692e-4e58-a1f3-33b3773827cf">6,661,525</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNi0zLTEtMS0yMw_507d818f-8096-4263-93de-da83810707f9">6,737,848</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Other current assets&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNy0xLTEtMS0yMw_ce03fb66-8afa-46fe-9b52-45aec974c9fc">2,987,404</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNy0zLTEtMS0yMw_d0a2144f-d14a-438c-bd50-f99dcd07ef93">3,466,541</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total current assets&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfOC0xLTEtMS0yMw_3c9165ed-4c5e-4e7a-a7fd-cf6e9f1555be">66,823,172</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfOC0zLTEtMS0yMw_5143ffa2-2bda-4bb0-a134-6bd590c30a6a">68,684,845</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfOS0xLTEtMS0yMw_579011df-dbeb-45fa-b2d6-f98d99adda1a">566,907</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfOS0zLTEtMS0yMw_07b46f27-993f-4aea-8ee4-1de7798daf9a">528,882</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTAtMS0xLTEtMjM_16808d3a-4af7-4b80-b372-da3672478332">21,052,197</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTAtMy0xLTEtMjM_beaafc70-572a-40c3-b81d-425df09c5a89">21,444,545</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets, net&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTEtMS0xLTEtMjM_15b9d4fd-db67-4cb8-b0cb-9028eb2c9c34">87,210</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTEtMy0xLTEtMjM_07295245-0fd1-496b-9abb-c32fb5dc8894">87,210</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Other assets&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTItMS0xLTEtMjM_71556888-7456-4c55-8f6c-0177626438e7">2,565,354</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTItMy0xLTEtMjM_266faa81-67fc-4368-9e1e-5cba64b2c847">2,486,830</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total assets&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTMtMS0xLTEtMjM_9ea60236-9da2-4091-8685-c0eed74a7315">91,094,840</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTMtMy0xLTEtMjM_7f71037f-942b-4794-898a-e53067b6196f">93,232,312</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;vertical-align:bottom;">LIABILITIES AND EQUITY</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Accounts payable&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTYtMS0xLTEtMjM_92164262-f223-4194-ab76-b99a7ecf38ec">8,518,879</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTYtMy0xLTEtMjM_f84cd7ef-7fde-44ce-904d-3aedacfcc3d5">8,979,929</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTctMS0xLTEtMjM_65775db3-8775-4d76-8a06-2dab0e5ef6f1">7,770,977</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTctMy0xLTEtMjM_6216c867-a98b-45d9-ad4e-9169b4edada4">8,714,814</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTgtMS0xLTEtMjM_e64df72a-7cd7-4f5f-817a-09f221dc6bb3">16,289,856</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTgtMy0xLTEtMjM_af1f566d-861c-4fd2-a0a2-a498565c32f1">17,694,743</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Revolving line of credit&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTktMS0xLTEtMjM_efaa2422-0a83-4cab-9ea5-bbee6727d67e">12,000,000</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTktMy0xLTEtMjM_0ff6d434-b54c-460b-ad16-c2eea59b439b">9,800,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjAtMS0xLTEtMjM_d6713ead-9952-4ac3-b552-d78ae972296f">1,930,679</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjAtMy0xLTEtMjM_1b0f3c54-ef32-44b1-80b1-b9652d0f1f44">1,815,968</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total liabilities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjEtMS0xLTEtMjM_87ad3b6d-046b-41b7-bc5d-16ee902d5ef9">30,220,535</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjEtMy0xLTEtMjM_28ce9a8b-07bb-4cd6-9476-cd40fecd941b">29,310,711</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Equity:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Shareholders&#8217; equity:&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,727,250 and 15,723,075 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjUtMS0xLTEtMjY_8bf6b50d-3982-439d-a94a-9fbf74dc7607">51,755,834</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjUtMy0xLTEtMjg_78cd6883-988b-4dca-9d8c-3b8b2ccff0a2">52,410,941</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Retained earnings&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjYtMS0xLTEtMjY_23f8301a-d73b-4f34-b86f-a0e9f2165ada">9,329,983</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjYtMy0xLTEtMjg_bbcc4497-7b9e-4ff0-9ac9-64f21daf8a6f">11,709,222</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total shareholders&#8217; equity&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjctMS0xLTEtMjY_f84d3243-908c-418e-a971-bfa9babbdf40">61,085,817</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjctMy0xLTEtMjg_21892930-8ee9-4a68-b8fb-1cf778a8917d">64,120,163</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjgtMS0xLTEtMjY_4c6adb89-afba-4caf-aa09-21db57467986">211,512</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjgtMy0xLTEtMjg_76041745-e250-4015-ad11-7490d094af49">198,562</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total equity&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjktMS0xLTEtMjY_63a2c0cc-e85f-4c1e-88e1-e1b071ef9a59">60,874,305</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjktMy0xLTEtMjg_e7abc7d0-7136-44c9-989c-333171177589">63,921,601</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and equity&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMzAtMS0xLTEtMjY_72699e43-a310-41dd-a69b-be59cc0fa590">91,094,840</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMzAtMy0xLTEtMjg_de7daab5-1256-4581-aae2-93b8b4efbfc5">93,232,312</ix:nonFraction>&#160;</span></td></tr></table></div><div style="line-height:120%;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div id="i_0_54"></div><div style="line-height:120%;text-align:center;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;"></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;vertical-align:bottom;">1</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(Unaudited)</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:73.477239%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.894273%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.894273%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net revenues&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMi01LTEtMS01MjE0_43f0d38b-0695-44ff-a199-99dc003b375b">8,587,605</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMi03LTEtMS01MjE0_fdc9afaf-3b92-4be6-b0c2-beeca9b3f603">9,636,755</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Cost of products sold&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNC01LTEtMS01MjE0_636cc67f-1b5b-4345-9d18-5b4d6756361a">1,527,961</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNC03LTEtMS01MjE0_2bed7e87-ea12-48db-ba4a-b9ecef266bab">1,381,497</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNS01LTEtMS01MjE0_1046ccbf-27d5-4b2e-810b-04e8ee88b2d6">4,670,511</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNS03LTEtMS01MjE0_71f7cd7b-5bcb-4583-b0ea-c86e9c3a92e8">5,293,020</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Research and development&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNi01LTEtMS01MjE0_2bec1ccd-0ca9-4457-a5da-cdabb6ef3de4">1,874,939</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNi03LTEtMS01MjE0_dde4f306-d981-413f-9eea-05a7965d3141">898,363</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">General and administrative&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNy01LTEtMS01MjE0_20e52fd7-0f5b-430b-9b9a-dde97e9baecc">2,330,281</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNy03LTEtMS01MjE0_be9cb784-a292-4091-9c9a-c3ccf7a838ac">2,110,233</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Amortization&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfOC01LTEtMS01MjE0_70f16a4f-69f7-40f5-8462-e80638538db0">636,135</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfOC03LTEtMS01MjE0_3f6d93af-ba22-4ed9-9e8e-24ceb638d1f8">611,444</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfOS01LTEtMS01MjE0_a4395b88-1f8b-4661-a249-a17351693a96">11,039,827</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfOS03LTEtMS01MjE0_1e4352bf-7bb8-4722-b714-f72f9ed23055">10,294,557</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTAtNS0xLTEtNTIxNA_dbfd9fa6-29ce-44a2-93c5-40839d75bc43">2,452,222</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTAtNy0xLTEtNTIxNA_e2b0630f-1613-4436-802f-2dd030d58551">657,802</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Interest income&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTEtNS0xLTEtNTIxNA_54861f66-cb21-4b14-853f-df3007c610d2">82,494</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTEtNy0xLTEtNTIxNA_84fd8f82-270e-4151-9c4a-411e1c5065e5">52,535</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Interest expense&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTItNS0xLTEtNTIxNA_10a18eeb-26c4-4ee2-96e3-d75752bb63a8">18,302</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTItNy0xLTEtNTIxNA_29e28b19-a7a1-4f30-9459-4300ce40ec9b">31,715</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTMtNS0xLTEtNTIxNA_d8fa958e-fcea-4d50-9391-b7c4f75776cb">2,388,030</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTMtNy0xLTEtNTIxNA_fd9bf5de-aa8c-47c8-b41b-1d431299a5d6">636,982</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTQtNS0xLTEtNTIxNA_34785651-6c39-4261-a221-b621f609b306">4,159</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTQtNy0xLTEtNTIxNA_6aea0200-200b-4fda-97f7-f0080e6a1f1e">656,587</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTUtNS0xLTEtNTIxNA_9fcfccbe-8f90-4318-99ae-4147c1b18f72">2,392,189</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTUtNy0xLTEtNTIxNA_87cbcef2-92df-4724-b453-8dc6ab5212ac">1,293,569</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net loss at subsidiary attributable to noncontrolling interests&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTYtNS0xLTEtNTIxNA_f53614b9-7a25-4a8d-9630-9513d8547835">12,950</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTYtNy0xLTEtNTIxNA_dedd24bc-c7e1-4167-8081-9beedf09a256">19,123</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTctNS0xLTEtNTIxNA_c90515c6-e5f0-4684-960d-1287c77d8a03">2,379,239</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTctNy0xLTEtNTIxNA_51fb11d8-8287-48da-98d5-ceb821b961d3">1,274,446</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Earnings (loss) per share attributable to common shareholders&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:5pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:5pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">- basic&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTktNS0xLTEtNTIxNA_48eac73e-7ef6-4caa-b92a-3cdaf7489ec2">0.15</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTktNy0xLTEtNTIxNA_dd4783aa-9b4a-42a0-b516-9dd90d9c2f40">0.08</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">- diluted&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMjAtNS0xLTEtNTIxNA_56d0ad3b-7c95-41d1-b5ed-767b4f0281e7">0.15</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMjAtNy0xLTEtNTIxNA_b92f23e4-9d13-43dd-aa5a-4ff2c1a55d69">0.08</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">- basic&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMjItNS0xLTEtNTIxNA_d6159259-601f-43a2-b3f5-7ee055363086">15,689,240</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMjItNy0xLTEtNTIxNA_469701ca-0a98-47c0-af28-728d0135325d">16,042,219</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">- diluted&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMjMtNS0xLTEtNTIxNA_fbd96162-d6a3-4892-9341-6feeeba568df">15,689,240</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMjMtNy0xLTEtNTIxNA_02e434d3-0706-45e9-8291-bf0e0d137ee5">16,042,219</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Comprehensive income (loss) attributable to common shareholders&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMDMxNzhBQUFBR1FBQUFCa0FBQUFGQUFBQUJRQUFBQUFBQUJSbkFBQSUzRA_eec7fca7-cf7b-4d00-85f3-d4289ccac721">2,379,239</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMDMxN2VBQUFBR1FBQUFCa0FBQUFIQUFBQUJ3QUFBQUFBQUJScUFBQSUzRA_c2ec9815-28e8-4f0d-8873-574a10623fca">1,274,446</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net loss at subsidiary attributable to noncontrolling interests&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMDMxNzdBQUFBR2dBQUFCb0FBQUFGQUFBQUJRQUFBQUFBQUJSb0FBQSUzRA_929d418d-7f6d-4a6a-888c-eeeb6adbf783">12,950</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMDMxNzFBQUFBR2dBQUFCb0FBQUFIQUFBQUJ3QUFBQUFBQUJSckFBQSUzRA_29e994f9-5594-4f78-a854-67e2247e76b6">19,123</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total comprehensive income (loss)&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMDMxNzRBQUFBR3dBQUFCc0FBQUFGQUFBQUJRQUFBQUFBQUJScEFBQSUzRA_456afc42-993b-4b69-a367-084844901df5">2,392,189</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMDMxNzBBQUFBR3dBQUFCc0FBQUFIQUFBQUJ3QUFBQUFBQUJSc0FBQSUzRA_38f9d2c3-311f-43fe-9341-866b14cfff68">1,293,569</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="line-height:120%;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div><span><br/></span></div><div id="i_0_66"></div><div style="line-height:120%;text-align:center;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;"></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;vertical-align:bottom;">2</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Condensed Consolidated Statements of Cash Flows</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(Unaudited)</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:65.254038%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.005874%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.005874%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMy0xLTEtMS0yOTM_b6f4e98b-4e4d-489c-9c7a-f10995055a01">2,392,189</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMy0zLTEtMS0yOTM_d069f32d-d884-43d0-adb2-67ce27defdc9">1,293,569</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net income (loss) to net cash used in operating activities:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfNS0xLTEtMS0yOTM_4a130545-32cc-42a5-8207-9bfa84bff941">692,991</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfNS0zLTEtMS0yOTM_b0568cf0-354f-48a3-baa2-2807ef9c6394">661,485</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Deferred tax expense&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfNi0xLTEtMS0yOTM_7236d89f-ea85-4e42-a257-a9bf2fdfe9a9">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfNi0zLTEtMS0yOTM_36983131-5cbf-4ec4-a0fa-b1389fd0063f">758,112</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfNy0xLTEtMS0yOTM_920273f5-ef02-4452-bc84-0f8e41874287">339,209</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfNy0zLTEtMS0yOTM_79fdf85f-b0d6-4f35-8794-7a7e03336720">254,585</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Excess tax (benefit) expense derived from exercise of stock options&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfOC0zLTEtMS0yOTM_bbbfadbf-69e6-4f44-aae8-3273a85527aa">92,741</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Noncash interest expense&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfOS0xLTEtMS0yOTM_58166d59-69b5-44f1-b446-ff84f2060532">18,303</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfOS0zLTEtMS0yOTM_11688785-ede5-4c0f-ba76-ec8011777df5">26,778</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Noncash investment gains&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTAtMS0xLTEtMjkz_4b4093f2-9be8-40b8-a18d-51ee3bfe7976">43,338</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTAtMy0xLTEtMjkz_cdefcc8c-aea9-4a32-af48-ddedc32d004d">4,807</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net changes in assets and liabilities affecting operating activities:&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTItMS0xLTEtMjkz_33cf1dd9-eed8-4f66-a5d9-ae5069f90c6b">2,093,950</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTItMy0xLTEtMjkz_5018784c-833f-45f8-a4f8-d978b924f166">2,395,348</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Inventories&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTMtMS0xLTEtMjkz_03661edf-e75a-47ce-955a-874cf6b1b472">76,323</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTMtMy0xLTEtMjkz_cde0ad6d-0746-46c7-8c39-e44906e7e4b5">275,175</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Other current assets and other assets&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTQtMS0xLTEtMjkz_13d0d4e5-9382-49d9-90ed-ad1254c1c3f0">600,884</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTQtMy0xLTEtMjkz_cf7a5941-1447-452a-bcac-81b6877e2841">132,819</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and other current liabilities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTUtMS0xLTEtMjkz_b5a4b6f4-e559-4ebd-ae9c-d74f930a0966">1,254,535</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTUtMy0xLTEtMjkz_db305cd1-d420-49c3-88b6-c900b5c63a42">1,216,345</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTYtMS0xLTEtMjkz_63341d00-dbe0-44f2-98d8-2d9cd529ae8e">103,991</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTYtMy0xLTEtMjkz_5742a76b-4945-4c4f-8f73-8599a1c16bb4">92,881</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by operating activities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTctMS0xLTEtMjkz_3c91d6da-f9e8-4a20-92a2-30010bc89104">235,589</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTctMy0xLTEtMjkz_541501c1-7615-44c9-a596-f421d7c708b5">1,439,371</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Additions to property and equipment&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTktMS0xLTEtMjkz_4de914f7-76c4-420d-bd66-070a307c2361">94,881</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTktMy0xLTEtMjkz_07839bb5-527c-4ad8-8469-b701d4bca32d">123,945</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjAtMS0xLTEtMjkz_f4b96057-c430-4bea-a694-e7025fb58e22">15,151,948</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjAtMy0xLTEtMjkz_6b5f223d-13cf-4a7a-b5bb-f4e21ef9fc5d">792,716</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale of marketable securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjEtMS0xLTEtMjkz_1ec1d424-cf85-4d0f-998a-ec0e9a3e0c0f">4,257,657</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjEtMy0xLTEtMjkz_0c9edd71-9ca2-4a74-a043-a680371687aa">941,087</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Additions to intangible assets&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjMtMS0xLTEtMjkz_c40c22ae-968a-4367-975b-27d4ea14d061">532,954</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjMtMy0xLTEtMjkz_8f6ec09e-f8be-414e-9430-720e98b84a54">453,961</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjQtMS0xLTEtMjkz_74388b97-6b98-4251-8953-115424f81c38">11,522,126</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjQtMy0xLTEtMjkz_8bb47f79-fb63-4ee0-8dd3-4bd406851f07">429,535</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Borrowings on line of credit&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjctMS0xLTEtMjkz_03461dcc-a659-4a56-969e-ba7c9314a272">12,000,000</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjctMy0xLTEtMjkz_72e78167-a83c-4dd3-bb8c-2b6fe7c9ab1c">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayments on line of credit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMDMxNTFBQUFBSEFBQUFCd0FBQUFCQUFBQUFRQUFBQUFBQUJpSEFBQSUzRA_56157e38-0dda-4acf-8bbb-717e5c278e83">9,800,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:zerodash" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMDMxNWZBQUFBSEFBQUFCd0FBQUFEQUFBQUF3QUFBQUFBQUJpR0FBQSUzRA_fa22cd34-87fb-41aa-98a7-67cc0fbb2753">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Sales of shares of common stock, net of offering costs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMDMxNTJBQUFBSFFBQUFCMEFBQUFCQUFBQUFRQUFBQUFBQUJqY0FBQSUzRA_be013311-28ec-4176-a5b5-edfdddaf3b3e">200,909</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMDMxNWNBQUFBSFFBQUFCMEFBQUFEQUFBQUF3QUFBQUFBQUJqZEFBQSUzRA_6267f0e5-2ce4-4eb6-9f15-cd889a919013">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Payments of deferred offering costs&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMDMxNTdBQUFBSGdBQUFCNEFBQUFCQUFBQUFRQUFBQUFBQUJqVUFBQSUzRA_642564b7-39be-4d2c-a1d7-b7fba36e8279">248,108</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMDMxNWJBQUFBSGdBQUFCNEFBQUFEQUFBQUF3QUFBQUFBQUJqVkFBQSUzRA_009ba1d5-d624-47c2-abe8-209a16cb5b65">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzItMS0xLTEtMjkz_cb1e6ed6-1a06-4c09-8e64-9609a7102536">1,016,156</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzItMy0xLTEtMjkz_4dddd682-2270-45c2-8b72-4a77c475f9e5">545,924</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) financing activities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzMtMS0xLTEtMjkz_8c2f83e9-4833-48fc-a15e-1ab5e59d3d96">1,136,645</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzMtMy0xLTEtMjkz_8c9182ab-94de-4e87-883f-ba7d7a343b3d">545,924</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzQtMS0xLTEtMjkz_5e7b54c9-8eb7-493c-b7fe-46fb675b7591">10,149,892</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzQtMy0xLTEtMjkz_e713253b-c73b-406b-a4f5-b49a1c3ae345">463,912</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of period&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzUtMS0xLTEtMjkz_93c81e29-7036-4948-ab50-c9d01a3c37a1">45,412,868</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bf8f59dc7274cd6980319cc241a28f2_I20161231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzUtMy0xLTEtMjkz_111df818-f773-4700-8d09-a89c2e771639">34,510,330</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of period&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzYtMS0xLTEtMjkz_baeb7beb-cd50-42b5-9aed-ba2833d9b494">35,262,976</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0dd9dd6ff2ca40c88619dd5d86f0eafb_I20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzYtMy0xLTEtMjkz_adc71879-d5ff-4594-94b3-bf444aea51d0">34,974,242</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="line-height:120%;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div><span><br/></span></div><div id="i_0_78"></div><div style="line-height:120%;text-align:center;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;"></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">3</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Condensed Consolidated Statement of Equity</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(Unaudited)</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099415%;"><tr><td style="width:1.0%;"></td><td style="width:33.171386%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.667660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.545156%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.518629%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.545156%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.667660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.545156%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.475410%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.545156%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.518629%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;height:7pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests&#160;</span></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Common stock&#160;</span></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Retained earnings&#160;</span></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total equity&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Shares&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Amount&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i097d668a5f1047f0be37d4b8f2dd8771_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMy0xLTEtMS0zMDA_99706fe8-758b-4edc-affb-d114b49b4632">15,723,075</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i097d668a5f1047f0be37d4b8f2dd8771_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMy0zLTEtMS0zMDA_8fb685e7-c918-4e4d-9cde-c6811b8460db">52,410,941</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fd3da4e3c75411aa04652f12b8f13df_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMy01LTEtMS0zMDA_bfd5e0a5-bd41-4738-9b4e-490d39825bce">11,709,222</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0420ad95a0194945bfcbfd1dbc3b688f_I20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMy03LTEtMS0zMDA_bae95abe-fdb4-4947-ad21-3f98c96df9a1">198,562</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMy05LTEtMS0zMDA_19012b83-666e-4df3-8cd0-3a6b699dfc0f">63,921,601</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from the sale of common stock, net of offering costs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMDIxMUFBQUFCQUFBQUFRQUFBQUJBQUFBQVFBQUFBQUFBQmpmQUFBJTNE_ec02ceae-7ab4-4b70-abce-6b736d42423b">30,704</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMDIxZkFBQUFCQUFBQUFRQUFBQURBQUFBQXdBQUFBQUFBQmpnQUFBJTNE_fa457348-5c8e-49cd-8a90-88c2612abe12">200,909</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMDI3OUFBQUFCQUFBQUFRQUFBQUpBQUFBQ1FBQUFBQUFBQmpoQUFBJTNE_2d4fa339-9ce0-483a-8d2b-a25506d81320">200,909</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfNS0xLTEtMS0zMDA_d3e5967e-2ebd-4719-8c38-c95e12a924bd">145,550</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfNS0zLTEtMS0zMDA_356e405b-3f7b-4a57-8107-1bc60944ec6c">339,209</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfNS05LTEtMS0zMDA_a2f26eea-ceb3-400d-8379-5a075e13dcf6">339,209</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfOC0xLTEtMS0zMDA_9a788407-af2e-4389-aa5e-ce5a6bd22f10">172,079</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfOC0zLTEtMS0zMDA_645d82db-4ea0-496e-ad2b-b1e7f4206446">1,195,225</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfOC05LTEtMS0zMDA_efbc4edb-c638-4c15-9e1d-b5f04cb45737">1,195,225</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ied2c88c7a3e94ca69560e97f372df5eb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfOS01LTEtMS0zMDA_32a14ae8-94e9-4578-86f8-5f11dbcfd313">2,379,239</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i895db0703de048cb8eb76978269e35a6_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfOS03LTEtMS0zMDA_455aa193-9635-4525-933d-33b61ce6ce16">12,950</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfOS05LTEtMS0zMDA_62e472bf-3567-4740-b1ba-496dea0394d4">2,392,189</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2018&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic602d02dff724990b5feb87e55fbb783_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMTAtMS0xLTEtMzAw_6c3a311e-84d3-449e-9759-78fac3ebc8e6">15,727,250</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic602d02dff724990b5feb87e55fbb783_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMTAtMy0xLTEtMzAw_4b8fd5c5-eda9-4db7-9bf1-2b701d6b03d3">51,755,834</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i26a1fb7ff6bd4d2085da7c1c604620e1_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMTAtNS0xLTEtMzAw_6c49c6a7-2528-43b8-80ae-da44c3ad1fd4">9,329,983</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5909472559854a45a161ee9683451710_I20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMTAtNy0xLTEtMzAw_c664ec5b-a4ed-49df-9931-bdbdfbf31c6e">211,512</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMTAtOS0xLTEtMzAw_740ebd61-bdee-4f4b-bc38-fa9685a71381">60,874,305</ix:nonFraction>&#160;</span></td></tr></table></div><div style="line-height:120%;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div><span><br/></span></div><div id="i_0_90"></div><div style="line-height:120%;text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">4</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;text-align:center;"><span><br/></span></div><div id="i_0_101"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(1) <ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDEvZnJhZzo2MjFjNzE1Y2FiOTQ0Y2I1OGFiMWNkMGMxYmU2OWE2MC90ZXh0cmVnaW9uOjYyMWM3MTVjYWI5NDRjYjU4YWIxY2QwYzFiZTY5YTYwXzIxOTkwMjMyNzkwMjU_d1eae438-5d29-42b0-acf0-9d0de76cd6c3" continuedAt="ia9254ac58b434cbe9c7a5373640882b8" escape="true">ORGANIZATION AND&#160;BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="ia9254ac58b434cbe9c7a5373640882b8" continuedAt="i3f4c5b324c2b49bb827b5819fa444768"><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December&#160;31, 2017 audited consolidated financial statements, with the exception of the impacts of adopting accounting pronouncements during 2018, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2017 (the &#8220;2017 Annual Report on Form 10-K&#8221;). The results of operations for the three months ended March&#160;31, 2018 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Total comprehensive income (loss) consisted solely of net income (loss) for the three months ended March&#160;31, 2018 and 2017.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;vertical-align:bottom;">Adoption of Revenue Accounting Standard</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) amended guidance in the form of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Net Product Revenue</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 45 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Sales Rebates and Discounts</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">5</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Notes to Condensed Consolidated Financial Statements - continued</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(Unaudited)</span></div><div><span><br/></span></div></div><ix:continuation id="i3f4c5b324c2b49bb827b5819fa444768" continuedAt="i94424bd4160a4a4da5378eb45c38e8e0"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Sales Returns</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other tactor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;vertical-align:bottom;">Recent Accounting Guidance</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDEvZnJhZzo2MjFjNzE1Y2FiOTQ0Y2I1OGFiMWNkMGMxYmU2OWE2MC90ZXh0cmVnaW9uOjYyMWM3MTVjYWI5NDRjYjU4YWIxY2QwYzFiZTY5YTYwXzEwNDQ1MzYwNjI0NTM2_214a318d-b78a-407e-8f6f-d9ea65e78300" continuedAt="i1c4db928ec224017aad64f9b1d9fe636" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Recent Adopted Accounting Pronouncements </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, &#8220;Revenue from Contracts with Customers.&#8221; (&#8220;ASC 606&#8221;)  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018.  As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. The Company is currently applying the standard in its current practices. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In November 2016, the FASB issued ASU No. 2016-18, &#8220;Statement of Cash Flows: Restricted Cash.&#8221; This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the &#8220;beginning-of-period&#8221; and &#8220;end-of-period&#8221; total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, &#8220;Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.&#8221; The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Recent Accounting Pronouncements - Not Yet Adopted </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-12, &#8220;Leases.&#8221; The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients available. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">6</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Notes to Condensed Consolidated Financial Statements - continued</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(Unaudited)</span></div><div><span><br/></span></div></div><ix:continuation id="i94424bd4160a4a4da5378eb45c38e8e0" continuedAt="ib8847fe28a7348729f9a60859e9b56fd"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"><ix:continuation id="i1c4db928ec224017aad64f9b1d9fe636">its current lease agreements for the impact of its pending adoption of the new standard on its consolidated financial statements and disclosures. The Company&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of office and wet laboratory space in Nashville, Tennessee by Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary, in which it operates the CET Life Sciences Center.  This lease currently expires in April 2023.</ix:continuation></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;vertical-align:bottom;">Accounting Policies:</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDEvZnJhZzo2MjFjNzE1Y2FiOTQ0Y2I1OGFiMWNkMGMxYmU2OWE2MC90ZXh0cmVnaW9uOjYyMWM3MTVjYWI5NDRjYjU4YWIxY2QwYzFiZTY5YTYwXzEwNDQ1MzYwNjI0NTM1_3ce7a717-f273-4fbd-9ddc-344f69f374a2" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;text-decoration: underline;vertical-align:bottom;">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the allowances for obsolescent or unmarketable inventory.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;vertical-align:bottom;"><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDEvZnJhZzo2MjFjNzE1Y2FiOTQ0Y2I1OGFiMWNkMGMxYmU2OWE2MC90ZXh0cmVnaW9uOjYyMWM3MTVjYWI5NDRjYjU4YWIxY2QwYzFiZTY5YTYwXzIxOTkwMjMyNzkwMjI_4cc3b3ec-711f-47eb-8c26-6ee192a7feb5" continuedAt="ic978e128f49d4d2e9cde8e9fc0d4b593" escape="true">Operating Segments</ix:nonNumeric></span></div></ix:continuation><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"><ix:continuation id="ib8847fe28a7348729f9a60859e9b56fd"><ix:continuation id="ic978e128f49d4d2e9cde8e9fc0d4b593">The Company has&#160;<ix:nonFraction unitRef="segment" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDEvZnJhZzo2MjFjNzE1Y2FiOTQ0Y2I1OGFiMWNkMGMxYmU2OWE2MC90ZXh0cmVnaW9uOjYyMWM3MTVjYWI5NDRjYjU4YWIxY2QwYzFiZTY5YTYwXzEwOTk1MTE2NTEyMzI_59824400-253f-4afc-97b4-72a8eb8a55e7">one</ix:nonFraction>&#160;operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="i_0_114"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(2) <ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90ZXh0cmVnaW9uOjc5MTYyOTJkZjVhMDQwYmViMDZkMDVlNDFmYWMwZTczXzEwOTk1MTE2MzQ0Njg_62fafb61-4077-4589-83d1-d0317e8ea720" continuedAt="ib2f32d1113974073864700c991450c8e" escape="true">MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="ib2f32d1113974073864700c991450c8e" continuedAt="ic3ce83519c1e4ece960f516ce7e465af"><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency issued mortgage-backed securities, U.S. government agency notes and bonds, Small Business Administration (&#8220;SBA&#8221;) loan pools, and corporate bonds.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of March 31, 2018&#160;and December 31, 2017,&#160;the marketable securities are comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).&#160;</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="text-indent:-45pt;padding-left:81pt;line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Level 1 -&#160;Quoted prices for identical instruments in active markets.</span></div><div style="text-indent:-45pt;padding-left:81pt;line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Level 2 -&#160;Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="text-indent:-45pt;padding-left:81pt;line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Level 3 -&#160;Significant inputs to the valuation model are unobservable.</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">7</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Notes to Condensed Consolidated Financial Statements - continued</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(Unaudited)</span></div><div><span><br/></span></div></div><ix:continuation id="ic3ce83519c1e4ece960f516ce7e465af"><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;vertical-align:bottom;">&#160;</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90ZXh0cmVnaW9uOjc5MTYyOTJkZjVhMDQwYmViMDZkMDVlNDFmYWMwZTczXzEwOTk1MTE2MzQ0Njc_644507d4-5a9a-4ca7-bd69-570e27b03bae" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:27.368576%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">March 31, 2018&#160;</span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Level 1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Level 2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Level 1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Level 2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury notes and bonds&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i91ee759fede74a44afc15799417026fc_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAxY0FBQUFBd0FBQUFNQUFBQUJBQUFBQVFBQUFBQUFBQmpzQUFBJTNE_0da431b3-b3cf-4824-9b4e-02f69c4c0171">6,486,345</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4184f63683bf45109fe4a49c88baafbc_I20180331" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAxYUFBQUFBd0FBQUFNQUFBQURBQUFBQXdBQUFBQUFBQmp0QUFBJTNE_7373a3b6-4498-4b5f-b856-262f3b4c3803">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4572e5a71c344688b9efe5e38ee4a0e8_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMzRBQUFBQXdBQUFBTUFBQUFGQUFBQUJRQUFBQUFBQUJqd0FBQSUzRA_ca10405f-815e-4391-b5f5-20f0412980fb">6,486,345</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iac05f8bde425448ea4955ae4d2988a48_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMzBBQUFBQXdBQUFBTUFBQUFIQUFBQUJ3QUFBQUFBQUJqeUFBQSUzRA_91b3a8d1-2789-4504-b377-1ab3dc402bd8">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i43d4a46326a24d6caca1fac6793144ce_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyNDZBQUFBQXdBQUFBTUFBQUFKQUFBQUNRQUFBQUFBQUJqMEFBQSUzRA_d00cfea6-e92a-4100-876d-259e23a90afa">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51f8d7b7f57f4d7388487c437f5ab518_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyNGFBQUFBQXdBQUFBTUFBQUFMQUFBQUN3QUFBQUFBQUJqMkFBQSUzRA_e02f7047-857f-4fc2-a0b7-c3204d3f76d4">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">U.S. Agency issued mortgage-backed securities &#8211; variable rate&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c6551d700a840f38a0908ea87bf44cf_I20180331" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzMtMS0xLTEtMzA4_6573151a-e0ed-4ab9-9488-6a9daec3aa93">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d63d8a95b20480d99100f9855f3f288_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzMtMy0xLTEtMzA4_ff515aa1-d582-4baf-8a0b-e2ca7db96b22">1,569,884</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0aea36d855cf456e880b35e2dc2c0505_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzMtNS0xLTEtMzA4_a38d56f0-bc91-402d-b03d-76f951b1a653">1,569,884</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i740c45d85a2942c196e262b2964e237b_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzMtNy0xLTEtMzE2_bd8919c3-1714-4796-ba7a-873382753c0a">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i996d7d1b56cb43219465772f1f7597fe_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzMtOS0xLTEtMzE2_1bc95a17-7bf3-4de8-b552-8dbbbdc21600">3,539,102</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie54bf1c8e2d14928a9a06a734dfd7c6c_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzMtMTEtMS0xLTMxNg_d7375a00-43a3-4be0-a9fd-9986eaae9a6b">3,539,102</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">U.S. Agency notes and bonds &#8211; fixed rate&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i439c1bc3ca8e4e5b9ea4d7bdb13d6991_I20180331" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzQtMS0xLTEtMzA4_1d63ccb7-3af0-4994-b5ca-0cc187873718">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01938b90ab854812b8ec66565464d607_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzQtNy0xLTEtMzE2_1a9497ea-e8ca-40b0-b38b-aa4fe4081f55">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5149372296b940a2aa525db6faa8f3c4_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzQtOS0xLTEtMzE2_9038d103-20bd-496b-a7f3-cc30cf3d0f19">198,293</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id5a2b34ed5004b8fa2acfe953a3cc3c4_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzQtMTEtMS0xLTMxNg_8ef1fca3-fc7d-4fd4-a68a-eb5b32d0d505">198,293</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2830ebd535c84a6496a304acfc539e9a_I20180331" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMTdBQUFBQmdBQUFBWUFBQUFCQUFBQUFRQUFBQUFBQUJqNEFBQSUzRA_bcc7156d-e7f8-402d-897d-7c5b176b7e79">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic4dd4eb6277e4ca19f808c8a63b5fd3e_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMWJBQUFBQmdBQUFBWUFBQUFEQUFBQUF3QUFBQUFBQUJqNUFBQSUzRA_57744f62-48f4-42b1-a33a-1170fee98168">2,502,977</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i18a7c5c9ec3446ddad8bd6afcd563cf6_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMjdBQUFBQmdBQUFBWUFBQUFGQUFBQUJRQUFBQUFBQUJqNkFBQSUzRA_745f70b0-3374-4a9b-8593-e69dda538517">2,502,977</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6aae0fc592af4b14936eced6617fdc55_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMmJBQUFBQmdBQUFBWUFBQUFIQUFBQUJ3QUFBQUFBQUJqN0FBQSUzRA_175dd3bd-c584-4241-a628-1f232ec9ad4d">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d02d8434f0641b9a2539c9d2707cf7b_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyN2RBQUFBQmdBQUFBWUFBQUFKQUFBQUNRQUFBQUFBQUJqOEFBQSUzRA_87e76c5b-e311-4df7-b63b-c92d2a727984">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i863ba3e77c42420dbba1bfa4d84f2196_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyNzNBQUFBQmdBQUFBWUFBQUFMQUFBQUN3QUFBQUFBQUJqOUFBQSUzRA_1da23d35-098a-4fa0-82fb-ff36b936c789">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">SBA loan pools &#8211; variable rate&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia15f718fd7ee4613bd4f49589b3d8fdc_I20180331" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzUtMS0xLTEtMzA4_9c653172-aa0c-4545-bda8-d9e8b1a31079">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe82cbc40bcb489390a75fce71b8b80f_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzUtMy0xLTEtMzA4_35fa2976-28bb-4de9-a8ad-1b6b4072afee">548,641</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ae969ed44e419f8fc0f2099a9510cd_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzUtNS0xLTEtMzA4_883e3ab8-1c4c-4976-aca1-4bf5b2440f69">548,641</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ed094dbab104669b5bce32fe7460a28_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzUtNy0xLTEtMzE2_f6556c4e-cedc-4c04-ae9d-5c6d37536355">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i84d27aa248d24ab8b554e59624c79428_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzUtOS0xLTEtMzE2_704f6513-28d5-45c4-be70-ff024c1470ab">935,081</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieed830091dab43ba8375cdfb0f7f2a8c_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzUtMTEtMS0xLTMxNg_d506ce2d-f481-4272-a592-92265bbf1eda">935,081</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Short-term cash investments&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde5b053a5b6476bb846c88390de0bc5_I20180331" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzYtMS0xLTEtMzA4_e2b8d65c-87bb-492f-8299-9bfd8e613a3b">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id98aa82685604140986e94a71f9d1936_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzYtMy0xLTEtMzA4_3cd2c97e-666c-48cd-a68d-1e2b81f4bac1">4,502,258</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c8ca872cb5c4f4596ce2fd08ca9aa5e_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzYtNS0xLTEtMzA4_a86ef7a7-8f69-485f-9aba-9c5e48be2b27">4,502,258</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5c0c160863d4cceb26f484a2325fb1d_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzYtOS0xLTEtMzE2_f6fb5afb-d9ec-41bd-a31c-a3b3ce0813b4">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i381dc586d9494541bcf340e8bda4d8d0_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMTZBQUFBQndBQUFBY0FBQUFCQUFBQUFRQUFBQUFBQUJQV0FBQSUzRA_86c6bd71-0d57-430f-911d-833344704092">6,486,345</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0982f8386a84f56bf35e403d479f381_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMWFBQUFBQndBQUFBY0FBQUFEQUFBQUF3QUFBQUFBQUJQWEFBQSUzRA_b95e9e56-d29a-4530-ad31-0a11ca9a65f8">9,123,760</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMjZBQUFBQndBQUFBY0FBQUFGQUFBQUJRQUFBQUFBQUJQWUFBQSUzRA_1a704342-63e5-4733-b3d1-fcf65df60d6e">15,610,105</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb29255b0cce4beabad9c0ef7e86504e_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyN2VBQUFBQndBQUFBY0FBQUFKQUFBQUNRQUFBQUFBQUJQY0FBQSUzRA_d17edcc7-d42a-4f10-a46f-7b062f65395e">4,672,476</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyNzBBQUFBQndBQUFBY0FBQUFMQUFBQUN3QUFBQUFBQUJQZEFBQSUzRA_9d1529bf-6075-45df-a9a1-310f0d01ea6e">4,672,476</ix:nonFraction>&#160;</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i_0_127"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;vertical-align:bottom;">(3) <ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90ZXh0cmVnaW9uOmU3ZWVlOTEzM2UwNTRkOTI4MTlhMzUwZGY2Yzg3MjEwXzIxOTkwMjMyNTY2NDc_b7049524-2d2f-45ad-873e-db20700d59a2" continuedAt="i2fb13b5b54a242139e12d0027cfb2a3b" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i2fb13b5b54a242139e12d0027cfb2a3b"><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90ZXh0cmVnaW9uOmU3ZWVlOTEzM2UwNTRkOTI4MTlhMzUwZGY2Yzg3MjEwXzIxOTkwMjMyNTY2NDY_fe8939b5-1e4d-42a3-8c87-e55d4443967a" escape="true"><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the&#160;three&#160;months ended&#160;March 31, 2018&#160;and 2017:</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:63.102639%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.008798%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.155425%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Numerator:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90YWJsZTplN2YyNzY3NGE4OWM0OGFlODI4Y2I2YTU3N2Q3YTkxNS90YWJsZXJhbmdlOmU3ZjI3Njc0YTg5YzQ4YWU4MjhjYjZhNTc3ZDdhOTE1XzEyLTEtMS0xLTMyMA_c90515c6-e5f0-4684-960d-1287c77d8a03">2,379,239</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90YWJsZTplN2YyNzY3NGE4OWM0OGFlODI4Y2I2YTU3N2Q3YTkxNS90YWJsZXJhbmdlOmU3ZjI3Njc0YTg5YzQ4YWU4MjhjYjZhNTc3ZDdhOTE1XzEyLTMtMS0xLTMyMg_51fb11d8-8287-48da-98d5-ceb821b961d3">1,274,446</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Denominator:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90YWJsZTplN2YyNzY3NGE4OWM0OGFlODI4Y2I2YTU3N2Q3YTkxNS90YWJsZXJhbmdlOmU3ZjI3Njc0YTg5YzQ4YWU4MjhjYjZhNTc3ZDdhOTE1XzE0LTEtMS0xLTMyNA_d6159259-601f-43a2-b3f5-7ee055363086">15,689,240</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90YWJsZTplN2YyNzY3NGE4OWM0OGFlODI4Y2I2YTU3N2Q3YTkxNS90YWJsZXJhbmdlOmU3ZjI3Njc0YTg5YzQ4YWU4MjhjYjZhNTc3ZDdhOTE1XzE0LTMtMS0xLTMyOA_469701ca-0a98-47c0-af28-728d0135325d">16,042,219</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90YWJsZTplN2YyNzY3NGE4OWM0OGFlODI4Y2I2YTU3N2Q3YTkxNS90YWJsZXJhbmdlOmU3ZjI3Njc0YTg5YzQ4YWU4MjhjYjZhNTc3ZDdhOTE1XzE2LTEtMS0xLTMyNg_fbd96162-d6a3-4892-9341-6feeeba568df">15,689,240</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90YWJsZTplN2YyNzY3NGE4OWM0OGFlODI4Y2I2YTU3N2Q3YTkxNS90YWJsZXJhbmdlOmU3ZjI3Njc0YTg5YzQ4YWU4MjhjYjZhNTc3ZDdhOTE1XzE2LTMtMS0xLTMzMA_02e434d3-0706-45e9-8291-bf0e0d137ee5">16,042,219</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">As of&#160;March 31, 2018&#160;and 2017, restricted stock awards and options to purchase&#160;<ix:nonFraction unitRef="shares" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90ZXh0cmVnaW9uOmU3ZWVlOTEzM2UwNTRkOTI4MTlhMzUwZGY2Yzg3MjEwXzEwOTk1MTE2Mjg3MDc_3cebe322-5c03-4c9e-b9ab-4426ab9716c9">247,530</ix:nonFraction>&#160;and&#160;<ix:nonFraction unitRef="shares" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90ZXh0cmVnaW9uOmU3ZWVlOTEzM2UwNTRkOTI4MTlhMzUwZGY2Yzg3MjEwXzEwOTk1MTE2Mjg3MTk_49501f3b-675a-43f9-b7a9-ea5fcfc4f5e3">237,875</ix:nonFraction>&#160;shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;"><span><br/></span></div><div id="i_0_140"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(4) <ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90ZXh0cmVnaW9uOjg1NTkzMTdlNjM1YTRjMWZiMDU3YjczYTY4N2FkMmNhXzEwOTk1MTE2MzEzODY_1578b962-f475-4616-97f6-8022fe4d29ea" continuedAt="i821fd2ed727142f7bdb1a7534da2d207" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i821fd2ed727142f7bdb1a7534da2d207" continuedAt="icfc23641eb2e4d10a79ec84864115faf"><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Product Revenues</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605. However, no cumulative effect adjustment to historical retained earnings was necessary as no revenue recognition differences were identified when comparing the revenue recognition criteria under ASC 606 to previous requirements. See further discussion in Note 1. </span></div></ix:continuation><div><span><br/></span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span></div><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90ZXh0cmVnaW9uOjg1NTkzMTdlNjM1YTRjMWZiMDU3YjczYTY4N2FkMmNhXzEwOTk1MTE2MzEzODU_4b90c663-8d41-421a-82fa-6afd6f3cf3b0" continuedAt="i0b1221336a4a4ba6a7d78e94aa2fc12e" escape="true"></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">8</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Notes to Condensed Consolidated Financial Statements - continued</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(Unaudited)</span></div><div><span><br/></span></div></div><ix:continuation id="icfc23641eb2e4d10a79ec84864115faf" continuedAt="ief7179c0b9254107afea4deb33d3513c"><ix:continuation id="i0b1221336a4a4ba6a7d78e94aa2fc12e"><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company&#8217;s net revenues consisted of the following for the&#160;three&#160;months ended&#160;March 31, 2018&#160;and 2017:</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:69.742313%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.762811%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.762811%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Products:&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Acetadote&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iffcc23dd7a9944139daf9824e5b8eac5_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzMtNS0xLTEtMzM2_422d4156-c242-4ed0-9098-c904825a0d7f">1,273,764</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6809c3be77f6432d9076c460384fbb07_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzMtNy0xLTEtMzM2_85a85149-e9b3-4724-a524-2c82c8df905d">1,265,440</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2cf28a7f39c448f96b2e5671107943f_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzQtNS0xLTEtMzM2_72ef0dbc-af9f-4359-af51-eb4d9837207c">141,392</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d8502d751864f05a59b40ecc159972b_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzQtNy0xLTEtMzM2_b31c72ed-5374-49ce-a5ae-100efcb633da">645,325</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Kristalose&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic700e54bd9e84fe38825f0e668b5fc38_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzUtNS0xLTEtMzM2_e5d663c4-0622-4298-a212-e1e4ebb4af0a">3,269,901</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5e9f1b87044a0da9566dff708f6520_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzUtNy0xLTEtMzM2_cd6b34f5-30a2-46f1-89c3-89e3a7f87098">2,386,591</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Vaprisol&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf73e673b6164c78ab232ce6f110e7d1_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzYtNS0xLTEtMzM2_ab72cb2c-228b-480d-817a-25eb033d7896">93,890</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i088036779adb405fb051b2f6ea583979_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzYtNy0xLTEtMzM2_b5e1da2a-ca6f-4e8b-9d9d-59089375be61">684,548</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Caldolor&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i302d2057998b42f88bce95c8b68a0dca_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzctNS0xLTEtMzM2_16f2b3cb-d83b-45f7-bcf3-d0af708ddc4d">1,039,747</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafc0d050afaf4677960684f8f326d0a1_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzctNy0xLTEtMzM2_5cf4557f-6022-44e8-af09-2ff19419d74b">813,027</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Ethyol&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i666c2dae486e4b1eac47ec35b708938f_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzgtNS0xLTEtMzM2_c2bd1caa-c577-4728-8bfb-bff0467b5d4b">2,256,073</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib034705aa5544216b55c469279e3eaba_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzgtNy0xLTEtMzM2_ca29b4fc-3ceb-4a2a-af21-c948d1a813c6">3,666,808</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">       Totect&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i17303c3256e5493faf87462aef420fab_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzktNS0xLTEtMzM2_517318dc-fbb0-4669-a482-1fb295208ba4">412,774</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d39aea30fbc46889b6cfa872b2b6fb7_D20170101-20170331" decimals="0" format="ixt:zerodash" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzktNy0xLTEtMzM2_a13a5acb-9cb2-4adf-a27f-ee859d8f773f">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Other&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id74555dabd6a4ff2ad0bdc7e28c863bc_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzEwLTUtMS0xLTMzNg_59fb9c43-001e-45df-a490-cc8f2eb0f8fd">100,064</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i654f0cb0d52e49d39635e4e808fc2055_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzEwLTctMS0xLTMzNg_f9788d0a-17ec-49db-a90f-116ba466d560">175,016</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:42pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total net revenues&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzExLTUtMS0xLTMzNg_08f7f0c5-39e9-4f92-9570-abaad6afb28d">8,587,605</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzExLTctMS0xLTMzNg_554dea69-e5e6-4c62-893d-907e14e5e2f5">9,636,755</ix:nonFraction>&#160;</span></td></tr></table></div></ix:continuation><div style="line-height:120%;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Cumberland supplies Perrigo Company (&#8220;Perrigo&#8221;) with an Authorized Generic version of the Company's Acetadote product. The Company's revenue generated by sales of its Authorized Generic distributed by Perrigo is included in the Acetadote product revenue presented above. The Company's share of Authorized Generic revenue was&#160;$<ix:nonFraction unitRef="usd" contextRef="i73e54bcae66640ebbb1fffa211e276c6_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90ZXh0cmVnaW9uOjg1NTkzMTdlNjM1YTRjMWZiMDU3YjczYTY4N2FkMmNhXzEwOTk1MTE2MzExMzk_1ee14944-8a6a-42ad-bdb2-d20cd1643268">0.8</ix:nonFraction> million&#160;and&#160;$<ix:nonFraction unitRef="usd" contextRef="i4eb22c1d61c749ddac462523b2b31161_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalesRevenueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90ZXh0cmVnaW9uOjg1NTkzMTdlNjM1YTRjMWZiMDU3YjczYTY4N2FkMmNhXzEwOTk1MTE2MzExNjA_eda9bd93-1df0-49fa-893d-869706846ae0">0.9</ix:nonFraction> million&#160;for first quarter of 2018 and 2017, respectively. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Other Revenues</span></div></ix:continuation><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"><ix:continuation id="ief7179c0b9254107afea4deb33d3513c">The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is entitled to receive non-refundable, up-front payments at the time the agreements are entered into and milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company recognizes revenue for these substantive milestones using the milestone method. The Company is also entitled to receive royalties on future sales of the products under the agreements.</ix:continuation> </span></div><div style="line-height:120%;text-align:justify;"><span><br/></span></div><div id="i_0_153"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(5) <ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90ZXh0cmVnaW9uOmY3ZWRlNjRlODVkYzQ1ZTE4MzM5NzA3OGY4NjAzOWJlXzIxOTkwMjMyNTkxNzI_b3e910c9-968c-4585-b39d-e6e814494798" continuedAt="i1fb06df9f9df41fbaf056a1e05a6be9b" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="i1fb06df9f9df41fbaf056a1e05a6be9b" continuedAt="i02645867b51d41ec85819f23d0dc2b4f"><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At&#160;March 31, 2018&#160;and&#160;December 31, 2017, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90ZXh0cmVnaW9uOmY3ZWRlNjRlODVkYzQ1ZTE4MzM5NzA3OGY4NjAzOWJlXzEwOTk1MTE2MzExODg_91ac3cac-0776-4096-9284-d71da1dabe87">0.1</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90ZXh0cmVnaW9uOmY3ZWRlNjRlODVkYzQ1ZTE4MzM5NzA3OGY4NjAzOWJlXzEwOTk1MTE2MzEyMDg_d7f0138d-c160-47d2-88ed-f614a7a856bd">0.2</ix:nonFraction> million, respectively.&#160;</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total at&#160;March 31, 2018&#160;and&#160;December 31, 2017.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span></div><ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90ZXh0cmVnaW9uOmY3ZWRlNjRlODVkYzQ1ZTE4MzM5NzA3OGY4NjAzOWJlXzIxOTkwMjMyNTkxNzE_a10c54b2-3d6a-4bc7-b23f-663d8306f805" continuedAt="ib0a8f392ad754e33b031ad581bfb9f9d" escape="true"></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">9</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Notes to Condensed Consolidated Financial Statements - continued</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(Unaudited)</span></div><div><span><br/></span></div></div><ix:continuation id="i02645867b51d41ec85819f23d0dc2b4f"><ix:continuation id="ib0a8f392ad754e33b031ad581bfb9f9d"><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">As of&#160;March 31, 2018&#160;and December 31, 2017, net inventory consisted of the following:&#160;</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:60.316716%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.475073%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.475073%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzEtMS0xLTEtNTMwNg_e83315db-a6f9-4a00-b723-793a26e7cbc3">2,642,543</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzEtMy0xLTEtNTMwNg_d335b4a4-70c1-4a9f-9a57-f22d4a7e8949">3,156,002</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzItMS0xLTEtNTMwNg_e28383f1-cfcc-440c-9290-700138150c6e">418,829</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzItMy0xLTEtNTMwNg_eb7c5989-3165-4efe-b45d-ef8c5e623378">249,964</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Finished goods&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzMtMS0xLTEtNTMwNg_1be2bac4-6cd1-4f7c-b05f-8c5941ae56ee">3,600,153</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzMtMy0xLTEtNTMwNg_e21bb61e-f334-49e9-9e6a-a3ce422dc059">3,331,882</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzAyMTFBQUFBQkFBQUFBUUFBQUFCQUFBQUFRQUFBQUFBQUJQa0FBQSUzRA_7ec3880e-bebb-4561-9d67-bd2506987106">6,661,525</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66977d80365d404296229eb847d696f2_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzAyMWZBQUFBQkFBQUFBUUFBQUFEQUFBQUF3QUFBQUFBQUJQbEFBQSUzRA_1c5a524b-e297-4dc2-a62d-22325fb97bba">6,737,848</ix:nonFraction>&#160;</span></td></tr></table></div></ix:continuation></ix:continuation><div style="line-height:120%;"><span><br/></span></div><div id="i_0_166"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(6) <ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzY1Mzc_bb0c26d8-0d59-4faa-aa0b-adb4a815022e" continuedAt="i550f65fb72ec4bfcbdc2049386fd3b59" escape="true">SHAREHOLDERS&#8217; EQUITY AND DEBT</ix:nonNumeric></span></div><ix:continuation id="i550f65fb72ec4bfcbdc2049386fd3b59"><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Share Repurchases</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company currently has a share repurchase program to repurchase up to&#160;$<ix:nonFraction unitRef="usd" contextRef="i3fd8c1a5a34842988819ab52812dc1e7_I20100513" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyMTk_d2a727f1-7133-4b0b-a532-f1163261e108">10</ix:nonFraction> million&#160;of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2016, the Company's Board of Directors established the current&#160;$<ix:nonFraction unitRef="usd" contextRef="ib436aa4112784a5bb575f9ce9fe4fb53_I20120430" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyMzY_19a740b5-f1af-4b76-b2db-a0e2f520b492"><ix:nonFraction unitRef="usd" contextRef="i0a9e1ab5b93d4567815cacdf06859be8_I20130131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyMzY_1f0a193a-fc53-4fe3-aefc-b40cc1513cc3"><ix:nonFraction unitRef="usd" contextRef="i47407fdc5afa40749b77a0412daf8956_I20110131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyMzY_5160aa19-e3cc-41bc-879c-eed8cb4f5b21"><ix:nonFraction unitRef="usd" contextRef="iebdcd0b9547b443b8727649905bdb07b_I20160131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyMzY_8e01842c-d3b1-4a4c-886b-5b34a069851e"><ix:nonFraction unitRef="usd" contextRef="if5236a3131db4202b5eaec29f686e679_I20150131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyMzY_fde360d7-764f-4ecb-ab2d-ee68e11724bd">10</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million repurchase program to replace the prior authorizations.  During the&#160;three months ended March 31, 2018&#160;and March 31, 2017, the Company repurchased&#160;<ix:nonFraction unitRef="shares" contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzIxOTkwMjMyNjQzMDI_5148ad9a-c338-4d7a-b412-7de06002be71">172,079</ix:nonFraction>&#160;shares and&#160;<ix:nonFraction unitRef="shares" contextRef="ic6b3a2fc1ae64e68a3298edf95187fcd_D20170101-20170331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzU5MTA_96e7135a-c219-43ab-a02a-ad13fe8c938d">155,150</ix:nonFraction>&#160;shares, respectively, of common stock for approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzIxOTkwMjMyNjQzMDQ_02417140-e444-4731-920e-04feb32360a2">1.2</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="ic6b3a2fc1ae64e68a3298edf95187fcd_D20170101-20170331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzU5NDU_bdb6e75c-7284-4eb2-b0cb-1f370f71baf0">1.0</ix:nonFraction> million, respectively.&#160;</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Share Sales</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to&#160;$<ix:nonFraction unitRef="usd" contextRef="i61a9610b573b4e75a7c8f0f35d1cb4d8_D20171101-20171130" decimals="INF" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3Xzg3OTYwOTMwMzc5NzA_a8b5165b-331a-4ca6-bb6c-c2ff4655ca2c">100</ix:nonFraction> million&#160;in corporate securities. The Shelf Registration was declared effective in January 2018. During the three months ended March 31, 2018, the Company issued &#160;<ix:nonFraction unitRef="shares" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3Xzg3OTYwOTMwMzc5ODY_4fa376fd-2212-4800-b1a9-bc10cea83c43"><ix:nonFraction unitRef="shares" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3Xzg3OTYwOTMwMzc5ODY_ea8b2942-a5ee-427d-8944-2a69eb3cbc5e">30,704</ix:nonFraction></ix:nonFraction>&#160;shares of common stock for gross proceeds of&#160;$<ix:nonFraction unitRef="usd" contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3Xzg3OTYwOTMwMzc5OTU_a27851c6-ddac-400f-b68b-ae72f387fac1">0.2</ix:nonFraction> million&#160;as part of its At-The-Market (&#8220;ATM&#8221;) sales agreement with B. Riley FBR.</span></div><div><span><br/></span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Restricted Share Grants&#160;</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">During the&#160;three months ended March 31, 2018, the Company issued&#160;<ix:nonFraction unitRef="shares" contextRef="i653bf892b8c94a22be15b4bc51db3a05_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzU5Njk_dc6c8d81-6cb8-4275-9e5a-046d351dda81">229,205</ix:nonFraction>&#160;shares of restricted stock to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyNjE_3db38b5b-b57e-4753-bab2-0401c4da4aa8">one</span>-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Debt Agreement</span></div><div style="line-height:120%;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">On July 31, 2017,&#160;the Company entered into a Revolving Credit Loan Agreement with Pinnacle Bank ("Pinnacle Agreement").  The Pinnacle Agreement replaced the June 2014 Revolving Credit Loan Agreement with SunTrust Bank, which was to expire on June 30, 2018. The Company had&#160;$<ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzU0OTc1NTgyNTIwOQ_efaa2422-0a83-4cab-9ea5-bbee6727d67e">12.0</ix:nonFraction> million&#160;&#160;in borrowings under that agreement at March&#160;31, 2018.&#160;The Pinnacle Agreement provides for an aggregate principal amount of up to&#160;$<ix:nonFraction unitRef="usd" contextRef="i2b744dac368c4c3eb91bc9bb77c5cf97_I20170731" decimals="0" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyODc_2bec098f-a91d-48e2-82a2-2832d8d6f07d">20</ix:nonFraction> million&#160;and has a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzNDI_faa1036d-aac4-495e-970e-7d7605ba1f7c">three</span>-year term expiring on July 31, 2020.  The initial revolving line of credit is up to&#160;$<ix:nonFraction unitRef="usd" contextRef="i2b744dac368c4c3eb91bc9bb77c5cf97_I20170731" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzMDM_bb3fd2f2-19b9-4459-864b-de17f7cdc5da">12</ix:nonFraction> million&#160;with the ability to increase the borrowing amount up to&#160;$<ix:nonFraction unitRef="usd" contextRef="i2b744dac368c4c3eb91bc9bb77c5cf97_I20170731" decimals="0" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzMTk_eb9de3cc-0acc-4c54-ba06-350bd4d27300">20</ix:nonFraction> million, upon the satisfaction of certain conditions.&#160;</span></div><div><span><br/></span></div><div style="line-height:120%;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of&#160;<ix:nonFraction unitRef="number" contextRef="i55c284425d4448d79d408df2a3a756f9_I20170731" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzNDY_414b703e-d751-4fcf-8963-09d44228986e">1.75</ix:nonFraction>%&#160;to&#160;<ix:nonFraction unitRef="number" contextRef="i288af4ef515f4257be46413b7b9d94ee_I20170731" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzNTc_3ce909d9-2a7e-4e7d-91a1-5c995ece1515">2.75</ix:nonFraction>%&#160;(representing an interest rate of&#160;<ix:nonFraction unitRef="number" contextRef="i1e981a44ed99406590f2ed76af33aa59_I20180331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzU4ODY_ba6c0a5e-942c-46da-8478-8d5997ea769a">3.3</ix:nonFraction>%&#160;at March 31, 2018).&#160;&#160;In addition, a fee of&#160;<ix:nonFraction unitRef="number" contextRef="ifb8bca4936ff40e2b30ed5d20dc32c4f_D20170731-20170731" decimals="4" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzNjY_847745fb-6675-43e3-accd-e0f60cda60bf">0.25</ix:nonFraction>%&#160;per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. &#160;</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Under the Pinnacle Agreement, Cumberland is subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.&#160; The Company achieved compliance with the Funded Debt Ratio covenant as of&#160;March 31, 2018&#160;through the utilization of the covenant cure section of the agreement.</span></div></ix:continuation><div id="i_0_179"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(7) <ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNzkvZnJhZzpkOWEyNjI5OGUyNzY0OGQ2YmQxOGExYTdkNDM0ZWMzNy90ZXh0cmVnaW9uOmQ5YTI2Mjk4ZTI3NjQ4ZDZiZDE4YTFhN2Q0MzRlYzM3XzEwOTk1MTE2MzczMDQ_ff147858-c9d0-4caf-beba-ebed9f03617b" continuedAt="i0506b6e45a22435b854e41e64803a966" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i0506b6e45a22435b854e41e64803a966" continuedAt="idcad6bae1621406ebdf9bae1dcb51568"><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#8220;the Tax Act&#8221;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to&#160;21% (2) eliminating the corporate alternative minimum tax ("AMT") and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The SEC staff issued Staff Accounting Bulletin (&#8220;SAB&#8221;) 118 which provides guidance for the tax effects of the Tax Act.  SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.  In accordance with SAB 118, a company must reflect the income tax effects of those </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">10</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Notes to Condensed Consolidated Financial Statements - continued</span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(Unaudited)</span></div><div><span><br/></span></div></div><ix:continuation id="idcad6bae1621406ebdf9bae1dcb51568"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">aspects of the Tax Act for which the accounting under ASC 740 is complete.  To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements.  If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In connection with our analysis of the impact of the Tax Act, we have a net tax benefit of&#160;$<ix:nonFraction unitRef="usd" contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNzkvZnJhZzpkOWEyNjI5OGUyNzY0OGQ2YmQxOGExYTdkNDM0ZWMzNy90ZXh0cmVnaW9uOmQ5YTI2Mjk4ZTI3NjQ4ZDZiZDE4YTFhN2Q0MzRlYzM3Xzg3OTYwOTMwMzg2Mjg_9f39563b-b512-46c5-9ceb-3a871779c001">0.1</ix:nonFraction> million of March&#160;31, 2018.  This net tax benefit consists entirely of the release of the valuation allowance against AMT credits that will be realizable under the Tax Act in future periods. While the Company does not expect to record further amounts related to the Tax Act, we will continue to evaluate additional guidance as it is released by the Internal Revenue Service and will record additional amounts if needed.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;"><span><br/></span></div><div id="i_0_192"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(8) <ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xOTIvZnJhZzpmZjQxMTY2MDZkZjc0ZWYyOTdmMTc3MmIxMDI3ZDZlNC90ZXh0cmVnaW9uOmZmNDExNjYwNmRmNzRlZjI5N2YxNzcyYjEwMjdkNmU0XzIxOTkwMjMyNTc3MDM_a21177b2-79f0-404b-ab43-2495283480c9" continuedAt="i08502294f25b43debb4b638b62f8b6ca" escape="true">COLLABORATIVE AGREEMENTS</ix:nonNumeric></span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"><ix:continuation id="i08502294f25b43debb4b638b62f8b6ca">Cumberland is a party to several collaborative arrangements with certain research institutions to identify and pursue promising pre-clinical pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, Collaborative Agreements. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or Federal Small Business Administration (SBIR/STTR) grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from private sector investments and grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).</ix:continuation></span></div><div style="line-height:120%;text-align:justify;"><span><br/></span></div><div id="i_0_205"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">(9) <ix:nonNumeric contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18yMDUvZnJhZzowZGJhOTMwOGU4MDE0M2Y0OGVjMWE4OTBmYjI5Njg4Zi90ZXh0cmVnaW9uOjBkYmE5MzA4ZTgwMTQzZjQ4ZWMxYTg5MGZiMjk2ODhmXzIxOTkwMjMyNjA4ODY_37f2a2e6-ff7e-4111-9577-26976f248a95" continuedAt="ica7e6249d3364c26b3ec4608ad52f2d8" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ica7e6249d3364c26b3ec4608ad52f2d8"><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Legal Matters</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company developed a new formulation of Acetadote (acetylcysteine) Injection as part of the Phase IV commitment in response to a request by the FDA regarding the role of EDTA in the product's formulation.  The Company has received several patents from the United States Patent and Trademark Office ("USPTO") since 2012 as well as notices that its Acetadote patents are being challenged on the basis of invalidity or non-infringement by others.&#160; </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">During the third quarter of 2015, an arbitrator issued a final award in the Company&#8217;s favor, enjoining Mylan Pharma Group Limited and Mylan Teoranta, together with all their affiliates (&#8220;Mylan&#8221;), from selling, delivering, or giving away any acetylcysteine injectable drug product to another entity or person until April 30, 2018.  The arbitration request was filed with the American Arbitration Association for claims against Mylan in connection with agreements which require that Mylan manufacture and supply acetylcysteine drug product, including Acetadote, for us exclusively until April 2016. As the prevailing party, the Company received reimbursement of its attorney&#8217;s fees and related costs associated with the arbitration.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">During the third quarter of 2015, the United States District Court for the Northern District of Illinois, Eastern Division ("District Court") ruled in the Company&#8217;s favor in its lawsuit against Mylan for infringement of its U.S. Patent number 8,399,445 (the &#8220;445 Acetadote Patent&#8221;).  The opinion upheld&#160;our 445 Acetadote Patent and expressly rejected Mylan's validity challenge. &#160; The District Court ruled&#160;that Mylan is liable to us for infringement of the 445 Acetadote patent in light of Mylan's&#160;Abbreviated New Drug Application in which Mylan sought to market a generic version of Acetadote.  On November 17, 2015, the District Court entered an order enjoining Mylan and its affiliates from selling or using its generic version of Acetadote until August 2025, the date of expiration of the 445 Acetadote Patent. On October 30, 2015, Mylan filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the "Appeals Court").</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">On January 26, 2017, the Appeals Court affirmed the District Court ruling in the Company's favor in its lawsuit against Mylan for infringement of the 445 Acetadote Patent. The Appeals Court opinion affirmed the District Court&#8217;s ruling upholding Cumberland's 445 Acetadote Patent and expressly rejected Mylan's validity challenge. Additional information on these developments is included in Part 1, Item 3, Legal Proceedings in our Annual Report on Form 10-K for the year ended December 31, 2017.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;"><span><br/></span></div><div id="i_0_232"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;"></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">11</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:43pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The following discussion contains certain forward-looking statements which reflect management&#8217;s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution you that our actual results may differ significantly from the results we discuss in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital required to finance the business model; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; and management of our growth and integration of our acquisitions. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2017 (&#8220;2017 Annual Report on Form 10-K&#8221;).  We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management&#8217;s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.</span></div><div style="line-height:120%;text-align:justify;"><span><br/></span></div><div id="i_0_243"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">OVERVIEW</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Our Business</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Our primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  We promote our approved products through our hospital and gastroenterology sales forces in the United States and are establishing a network of international partners to bring our products to patients in their countries.</span></div><div style="text-indent:18pt;line-height:174%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:174%;vertical-align:bottom;">Our portfolio of FDA approved brands includes:</span></div><div><span><br/></span></div><ul style="list-style-type:disc;list-style-position: inside;"><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Acetadote</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-weight:700;vertical-align:bottom;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;vertical-align:bottom;">acetylcysteine</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">) Injection, for the treatment of acetaminophen poisoning;</span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Caldolor</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-weight:700;vertical-align:bottom;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;vertical-align:bottom;">ibuprofen</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">) Injection, for the treatment of pain and fever;</span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Kristalose</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-weight:700;vertical-align:bottom;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;vertical-align:bottom;">lactulose</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;</span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Omeclamox</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-weight:700;vertical-align:bottom;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">-Pak</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">, (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;vertical-align:bottom;">omeprazole, clarithromycin, amoxicillin</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">) for the treatment of Helicobacter pylori (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;vertical-align:bottom;">H. pylori</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">) infection and related duodenal ulcer disease;</span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Vaprisol</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-weight:700;vertical-align:bottom;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;vertical-align:bottom;">conivaptan</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;&#160;</span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Ethyol</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-weight:700;vertical-align:bottom;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;vertical-align:bottom;"> (amifostine) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">Injection, for the reduction of xerostomia (dry mouth) in patients undergoing post-operative radiation treatment for head and neck cancer, and the renal toxicity associated with the administration of cisplatin in patients with advanced ovarian cancer; and</span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Totect</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-weight:700;vertical-align:bottom;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;vertical-align:bottom;">(dexrazoxane hydrochloride) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">Injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy in case of extravasation (drug leakage from the bloodstream into the tissues).</span></li></ul><div><span><br/></span></div><div style="text-indent:18pt;line-height:120%;"><span><br/></span></div><div style="text-indent:18pt;line-height:120%;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">12</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:43pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:18pt;line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Our pipeline of product candidates includes:</span></div><div><span><br/></span></div><ul style="list-style-type:disc;list-style-position: inside;"><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Hepatoren</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-weight:700;vertical-align:bottom;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;vertical-align:bottom;">ifetroban</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">) Injection, a Phase II candidate for the treatment of critically ill patients suffering from liver and kidney failure associated with hepatorenal syndrome (&#8220;HRS&#8221;);&#160;</span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Boxaban</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-weight:700;vertical-align:bottom;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;vertical-align:bottom;">(ifetroban) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">Oral Capsules, a Phase II candidate for the treatment of asthma patients with aspirin-exacerbated respiratory disease ("AERD");&#160;</span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Vasculan</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-weight:700;vertical-align:bottom;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;vertical-align:bottom;">(ifetroban) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">Oral Capsules, a Phase II candidate for the treatment of patients with the systemic sclerosis ("SSc") form of autoimmune disease;</span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Portaban</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-weight:700;vertical-align:bottom;vertical-align:top;">&#174; </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;vertical-align:bottom;">(ifetroban) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">Injection and Oral Capsules, a Phase II candidate for the treatment of patients with portal hypertension associated with liver disease; and</span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:100%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">RediTrex</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-weight:700;vertical-align:bottom;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;vertical-align:bottom;">methotrexate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">) Injection, an approval submission candidate for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as severe disabling psoriasis.</span></li></ul><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">We have both product development and commercial capabilities, and believe we can leverage our existing infrastructure to support our expected growth. Cumberland's management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales, marketing and finance. Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion opportunities. Cumberland's product development team creates proprietary product formulations, manages our clinical studies, prepares all regulatory submissions and manages our medical call center. The Company's quality and manufacturing professionals oversee the manufacture, release, and shipment of our products. Our marketing and sales professionals are responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Growth Strategy</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Our growth strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of differentiated products. We currently market seven FDA approved products for sale in the United States.  Through our international partners, we are working to bring our products to patients in their countries. We also look for opportunities to expand our products into additional patient populations through clinical trials, new indications, and select investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates to address unmet medical needs.  Further, we are supplementing these activities with the pipeline drug development activities at Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary. Specifically, we are seeking long term sustainable growth by executing the following plans:</span></div><ul style="list-style-type:disc;list-style-position: inside;"><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Support and expand the use of our marketed products. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;"> We continue to evaluate our products following their FDA approval to determine if further clinical work could expand the potential market opportunities.  We will continue to explore opportunities for label expansion to bring our products to new patient populations.  The Caldolor pediatric approval reflects our successful implementation of this strategy.  </span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Selectively add complementary brands.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;"> In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA approved drugs as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure.  Our acquisitions of the product rights to Ethyol and Totect in the U.S. represent recent examples of our execution of this strategy.</span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Progress clinical pipeline and incubate future product opportunities at CET.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">  We believe it is important to build a pipeline of innovative new product opportunities. Our ifetroban Phase II development programs represent the implementation of this strategy.  At CET, we are supplementing our acquisition and late-stage development activities with the early-stage drug development activities. CET partners with universities and other research organizations to develop promising, early-stage product candidates, and Cumberland has the opportunity to negotiate rights to further develop and commercialize them in the U.S and other markets.</span></li></ul><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span><br/></span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span><br/></span></div><ul style="list-style-type:disc;list-style-position: inside;"><li style="list-style:none;line-height:120%;"></li><li style="list-style:none;line-height:120%;"></li><li style="list-style:none;line-height:120%;"></li><li style="list-style:none;"></li></ul><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">13</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:43pt;width:100%;"><div><span><br/></span></div></div><ul style="list-style-type:disc;list-style-position: inside;"><li style="list-style:none;line-height:120%;"></li><li style="list-style:none;line-height:120%;"></li><li style="list-style:none;line-height:120%;"></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Leverage our infrastructure through co-promotion partnerships.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;"> We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic partners that can accentuate our operational effectiveness and maximize the opportunity for our brands. Our recent co-promotion partnership with Poly Pharmaceuticals, Inc. allows us to expand current promotional support for Kristalose across the United States.</span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Continue to build the international contribution to our business.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">  We have established our own commercial capabilities, including two sales divisions to cover the U.S. market for our products.  We are also building a network of select international partners to register our products and make them available to patients in their countries.  We will continue to expand our network of international partners and continue to support our partners&#8217; registration and commercialization efforts in their respective territories.</span></li><li style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;vertical-align:bottom;">Continue to manage our operations with financial discipline.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;vertical-align:bottom;">  We continually work to manage our expenses in line with our revenues in order to deliver positive cash flow from operations. We remain in a strong financial position, with high margins, and a strong balance sheet. </span></li></ul><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Cumberland was incorporated in 1999 and has been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common stock and listing on the NASDAQ exchange. Our website address is www.cumberlandpharma.com. We make available through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all other material press releases, filings and amendments to those reports as soon as reasonably practicable after their filing with the SEC. These filings are also available to the public at&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">www.sec.gov.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="line-height:174%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;vertical-align:bottom;">RECENT DEVELOPMENTS</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Shelf Registration</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At-The-Market ("ATM") feature enabling the Company to sell common shares at market prices, along with an agreement with B. Riley FBR to support such a placement of shares.</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">GEL Agreement&#160;</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">In March 2018, we reached agreement with Gastro-Entero-Logic LLC ("GEL"), to acquire the assets associated with Omeclamox-Pak including the product&#8217;s FDA approved New Drug Application, trademarks and other assets. As a result of this acquisition we will no longer be obligated to provide GEL with royalty or fees for overseeing the product&#8217;s manufacturing. As part of this transaction, we will become responsible for maintaining the FDA approval and for overseeing the product&#8217;s packaging. </span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">New CET Collaboration Agreements</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;vertical-align:bottom;">At CET, we are working with a select group of academic research institutions located in the mid-south region of the U.S. These relationships enable CET to identify therapeutic compounds addressing poorly met medical needs and partner with university-based researchers to advance their scientific discoveries through pre-clinical development.  CET contributes product design and development support services to help our collaborators bridge the gap between discovery and clinical investigation.  </span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;vertical-align:bottom;">In February 2018, CET and Louisiana State University entered into an agreement, adding to CET&#8217;s roster of academic collaborations which also includes Vanderbilt University, the University of Mississippi, and the University of Tennessee Research Foundation. These partnerships combine the strengths and capabilities of each organization by working together to identify, formulate, and develop attractive new biomedical products.</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Ethyol Study Publication</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;vertical-align:bottom;">In January 2018, the Company announced a new publication in&#160;Leukemia &amp; Lymphoma, with study results showing that amifostine decreases gastro-intestinal (GI) toxicity in patients who receive treatment for their multiple myeloma. Cumberland markets branded amifostine in the&#160;U.S.&#160;under the name Ethyol.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;"></span></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">14</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:43pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Omeclamox-Pak Study Publication</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;vertical-align:bottom;">In March 2018, the Company announced a publication of an open access article in&#160;Infection and Drug Resistance, with results demonstrating an 85% eradication rate of Helicobacter pylori (H. pylori) infection using clarithromycin-based triple therapy. Cumberland markets a branded clarithromycin-based triple therapy in the&#160;U.S.&#160;under the name Omeclamox-Pak.</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Caldolor</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;vertical-align:bottom;">During the first quarter, the Company completed and filed the application for FDA approval of its Next Generation Caldolor product featuring an improved package and formulation.  Cumberland continued to advance its study of Caldolor in patients ranging from newborn to six months of age. The Company also learned that Caldolor was approved for sale in India during the first quarter. Cumberland is preparing for the launch of the brand with its partner for that market.</span></div><div style="line-height:120%;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">RediTrex Approval Submission</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;vertical-align:bottom;">We also held a meeting with the FDA during 2017 to discuss the approval pathway for our injectable methotrexate products in the United States. As a result, we are now gathering the relevant information and preparing the submission for that approval during 2018.</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Ifetroban Phase II Studies</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;vertical-align:bottom;">In early 2017, the FDA cleared Cumberland&#8217;s investigational new drug (&#8220;IND&#8221;) application for Boxaban - the Company&#8217;s AERD clinical program. Following this clearance, we initiated a follow-on multicenter Phase II efficacy study to evaluate the efficacy of Boxaban in seventy-six patients with symptomatic AERD. Enrollment in this multi-center, placebo controlled study is now underway at a growing number of allergy and asthma centers across the United States. We also continued to advance our Vasculan and Portaban clinical pipeline programs, with patient enrollment progressing in each of those Phase II studies.</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">New Hospital Product Candidate</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;vertical-align:bottom;">Cumberland was responsible for the formulation, development and FDA approval of both Acetadote and Caldolor. Our Medical Advisory Board has helped us identify additional opportunities that address unmet or poorly met medical needs. As a result, Cumberland has successfully designed, formulated and completed the preclinical studies for a cholesterol reducing agent for use in the hospital setting. During 2017, we completed a Phase I study which defined the pharmacokinetic properties and provided a favorable safety profile for this new product candidate. The study results and a proposed clinical development plan were discussed with the FDA and, as a result, a Phase II study is being designed.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;vertical-align:bottom;">COMPETITION</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The pharmaceutical industry is characterized by intense competition and rapid innovation. Our continued success in developing and commercializing pharmaceutical products will depend, in part, upon our ability to compete against existing and future products in our target markets. For more information see Part 1, Item 1, Business-Competitors in our Annual Report on Form 10-K for the year ended December 31, 2017 which is incorporated by reference and has been updated as follows:</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;vertical-align:bottom;">Ethyol</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-weight:700;line-height:120%;vertical-align:bottom;vertical-align:top;">&#174;</sup></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Ethyol is our patented, branded amifostine product indicated to reduce xerostomia (dry mouth) as a side-effect in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.  We launched the product in late 2016, and the authorized generic form of the product was withdrawn by Clinigen who markets branded Ethyol internationally. We have an exclusive license to promote, sell and distribute Ethyol in the United States, under various patents. There are several Ethyol patents associated with the subcutaneous administration of the product that are not yet Orange Book listed. In July 2017, Mylan Laboratories Ltd. (&#8220;Mylan&#8221;) received approval for an Abbreviated New Drug Application for a generic amifostine product. Sun Pharmaceuticals Industries Limited (&#8220;Sun&#8221;) had also previously received approval for a generic amifostine product. Both the Mylan and Sun approvals appear to be only for the ovarian cancer indication but not the xerostomia indication. Therefore, we believe that Ethyol is currently the only amifostine product with FDA approval for both the xerostomia and ovarian cancer indications.</span></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;vertical-align:bottom;">Totect</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;font-style:italic;font-weight:700;line-height:120%;vertical-align:bottom;vertical-align:top;">&#174;</sup></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Totect is our patented, branded dexrazoxane injection product indicated for the treatment of the extravasation associated with anthracycline chemotherapy. We have an exclusive license to promote, sell and distribute Totect in the United States, under U.S. Patent number 6,727,253 which has claims directed to methods of preventing or treating local tissue damage in patients receiving topoisomerase II poison. This Totect patent is listed in the FDA Orange Book and is scheduled to expire in March </span></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">15</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:43pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;text-align:justify;margin-top:8pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">2020. Pfizer Inc.&#8217;s Zinecard&#174; brand is a dexrazoxane product with FDA approval for a different indication - the cardiac complications associated with certain chemotherapeutic agents. Mylan, Gland Pharma Ltd and West-Ward Pharmaceuticals Corp have previously received FDA approval for a generic dexrazoxane with the Zinecard cardiac protection indication. When we launched Totect, the FDA reported a national dexrazoxane shortage with both the Pfizer and Mylan products unavailable. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Following our launch, supplies of dexrazoxane became available from Mylan, Pfizer, and two approved generic suppliers, all with labeling for the cardiac indication. Totect is the only dexrazoxane available in the U.S. FDA approved for the extravasation indication.</span></div><div><span><br/></span></div><div style="line-height:120%;text-align:justify;"><span><br/></span></div><div id="i_0_254"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Please see a discussion of our critical accounting policies and significant judgments and estimates in the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2017 Annual Report on Form 10-K.</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Accounting Estimates and Judgments</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, fair value of marketable securities, inventories, provision for income taxes, share-based compensation, research and development expenses and intangible assets.</span></div><div id="i_0_265"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;vertical-align:bottom;">Three months ended March 31, 2018</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;vertical-align:bottom;">compared to the&#160;three months ended March 31, 2017</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The following table presents the unaudited interim statements of operations for the&#160;three months ended March 31, 2018&#160;and&#160;2017:</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:47.557522%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.634218%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.076696%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.519174%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,&#160;</span></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net revenues&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">8,587,605&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">9,636,755&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(1,049,150)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Cost of products sold&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,527,961&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,381,497&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">146,464&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">4,670,511&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">5,293,020&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(622,509)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Research and development&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,874,939&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">898,363&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">976,576&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">General and administrative&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,330,281&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,110,233&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">220,048&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Amortization&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">636,135&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">611,444&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">24,691&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">11,039,827&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">10,294,557&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">745,270&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(2,452,222)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(657,802)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(1,794,420)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Interest income&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">82,494&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">52,535&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">29,959&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Interest expense&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(18,302)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(31,715)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">13,413&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(2,388,030)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(636,982)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(1,751,048)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(4,159)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(656,587)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">652,428&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(2,392,189)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(1,293,569)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(1,098,620)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">16</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:43pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The following table summarizes net revenues by product for the periods presented:&#160;</span></div><div style="line-height:120%;text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.906433%;"><tr><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.158537%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.562195%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.158537%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.562195%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.158537%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Products:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Acetadote&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,273,764&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,265,440&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">8,324&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">141,392&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">645,325&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(503,933)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Kristalose&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,269,901&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,386,591&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">883,310&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Vaprisol&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">93,890&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">684,548&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(590,658)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Caldolor&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,039,747&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">813,027&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">226,720&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Ethyol&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,256,073&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,666,808&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(1,410,735)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Totect&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">412,774&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">412,774&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Other&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">100,064&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">175,016&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(74,952)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total net revenues&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">8,587,605&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">9,636,755&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(1,049,150)</span></td></tr></table></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Net revenues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"> Net revenues for the three months ended March 31, 2018 were $8.6 million compared to $9.6 million for the three months ended March 31, 2017, representing a decrease of $1.0 million, or 10.9%.  As detailed in the table above, four of our seven marketed products experienced increases in net revenue: Acetadote, Kristalose, Caldolor and Totect.  These increases partially offset the revenue decreases that were attributed primarily to Ethyol and Vaprisol.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Kristalose revenue increased by $0.9 million primarily as a result of increased sales volume during the three months ended March 31, 2018. The product's 37.0% increase in net revenue was also partially attributable to a modest improvement in net pricing during the period. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The Company began shipments of Totect in July of 2017, resulting in $0.4 million in sales during the three months ended March 31, 2018. The 2017 launch of Totect was positively impacted by a national shortage of dexrazoxane, resulting in strong initial demand for the product.  Following our launch, supplies of dexrazoxane became available from competing suppliers, all with labeling for the cardiac indication. Totect is the only dexrazoxane available in the U.S. FDA approved for the extravasation indication.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Caldolor revenue experienced an increase of $0.2 million during the three months ended March 31, 2018 compared to the same period last year.  This 27.9% increase in revenue in the three months ended March 31, 2018 primarily resulted from an increase in domestic and international shipments and also impacted by a modest increase in pricing.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Acetadote revenue included net sales of our branded product and our share of net sales from our Authorized Generic. During the three months ended March 31, 2018 the Acetadote net revenue grew 1% as a result of increased sales volumes.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Ethyol revenue for the three months ended March 31, 2018 was $2.3 million, which is a decrease of $1.4 million from the three months ended March 31, 2017. The decrease was primarily the result of lower sales volume when compared to the prior year period, when wholesalers began to increase their inventory to meet hospital demand.  The Ethyol shipments for the three months ended March 31, 2018 are consistent with the quarterly shipments experienced during the second half of 2017.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Vaprisol revenue decreased $0.6 million during the three months ended March 31, 2018 compared to the prior year period primarily due to decreased sales volume. We experienced decreased sales volume during the three months ended March 31, 2018 as the manufacturer was temporarily unable to provide requested supplies of Vaprisol which led to limited inventory and sales of the product.  During April 2018, the Vaprisol inventory supply issue was resolved as we received new shipments from our manufacturer. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Omeclamox-Pak revenue decreased $0.5 million during the three months ended March 31, 2018 compared to the prior year.  The decrease was primarily the result of lower sales volume and higher expired product sales returns. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;"></span></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">17</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:43pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Cost of products sold.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">  Cost of products sold for the three months ended March 31, 2018 were $1.5 million, compared to $1.4 million for the same period last year, representing an increase of approximately $0.1 million, or 10.6%.  Cost of products sold, as a percentage of net revenues were 17.8% compared to 14.3% during the prior year. The increase in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix during the period compared to the prior year. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Selling and marketing.  Selling and marketing expenses for the three months ended March 31, 2018 were $4.7 million, compared to $5.3 million for the prior year period, representing a decrease of approximately $0.6 million. This decrease was primarily the result of decreased royalties related to decreased product sales as well as lower promotional spending for the three months ended March 31, 2018. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Research and development.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">  Research and development costs for the three months ended March 31, 2018 were $1.9 million, compared to $0.9 million for the same period last year, representing an increase of approximately $1.0 million. A portion of our research and development costs are variable based on the number of trials, study sites and patients involved in the development of our product candidates. The increase was primarily the result of additional investment in our ongoing clinical initiatives associated with our pipeline products as well as increases in our FDA fees.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">General and administrative.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">  General and administrative expenses were $2.3 million for the three months ended March 31, 2018, compared to $2.1 million during the same period last year.  The $0.2 million increase from the prior year was primarily driven by increases an increase in compensation and benefits, including non-cash stock based compensation.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Amortization.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">  Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the three months ended March 31, 2018 totaled approximately $0.6 million, which was an increase of $0.02 million over the prior year. The increase in amortization was attributable to additional product and license rights and capitalized patents.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Income taxes. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"> Income tax expense for the three months ended March 31, 2018 totaled $4,159 compared to $656,587 in the three months ended March 31, 2017.  As a percentage of income (loss) before income taxes, income taxes were 0.2% for the three months ended March 31, 2018 compared to 103.1% for the three months ended March 31, 2017.  The effective tax rate for the three months ended March 31, 2017 was primarily impacted by a valuation allowance of $1.0 million for our federal Orphan Drug and Research and Development tax credits.  The additional valuation allowance was the result of our adoption of the FASB guidance on stock based compensation and our continued evaluation of our utilization of net operating loss carryforwards, including updates to our forecasts of future taxable income.  These non-cash valuation allowance adjustments impacted our effective tax rate during the three months ended March 31, 2017.  </span></div><div><span><br/></span></div><div id="i_0_276"></div><div style="text-align:justify;"><span><br/></span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Working Capital</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Our primary sources of liquidity are cash flows provided by our operations, the availability under our line of credit and the cash proceeds from our initial public offering of common stock that was completed in August 2009. We believe that our internally generated cash flows and our line of credit will be adequate to finance internal growth and fund capital expenditures for the foreseeable future. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">We invest a portion of our cash reserves in marketable securities including short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency notes and bonds, corporate bonds, and other marketable securities.&#160; At&#160;March 31, 2018&#160;and&#160;December 31, 2017, we had approximately&#160;$15.6 million&#160;and&#160;$4.7 million, respectively, invested in marketable securities.</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The following table summarizes our liquidity and working capital as of&#160;March 31, 2018&#160;and December 31, 2017:</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099415%;"><tr><td style="width:1.0%;"></td><td style="width:56.718331%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.268256%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.545156%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.268256%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">March 31, 2018&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017&#160;</span></td></tr><tr><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">35,262,976&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">45,412,868&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Marketable securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">15,610,105&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">4,672,476&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and marketable securities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">50,873,081&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">50,085,344&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Working capital (current assets less current liabilities)&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">50,533,316&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">50,990,102&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Current ratio (multiple of current assets to current liabilities)&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">4.1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3.9&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Revolving line of credit availability&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,200,000&#160;</span></td></tr></table></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">18</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:43pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The following table summarizes our net changes in cash and cash equivalents for the three months ended&#160;March 31, 2018&#160;and&#160;March&#160;31, 2017:</span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:64.275660%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.422287%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.568915%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:16pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in):&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Operating activities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">235,589&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,439,371&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Investing activities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(11,522,126)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(429,535)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Financing activities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,136,645&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(545,924)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(10,149,892)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">463,912&#160;</span></td></tr></table></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The net $10.1 million decrease in cash and cash equivalents for the three months ended March&#160;31, 2018 was attributable to cash used in investing activities partially offset by cash provided by financing and operating activities.  Cash provided by operating activities of $0.2 million was primarily impacted by changes in our working capital which provided net cash of $1.6 million, including net collections of accounts receivable of $2.1 million and non-cash expenses of depreciation and amortization and share-based compensation expense totaling $1.0 million. The generation of operating cash was offset by a net loss for the period of $2.4 million. Cash used in investing activities included net cash investment in marketable securities of $10.9 million and additions to intangibles of $0.5 million.  Our financing activities included $2.2 million in net cash provided by borrowings under our line of credit offset by $1.0 million in cash used to repurchase shares of our common stock. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The net $0.5 million increase in cash and cash equivalents for the three months ended March 31, 2017 was attributable to cash provided by operating activities offset by cash used in investing and financing activities.  Cash provided by operating activities of $1.4 million was primarily impacted by changes in our working capital of $1.1 million, including a decrease in accounts receivable of $2.4 million and non-cash expenses of depreciation and amortization and share-based compensation expense totaling $0.9 million. These were offset by net reductions in accounts payable and accrued liabilities of $1.2 million.  Cash provided by operating activities also includes the net loss for the period of $1.3 million.  Cash used by investing activities included a net cash investment in our intangible assets of $0.5 million.  Our financing activities included $0.5 million in cash used to repurchase shares of our common stock.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;vertical-align:bottom;">Debt Agreement</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">On July&#160;31, 2017, we entered into a Revolving Credit Loan Agreement with Pinnacle Bank (the "Pinnacle Agreement").  The new agreement replaced the June 2014 Revolving Credit Loan Agreement with SunTrust Bank which was to expire on June 30, 2018.  The Company had $12 million in borrowings under that agreement at March&#160;31, 2018. The Pinnacle Agreement provides for an aggregate principal amount of up to $20 million and has a three-year term expiring on July 31, 2020.  The initial revolving line of credit is up to $12 million with the ability to increase the borrowing amount up to $20 million, upon the satisfaction of certain conditions. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 3.3% at March&#160;31, 2018).&#160;In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets.  </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Under the Pinnacle Agreement, we are subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  We achieved compliance with the Funded Debt Ratio covenant as of March&#160;31, 2018 through the utilization of the covenant cure section of the agreement.&#160;We expect to maintain compliance with this covenant in future periods, including the use of the covenant cure section of the agreement.  </span></div><div><span><br/></span></div><div id="i_0_287"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">During the&#160;three months ended&#160;March 31, 2018&#160;and&#160;2017, we did not engage in any off-balance sheet arrangements.</span></div><div id="i_0_298"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Interest Rate Risk</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. </span></div><div><span style="color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"></span></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">19</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:43pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts. Based on the $15.6 million in marketable securities outstanding at March&#160;31, 2018, a 1% decrease in the fair value of the securities would result in a reduction in pretax net income (loss) of $0.2 million.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Based on current interest rates, we do not believe we are exposed to significant downside risk related to change in interest on our investment accounts.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The interest rate risk related to borrowings under our line of credit is based on  LIBOR plus an interest rate spread.  There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 3.3% at March&#160;31, 2018). As of March&#160;31, 2018, we had $12.0 million in borrowings outstanding under our revolving credit facility. </span></div><div><span><br/></span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Exchange Rate Risk</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">While we operate primarily in the United States, we are exposed to foreign currency risk.  Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations.  We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice.  Foreign currency exchange gains and losses were immaterial for the three months ended March&#160;31, 2018 and 2017.  Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.</span></div><div id="i_0_309"></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Item&#160;4. Controls and Procedures</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">We maintain disclosure controls and procedures that are designed with the objective of providing reasonable assurance that information required to be disclosed in our reports filed or submitted to the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of March&#160;31, 2018. Based on that evaluation, our CEO and CFO concluded that, our disclosure controls and procedures are considered effective to ensure that material information relating to us and our consolidated subsidiaries is made known to officers in order to allow for timely decisions regarding required disclosure.  </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">During the three months ended March&#160;31, 2018, there has not been any change in our internal control over financial reporting that has materially affected, or is likely to materially affect, our internal control over financial reporting. </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i_0_321"></div><div style="line-height:120%;text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">20</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:43pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;text-align:center;"><span><br/></span></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">PART II &#8211; OTHER INFORMATION</span></div><div id="i_0_332"></div><div style="line-height:120%;margin-top:14pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Item&#160;1. Legal Proceedings</span></div><div style="line-height:120%;text-align:justify;margin-top:5pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">See the discussion of our Acetadote patent defense legal proceedings contained in Note 7 - Commitments and Contingencies - Legal Matters in the accompanying condensed consolidated financial statements and in the section entitled &#8220;Business - Patents, Trademarks and Other Intellectual Proprietary Rights&#8221;, of our 2017 Annual Report on Form 10-K, which is incorporated by reference herein.</span></div><div id="i_0_343"></div><div style="line-height:120%;margin-top:12pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Item&#160;1A. Risk Factors</span></div><div style="line-height:120%;text-align:justify;margin-top:5pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Information regarding risk factors appears in the 2017 Annual Report on Form 10-K under the section titled "Risk Factors."</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">&#160;</span></div><div id="i_0_354"></div><div style="line-height:120%;margin-top:12pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="line-height:120%;margin-top:5pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Purchases of Equity Securities</span></div><div style="line-height:120%;text-align:justify;margin-top:5pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">We currently have a share repurchase program to purchase up to&#160;$10 million&#160;of our common stock pursuant to Rule 10b-18 of the Securities Exchange Act. In January 2016, our Board of Directors established the current&#160;$10 million&#160;repurchase program to replace the prior authorizations for repurchases of our outstanding common stock. &#160;</span></div><div style="line-height:120%;margin-top:5pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The following table summarizes the activity, by month, during the three months ended March 31, 2018:</span></div><div style="line-height:120%;margin-top:5pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">&#160;</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807018%;"><tr><td style="width:1.0%;"></td><td style="width:17.282511%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.282511%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.736921%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.050822%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.547384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.282511%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.547384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.869955%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Period&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Total</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Number&#160;of</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Shares (or</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Units)</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Purchased (1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Average</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Price&#160;Paid</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">per&#160;Share</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">(or Unit)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Total&#160;Number&#160;of</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Shares (or Units)</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Purchased&#160;as&#160;Part</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">of Publicly</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Announced Plans</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">or Programs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Maximum&#160;Number</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">(or Approximate</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Dollar Value) of</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Shares&#160;(or&#160;Units)</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">that May Yet Be</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">Purchased&#160;Under</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">the Plans or</span></div><div style="line-height:100%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;vertical-align:bottom;">        Programs&#160;(1)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">January&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">58,023&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$7.08&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">58,023&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$3,426,680&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">February&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">29,487&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.97&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">29,487&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,221,153&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">March&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">84,569&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.84&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">84,569&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,642,393&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">172,079&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">172,079&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">(1) Shares repurchased by the Company under the share repurchase program established by our Board of Directors. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">(2) Of this amount, 60,094 shares were repurchased directly through private purchases at the then-current fair market value of common stock.</span></div><div><span><br/></span></div><div id="i_0_366"></div><div style="line-height:120%;margin-top:12pt;margin-bottom:0pt;-sec-extract:summary;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;"></span></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">21</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:43pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;margin-top:12pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Item&#160;6. Exhibits</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.929825%;"><tr><td style="width:1.0%;"></td><td style="width:10.368024%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.016591%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.615385%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">No.&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Description&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">31.1*&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;-sec-extract:exhibit;" href="q12018-exhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2*&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;-sec-extract:exhibit;" href="q12018-exhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1**&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;vertical-align:bottom;-sec-extract:exhibit;" href="q12018-exhibit321.htm">Certification of Chief Executive and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS*&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH*&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL*&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF*&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB*&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE*&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:27pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:27pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:27pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Filed herewith.&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">**&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Furnished herewith.&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div id="i_0_378"></div><div style="line-height:120%;text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">22</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:43pt;width:100%;"><div><span><br/></span></div></div><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">SIGNATURES</span></div><div style="line-height:120%;margin-top:9pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">&#160;</span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"></span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:34.510264%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.146041%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.692082%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.076246%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.105572%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.146041%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:33.923754%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Cumberland Pharmaceuticals Inc.&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">May 9, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">By:&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-style:italic;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">/s/ Michael Bonner&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="line-height:120%;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">23</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>q12018-exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1 Q1 2018
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2018 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="line-height:120%;text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Exhibit 31.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">1</font></div><div style="line-height:120%;text-align:center;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CERTIFICATION OF CHIEF EXECUTIVE OFFICE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">R</font></div><div style="line-height:120%;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">PURSUANT TO SECTION&#160;302 O</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">F</font></div><div style="line-height:120%;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">THE SARBANES-OXLEY ACT OF 200</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">2</font></div><div style="line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">I, A.J. Kazimi, certify that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#58;</font></div><div style="padding-left:18pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div><div style="padding-left:18pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#34;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;&#34;</font></div><div style="padding-left:18pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#34;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;&#34;</font></div><div style="padding-left:18pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:54pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:54pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">(b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:54pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">(c)   Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:54pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">(d)   Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:18pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#34;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:54pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">(</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">a</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:54pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">(</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">b</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:120%;vertical-align:bottom;"></font><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:49.395007%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.698972%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.443172%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.262849%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">May 9, 2018</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">By&#58;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-style:italic;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; A.J. Kazimi&#160;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">A.J. Kazimi&#160;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer&#160;</font></td></tr></table></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>q12018-exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2 Q1 2018
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2018 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="line-height:120%;text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Exhibit 31.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">2</font></div><div style="line-height:120%;text-align:center;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CERTIFICATION OF CHIEF FINANCIAL OFFICE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">R</font></div><div style="line-height:120%;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">PURSUANT TO SECTION&#160;302 O</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">F</font></div><div style="line-height:120%;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">THE SARBANES-OXLEY ACT OF 200</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">2</font></div><div style="line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">I, Michael Bonner, certify that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#58;</font></div><div style="padding-left:18pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div><div style="padding-left:18pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#34;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;&#34;</font></div><div style="padding-left:18pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#34;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;&#34;</font></div><div style="padding-left:18pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:54pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Designed</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;vertical-align:bottom;"> such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:54pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:54pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:54pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:18pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#34;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:54pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">(</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">a</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:54pt;line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">(</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">b</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="line-height:120%;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:12pt;line-height:120%;vertical-align:bottom;"></font><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:49.835536%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.258443%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.443172%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.262849%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">May 9, 2018</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">By&#58;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-style:italic;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michael Bonner&#160;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner&#160;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer&#160;</font></td></tr></table></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>q12018-exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1 Q1 2018
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2018 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:43pt;width:100%;"><div><font><br></font></div></div><div style="line-height:120%;text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">Exhibit 32.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">1</font></div><div style="line-height:120%;text-align:center;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CERTIFICATION OF CHIEF EXECUTIVE AN</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">D</font></div><div style="line-height:120%;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">CHIEF FINANCIAL OFFICE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">R</font></div><div style="line-height:120%;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">PURSUANT TO 18 U.S.C. SECTION&#160;1350</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">,</font></div><div style="line-height:120%;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">AS ADOPTED PURSUANT TO SECTION&#160;90</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">6</font></div><div style="line-height:120%;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">OF THE SARBANES-OXLEY ACT OF 200</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;vertical-align:bottom;">2</font></div><div style="line-height:120%;margin-top:9pt;margin-bottom:0pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">In connection with the Quarterly Report on Form&#160;10-Q for the fiscal quarter ended March&#160;31, 2018 of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer and Michael Bonner, Chief Financial Officer of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">&#58;</font></div><div style="line-height:120%;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:12pt;line-height:120%;vertical-align:bottom;"></font><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.902344%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and&#160;</font></td></tr></table></div><div style="line-height:120%;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:12pt;line-height:120%;vertical-align:bottom;"></font><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.902344%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#34;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.&#34;&#160;</font></td></tr></table></div><div style="line-height:120%;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">&#160;</font></div><div style="line-height:120%;text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:12pt;line-height:120%;vertical-align:bottom;"></font><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:38.964844%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-style:italic;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; A. J. Kazimi&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">A.J. Kazimi&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">May 9, 2018</font></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-style:italic;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michael Bonner&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">May 9, 2018</font></td></tr></table></div><div style="line-height:120%;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;vertical-align:bottom;">&#160;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cpix-20180331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:6f9d426d-7cdf-4d24-852c-1304a591467b,g:9b882308-6c8b-47b4-823c-512a5c520540-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:cpix="http://cumberlandpharma.com/20180331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:link="http://www.xbrl.org/2003/linkbase" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cumberlandpharma.com/20180331">
  <xs:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <xs:element id="cpix_DocumentAndEntityInformationAbstract" abstract="true" name="DocumentAndEntityInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_UsTreasuryNotesAndBondsSecuritiesDomain" abstract="false" name="UsTreasuryNotesAndBondsSecuritiesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_EthyolMember" abstract="true" name="EthyolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SunTrustBankMember" abstract="true" name="SunTrustBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_EquityAndDebtAbstract" abstract="true" name="EquityAndDebtAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_OtherLongTermObligationsExcludingCurrentPortion" abstract="false" name="OtherLongTermObligationsExcludingCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_GenericAcetadoteMember" abstract="true" name="GenericAcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LoanPoolsMember" abstract="false" name="LoanPoolsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_Denominator" abstract="true" name="Denominator" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ProductsAbstract" abstract="true" name="ProductsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ShareholdersEquityTextualAbstract" abstract="true" name="ShareholdersEquityTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInCurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_TotectMember" abstract="true" name="TotectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20180331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20180331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20180331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20180331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1002002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1003003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited">
        <link:definition>1004004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquityUnaudited" roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited">
        <link:definition>1006006 - Statement - Condensed Consolidated Statement of Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://cumberlandpharma.com/role/OrganizationandBasisofPresentation">
        <link:definition>2107101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2208201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationOrganizationDetails" roleURI="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails">
        <link:definition>2409401 - Disclosure - Organization and Basis of Presentation Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://cumberlandpharma.com/role/MarketableSecurities">
        <link:definition>2110102 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://cumberlandpharma.com/role/MarketableSecuritiesTables">
        <link:definition>2311301 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://cumberlandpharma.com/role/MarketableSecuritiesDetails">
        <link:definition>2412402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>2113103 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>2314302 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://cumberlandpharma.com/role/EarningsLossPerShareDetails">
        <link:definition>2415403 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTextualDetails" roleURI="http://cumberlandpharma.com/role/EarningsLossPerShareTextualDetails">
        <link:definition>2416404 - Disclosure - Earnings (Loss) Per Share - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://cumberlandpharma.com/role/Revenues">
        <link:definition>2117104 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://cumberlandpharma.com/role/RevenuesTables">
        <link:definition>2318303 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://cumberlandpharma.com/role/RevenuesDetails">
        <link:definition>2419405 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://cumberlandpharma.com/role/Inventories">
        <link:definition>2120105 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://cumberlandpharma.com/role/InventoriesTables">
        <link:definition>2321304 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://cumberlandpharma.com/role/InventoriesDetails">
        <link:definition>2422406 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTextualDetails" roleURI="http://cumberlandpharma.com/role/InventoriesTextualDetails">
        <link:definition>2423407 - Disclosure - Inventories - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebt" roleURI="http://cumberlandpharma.com/role/ShareholdersEquityandDebt">
        <link:definition>2424408 - Disclosure - Shareholders' Equity and Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtShareholdersEquityDetails" roleURI="http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails">
        <link:definition>2425409 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtDebtDetails" roleURI="http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails">
        <link:definition>2426410 - Disclosure - Shareholders' Equity and Debt - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>2127106 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTextualDetails" roleURI="http://cumberlandpharma.com/role/IncomeTaxesTextualDetails">
        <link:definition>2428411 - Disclosure - Income Taxes - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://cumberlandpharma.com/role/CollaborativeAgreements">
        <link:definition>2129107 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://cumberlandpharma.com/role/CommitmentsandContingencies">
        <link:definition>2130108 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cpix-20180331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:6f9d426d-7cdf-4d24-852c-1304a591467b,g:9b882308-6c8b-47b4-823c-512a5c520540-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="cpix-20180331.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e3d4b11e-66e5-4876-a225-9ede96cc2605" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dbc01168-79f7-4bda-ab50-e279d68b53ff" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e3d4b11e-66e5-4876-a225-9ede96cc2605" xlink:to="loc_us-gaap_StockholdersEquity_dbc01168-79f7-4bda-ab50-e279d68b53ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c70877a3-83ab-4912-8de7-1929d1f2ac26" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e3d4b11e-66e5-4876-a225-9ede96cc2605" xlink:to="loc_us-gaap_MinorityInterest_c70877a3-83ab-4912-8de7-1929d1f2ac26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f6e10ea-9ee3-4c54-9754-690406bdc676" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6dd639c2-7de2-4106-b61a-dcbdde9d1e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f6e10ea-9ee3-4c54-9754-690406bdc676" xlink:to="loc_us-gaap_Liabilities_6dd639c2-7de2-4106-b61a-dcbdde9d1e6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_93f4b11d-faa1-4232-8304-714a8ad355c6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f6e10ea-9ee3-4c54-9754-690406bdc676" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_93f4b11d-faa1-4232-8304-714a8ad355c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2a119ff6-439d-4abb-a390-2beb3d0f5595" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b5f5d44c-2d94-4409-9a19-14b2d04b8260" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a119ff6-439d-4abb-a390-2beb3d0f5595" xlink:to="loc_us-gaap_AssetsCurrent_b5f5d44c-2d94-4409-9a19-14b2d04b8260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_885bee7e-8448-4464-89b5-ceaf77b0f865" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a119ff6-439d-4abb-a390-2beb3d0f5595" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_885bee7e-8448-4464-89b5-ceaf77b0f865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4131891b-e990-4324-b2e5-0714962d9b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a119ff6-439d-4abb-a390-2beb3d0f5595" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4131891b-e990-4324-b2e5-0714962d9b8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d936d1e0-91c6-4249-967e-bae44dba5167" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a119ff6-439d-4abb-a390-2beb3d0f5595" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d936d1e0-91c6-4249-967e-bae44dba5167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_7ace97b5-97e7-4965-a393-e96d3763acc7" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a119ff6-439d-4abb-a390-2beb3d0f5595" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_7ace97b5-97e7-4965-a393-e96d3763acc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ae95a0dd-2d7e-48e9-ad54-994b745e8a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_52b01b02-3f00-4f58-8659-516f44f1e818" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ae95a0dd-2d7e-48e9-ad54-994b745e8a6a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_52b01b02-3f00-4f58-8659-516f44f1e818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_f066a7c7-c2b1-4761-bb63-d58be3cfc3c0" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ae95a0dd-2d7e-48e9-ad54-994b745e8a6a" xlink:to="loc_us-gaap_MarketableSecurities_f066a7c7-c2b1-4761-bb63-d58be3cfc3c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_40788921-91d2-43e7-9b07-e8b2485fd238" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ae95a0dd-2d7e-48e9-ad54-994b745e8a6a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_40788921-91d2-43e7-9b07-e8b2485fd238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_602dece3-6fca-4765-8ad4-b2c1f1d92a47" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ae95a0dd-2d7e-48e9-ad54-994b745e8a6a" xlink:to="loc_us-gaap_InventoryNet_602dece3-6fca-4765-8ad4-b2c1f1d92a47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_6e3e4eae-1d26-4dc2-a651-1ce8acc494d8" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ae95a0dd-2d7e-48e9-ad54-994b745e8a6a" xlink:to="loc_us-gaap_OtherAssetsCurrent_6e3e4eae-1d26-4dc2-a651-1ce8acc494d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a86dbd76-4caf-4b0e-a2b0-0e9c80944ffc" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2a4d8472-5b0a-487e-a01d-9fae59822f44" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a86dbd76-4caf-4b0e-a2b0-0e9c80944ffc" xlink:to="loc_us-gaap_CommonStockValue_2a4d8472-5b0a-487e-a01d-9fae59822f44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6e6c8c3a-f2c9-4d7e-9152-1929b43ca91e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a86dbd76-4caf-4b0e-a2b0-0e9c80944ffc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6e6c8c3a-f2c9-4d7e-9152-1929b43ca91e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_977c5e45-214c-4407-a81f-e04d8a05e834" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_aa394cd6-0588-4ca1-8b7f-8d1122745264" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_977c5e45-214c-4407-a81f-e04d8a05e834" xlink:to="loc_us-gaap_LiabilitiesCurrent_aa394cd6-0588-4ca1-8b7f-8d1122745264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_99fa6efc-8cc2-4302-b069-bc9653d2fad5" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_977c5e45-214c-4407-a81f-e04d8a05e834" xlink:to="loc_us-gaap_LongTermLineOfCredit_99fa6efc-8cc2-4302-b069-bc9653d2fad5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_8e3ddd1d-0f52-49d4-8bdd-5eda21aae780" xlink:href="cpix-20180331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_977c5e45-214c-4407-a81f-e04d8a05e834" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_8e3ddd1d-0f52-49d4-8bdd-5eda21aae780" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0640aa24-5dd1-48bc-8ad1-07b3be2ad6ec" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ad9b6be1-be73-4677-a002-55549ab891e6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0640aa24-5dd1-48bc-8ad1-07b3be2ad6ec" xlink:to="loc_us-gaap_AccountsPayableCurrent_ad9b6be1-be73-4677-a002-55549ab891e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a0523e4f-6db0-439c-9d31-ab5301758c69" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0640aa24-5dd1-48bc-8ad1-07b3be2ad6ec" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a0523e4f-6db0-439c-9d31-ab5301758c69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b189229d-5668-49c6-9647-93a8ac5b14d1" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNet_c76afda6-0976-4fc2-92b4-16b03acee315" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b189229d-5668-49c6-9647-93a8ac5b14d1" xlink:to="loc_us-gaap_SalesRevenueNet_c76afda6-0976-4fc2-92b4-16b03acee315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_982d290b-0033-4d64-b3a0-8dae4b9911ea" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b189229d-5668-49c6-9647-93a8ac5b14d1" xlink:to="loc_us-gaap_CostsAndExpenses_982d290b-0033-4d64-b3a0-8dae4b9911ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_542419ce-b99e-4108-99ac-55ef611dadb3" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7a7a1748-9e3e-445d-a781-8b538fba28bd" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_542419ce-b99e-4108-99ac-55ef611dadb3" xlink:to="loc_us-gaap_ProfitLoss_7a7a1748-9e3e-445d-a781-8b538fba28bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8bd3e846-5cf0-44db-985a-a1652589b685" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_542419ce-b99e-4108-99ac-55ef611dadb3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8bd3e846-5cf0-44db-985a-a1652589b685" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f3d1477b-f7a7-45be-acd7-794b1987ece0" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsSold_87b61f9e-1a6d-4f1a-8ffe-117614b53780" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f3d1477b-f7a7-45be-acd7-794b1987ece0" xlink:to="loc_us-gaap_CostOfGoodsSold_87b61f9e-1a6d-4f1a-8ffe-117614b53780" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_6c5bf118-2ab4-4366-936c-8dbddc433614" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f3d1477b-f7a7-45be-acd7-794b1987ece0" xlink:to="loc_us-gaap_SellingAndMarketingExpense_6c5bf118-2ab4-4366-936c-8dbddc433614" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7865e011-a631-4230-b0a7-2fed03979031" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f3d1477b-f7a7-45be-acd7-794b1987ece0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7865e011-a631-4230-b0a7-2fed03979031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fc5f378e-b55b-4fef-bf39-75e736930392" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f3d1477b-f7a7-45be-acd7-794b1987ece0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fc5f378e-b55b-4fef-bf39-75e736930392" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_280a35ee-5071-464a-9e1f-a605ae93b4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f3d1477b-f7a7-45be-acd7-794b1987ece0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_280a35ee-5071-464a-9e1f-a605ae93b4f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c259bd31-18c9-4e39-a4ba-2c4ad568ea90" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7d670f25-6b74-4aaa-87cb-467452da379d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c259bd31-18c9-4e39-a4ba-2c4ad568ea90" xlink:to="loc_us-gaap_OperatingIncomeLoss_7d670f25-6b74-4aaa-87cb-467452da379d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_89980836-2ab8-46bc-bef2-3bf3f8a87ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c259bd31-18c9-4e39-a4ba-2c4ad568ea90" xlink:to="loc_us-gaap_InvestmentIncomeInterest_89980836-2ab8-46bc-bef2-3bf3f8a87ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bbe80d05-8050-429a-a142-713c46cbe407" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c259bd31-18c9-4e39-a4ba-2c4ad568ea90" xlink:to="loc_us-gaap_InterestExpense_bbe80d05-8050-429a-a142-713c46cbe407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e48dd11f-cf29-4837-be07-105a715f3d38" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2b920d3c-3ee2-4b54-9bcc-5502c1bf43e5" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e48dd11f-cf29-4837-be07-105a715f3d38" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2b920d3c-3ee2-4b54-9bcc-5502c1bf43e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8c32e700-fa07-44ce-a5b3-d19c6423dfe9" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e48dd11f-cf29-4837-be07-105a715f3d38" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8c32e700-fa07-44ce-a5b3-d19c6423dfe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4fcb7e52-704f-487a-abcf-644b48f682ad" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d1916ddd-38af-4da4-94d1-a1955b480bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_4fcb7e52-704f-487a-abcf-644b48f682ad" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d1916ddd-38af-4da4-94d1-a1955b480bf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ebeff856-d565-4c14-87e2-7c5b54f76c00" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_4fcb7e52-704f-487a-abcf-644b48f682ad" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ebeff856-d565-4c14-87e2-7c5b54f76c00" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bbdd97d5-3294-4e58-9a6d-469a9ee9a959" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d13b5059-8ae4-4787-b8a7-43a1cebe8210" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bbdd97d5-3294-4e58-9a6d-469a9ee9a959" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d13b5059-8ae4-4787-b8a7-43a1cebe8210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_76f5e48d-8071-4f6d-a1fe-e539547d24b6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bbdd97d5-3294-4e58-9a6d-469a9ee9a959" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_76f5e48d-8071-4f6d-a1fe-e539547d24b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ad201c4f-3ba8-4563-93ff-5e2b18664438" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bbdd97d5-3294-4e58-9a6d-469a9ee9a959" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ad201c4f-3ba8-4563-93ff-5e2b18664438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a3b44c1f-32f7-46be-aeb4-ca3dddf009ed" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bbdd97d5-3294-4e58-9a6d-469a9ee9a959" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a3b44c1f-32f7-46be-aeb4-ca3dddf009ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3eb8bef4-ec75-4c31-aa0d-67bccd398739" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_bd2c237d-8485-4de0-98b4-7328482011a4" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3eb8bef4-ec75-4c31-aa0d-67bccd398739" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_bd2c237d-8485-4de0-98b4-7328482011a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_d2d49af3-becd-42f2-a2f0-70b86c41db17" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3eb8bef4-ec75-4c31-aa0d-67bccd398739" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_d2d49af3-becd-42f2-a2f0-70b86c41db17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cdc8a1c0-e368-4f4e-9ab7-f5b8c9ffe58d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3eb8bef4-ec75-4c31-aa0d-67bccd398739" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cdc8a1c0-e368-4f4e-9ab7-f5b8c9ffe58d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_d6b0404c-1ee8-42b6-bebd-f88ef8f7f4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3eb8bef4-ec75-4c31-aa0d-67bccd398739" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_d6b0404c-1ee8-42b6-bebd-f88ef8f7f4a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bc1444d2-655b-4f03-9e29-a282010c3667" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3eb8bef4-ec75-4c31-aa0d-67bccd398739" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bc1444d2-655b-4f03-9e29-a282010c3667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_19acd99e-5e3f-46fe-9ac2-81aaca6da99d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6243fe2e-853b-45cc-b901-812040d3c529" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_19acd99e-5e3f-46fe-9ac2-81aaca6da99d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6243fe2e-853b-45cc-b901-812040d3c529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f2e4dd7f-fd53-4f68-9ed6-d15f3fe79051" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_19acd99e-5e3f-46fe-9ac2-81aaca6da99d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f2e4dd7f-fd53-4f68-9ed6-d15f3fe79051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6276dd0f-dbe3-4a2b-a522-60ece7270489" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_19acd99e-5e3f-46fe-9ac2-81aaca6da99d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6276dd0f-dbe3-4a2b-a522-60ece7270489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f66e7fdb-3a20-43ea-827c-98c8784af2de" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ad305e76-bf8d-4bea-80a4-cde2fba1c402" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f66e7fdb-3a20-43ea-827c-98c8784af2de" xlink:to="loc_us-gaap_ProfitLoss_ad305e76-bf8d-4bea-80a4-cde2fba1c402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1287c8d5-6d98-4fae-89cf-c9b7646e6717" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f66e7fdb-3a20-43ea-827c-98c8784af2de" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1287c8d5-6d98-4fae-89cf-c9b7646e6717" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_543a95fd-ae35-4690-b086-01e879281dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f66e7fdb-3a20-43ea-827c-98c8784af2de" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_543a95fd-ae35-4690-b086-01e879281dfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4409d15c-b805-4364-8c56-ea19199367b6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f66e7fdb-3a20-43ea-827c-98c8784af2de" xlink:to="loc_us-gaap_ShareBasedCompensation_4409d15c-b805-4364-8c56-ea19199367b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_dede2af2-3da4-4fea-8de4-d541beaeec2e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f66e7fdb-3a20-43ea-827c-98c8784af2de" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_dede2af2-3da4-4fea-8de4-d541beaeec2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b991645b-a53f-4005-9a26-b2483e2eec3f" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f66e7fdb-3a20-43ea-827c-98c8784af2de" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b991645b-a53f-4005-9a26-b2483e2eec3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_1f549084-f094-4bef-acc1-a460f49dba15" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f66e7fdb-3a20-43ea-827c-98c8784af2de" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_1f549084-f094-4bef-acc1-a460f49dba15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b6f6c53d-6a5b-432c-9018-8bdabd319271" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f66e7fdb-3a20-43ea-827c-98c8784af2de" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b6f6c53d-6a5b-432c-9018-8bdabd319271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a5cb8a25-1c54-48fb-ae58-13bc6a9edf0b" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f66e7fdb-3a20-43ea-827c-98c8784af2de" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a5cb8a25-1c54-48fb-ae58-13bc6a9edf0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e7e2d399-4d94-4418-a2af-2153de5895db" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f66e7fdb-3a20-43ea-827c-98c8784af2de" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e7e2d399-4d94-4418-a2af-2153de5895db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_c1726eed-b906-4e26-ae3e-f315b23fd351" xlink:href="cpix-20180331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f66e7fdb-3a20-43ea-827c-98c8784af2de" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_c1726eed-b906-4e26-ae3e-f315b23fd351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_82cc472d-6edb-44b1-be02-4b2dae9a029c" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f66e7fdb-3a20-43ea-827c-98c8784af2de" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_82cc472d-6edb-44b1-be02-4b2dae9a029c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedStatementofEquityUnaudited"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20180331.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20180331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/MarketableSecurities" xlink:type="simple" xlink:href="cpix-20180331.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20180331.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20180331.xsd#EarningsLossPerShare"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20180331.xsd#EarningsLossPerShareTables"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_34205cac-4b50-48fd-a140-076a6884a7be" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f8f581ae-2882-421f-b5dc-3526aa271355" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_34205cac-4b50-48fd-a140-076a6884a7be" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f8f581ae-2882-421f-b5dc-3526aa271355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_11756f49-ca07-4f08-b797-b4bac2d05bab" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_34205cac-4b50-48fd-a140-076a6884a7be" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_11756f49-ca07-4f08-b797-b4bac2d05bab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/EarningsLossPerShareTextualDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#EarningsLossPerShareTextualDetails"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/EarningsLossPerShareTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20180331.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20180331.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#RevenuesDetails"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20180331.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20180331.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/InventoriesDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b7bf8e64-073c-4f86-bb1e-f005ef4e1a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_404270eb-20d8-458f-afc9-8ccc368fea2b" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b7bf8e64-073c-4f86-bb1e-f005ef4e1a6b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_404270eb-20d8-458f-afc9-8ccc368fea2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_d9f70f91-905e-4643-9d8e-e6d3c734d0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b7bf8e64-073c-4f86-bb1e-f005ef4e1a6b" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_d9f70f91-905e-4643-9d8e-e6d3c734d0b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_62a22946-91fb-40fb-a54c-a22e1e5f44f6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b7bf8e64-073c-4f86-bb1e-f005ef4e1a6b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_62a22946-91fb-40fb-a54c-a22e1e5f44f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/InventoriesTextualDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#InventoriesTextualDetails"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/InventoriesTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20180331.xsd#ShareholdersEquityandDebt"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20180331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/IncomeTaxesTextualDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#IncomeTaxesTextualDetails"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/IncomeTaxesTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20180331.xsd#CollaborativeAgreements"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cpix-20180331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cpix-20180331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:6f9d426d-7cdf-4d24-852c-1304a591467b,g:9b882308-6c8b-47b4-823c-512a5c520540-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="cpix-20180331.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformation" xlink:type="extended" id="i0053f23ae3a0427f9740572d64575af9_2f5ed007-667b-4302-b4ee-e84a0487ab62"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i92d2ef0c43b04ee8af13c254ef353b3d_0e93c7e0-c8c5-4cce-868f-d9aa1179f91b"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" id="i6692810f31c64a52a1218bd731c9bb29_08aa5cca-3a6c-40c2-9bfd-9c1d7c2e6651"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" xlink:type="extended" id="ia606cdecae32425d9e7ad06d8fb0dce4_472aedfa-3111-4124-96d2-22e1667c5a6b"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="i3b0143e2c0a648f4a85338837e5585f8_07dfb4f1-4b24-4ce6-a3d9-89d7053e3404"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedStatementofEquityUnaudited"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited" xlink:type="extended" id="id4cc4b1507a64e2f9b657c7434245762_c2533a7a-3e1a-4dce-bb25-d2afc8b1301f">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c948b4d-e048-4456-b767-fa1ea6089b66" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7b399b50-c422-4f10-8a21-864dd183cc26" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0c948b4d-e048-4456-b767-fa1ea6089b66" xlink:to="loc_us-gaap_StatementTable_7b399b50-c422-4f10-8a21-864dd183cc26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0ab30c2d-47a1-4688-a400-dac7902b39a6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7b399b50-c422-4f10-8a21-864dd183cc26" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0ab30c2d-47a1-4688-a400-dac7902b39a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3965654f-0d17-41fc-93db-005b2e1e8326_default" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0ab30c2d-47a1-4688-a400-dac7902b39a6" xlink:to="loc_us-gaap_EquityComponentDomain_3965654f-0d17-41fc-93db-005b2e1e8326_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3965654f-0d17-41fc-93db-005b2e1e8326" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0ab30c2d-47a1-4688-a400-dac7902b39a6" xlink:to="loc_us-gaap_EquityComponentDomain_3965654f-0d17-41fc-93db-005b2e1e8326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_adc7178c-caf1-4f52-b5b6-3cd980ddc18d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3965654f-0d17-41fc-93db-005b2e1e8326" xlink:to="loc_us-gaap_CommonStockMember_adc7178c-caf1-4f52-b5b6-3cd980ddc18d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bbcff47a-a10a-4efa-81eb-f55f4385dbe7" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3965654f-0d17-41fc-93db-005b2e1e8326" xlink:to="loc_us-gaap_RetainedEarningsMember_bbcff47a-a10a-4efa-81eb-f55f4385dbe7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d6fa5a67-3ee5-40c8-9394-b4d600e0255d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3965654f-0d17-41fc-93db-005b2e1e8326" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d6fa5a67-3ee5-40c8-9394-b4d600e0255d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c948b4d-e048-4456-b767-fa1ea6089b66" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81c5a663-0f02-455c-9cc0-4b74fd1b0096" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81c5a663-0f02-455c-9cc0-4b74fd1b0096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_19d9be05-476a-4bb7-978a-57f87a618b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_19d9be05-476a-4bb7-978a-57f87a618b4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6c56f8cd-e5f5-43bb-a6b8-4815a61cc4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6c56f8cd-e5f5-43bb-a6b8-4815a61cc4ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_79408b8c-74ec-4768-b938-c50355f6db99" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_79408b8c-74ec-4768-b938-c50355f6db99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2f88c0f9-69c1-4357-90da-21a1943e2db8" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2f88c0f9-69c1-4357-90da-21a1943e2db8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72736815-fe3b-48db-b51e-85bc8fe46deb" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72736815-fe3b-48db-b51e-85bc8fe46deb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f0ffe988-cf84-4794-972e-1b68a68c8e84" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f0ffe988-cf84-4794-972e-1b68a68c8e84" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_c721872b-ea53-4efa-9040-fb115edc32be" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_c721872b-ea53-4efa-9040-fb115edc32be" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1977eca3-303e-415a-a3a7-2fefb61b8bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_ProfitLoss_1977eca3-303e-415a-a3a7-2fefb61b8bbc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_df240e3c-b679-423c-8f18-ede9e7a67d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_365e2bcf-405d-42a1-a70c-6b79665147c2" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20180331.xsd#OrganizationandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended" id="i2685eb44a7224e3ab9ff684a5411044d_6d705c5e-54fa-4264-bc6f-ae04912ba0c2"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20180331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended" id="i6b77309833cb403d87d017ba2ffbafcb_a2016f73-5015-4a0a-a2c4-4c4ce270ec09"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended" id="ib67eaf6455ac41819972edd83f259211_630aadc5-f825-45ba-8200-97ca1d20a396"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/MarketableSecurities" xlink:type="simple" xlink:href="cpix-20180331.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/MarketableSecurities" xlink:type="extended" id="i889ade827762413bbbae4bc253b02fcc_6ff37859-990d-4cd5-982c-29720f4f3892"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20180331.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="extended" id="if9c31097e1254bc19c355cc76bc9b828_ebe9ee4d-017f-42ca-90bc-1f14fd196264"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="i30825be48e524171b968a78e505a84cd_eda54e22-fa98-488d-b29e-78e0149989be">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_97ae5a12-59d4-457d-9759-ceb6d9ee866c" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81ce91e8-e514-4a7f-b7e6-58383f5d83b8" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_97ae5a12-59d4-457d-9759-ceb6d9ee866c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81ce91e8-e514-4a7f-b7e6-58383f5d83b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06c9ee86-655d-4e62-8243-ef392bf93f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81ce91e8-e514-4a7f-b7e6-58383f5d83b8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06c9ee86-655d-4e62-8243-ef392bf93f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f15f0f57-9512-44b8-8131-564405612d23_default" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06c9ee86-655d-4e62-8243-ef392bf93f6d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f15f0f57-9512-44b8-8131-564405612d23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f15f0f57-9512-44b8-8131-564405612d23" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06c9ee86-655d-4e62-8243-ef392bf93f6d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f15f0f57-9512-44b8-8131-564405612d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_923cd94c-83d8-4b5c-8a99-04bf33ef2b04" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f15f0f57-9512-44b8-8131-564405612d23" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_923cd94c-83d8-4b5c-8a99-04bf33ef2b04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_097a9cb5-8b8f-4275-ae50-f65b7fe24151" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f15f0f57-9512-44b8-8131-564405612d23" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_097a9cb5-8b8f-4275-ae50-f65b7fe24151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_12d5a003-c360-4343-b4ee-c9bc4f017ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81ce91e8-e514-4a7f-b7e6-58383f5d83b8" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_12d5a003-c360-4343-b4ee-c9bc4f017ea8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_12d5a003-c360-4343-b4ee-c9bc4f017ea8" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_12d5a003-c360-4343-b4ee-c9bc4f017ea8" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_UsTreasuryNotesAndBondsSecuritiesDomain_515c6707-1dc8-456e-b185-dce74003568c" xlink:href="cpix-20180331.xsd#cpix_UsTreasuryNotesAndBondsSecuritiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:to="loc_cpix_UsTreasuryNotesAndBondsSecuritiesDomain_515c6707-1dc8-456e-b185-dce74003568c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_e6dfd279-9807-4504-b660-515ad2ed1b75" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_e6dfd279-9807-4504-b660-515ad2ed1b75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_1990a339-b8bb-42f7-8be0-4581c959bd89" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:to="loc_us-gaap_AgencySecuritiesMember_1990a339-b8bb-42f7-8be0-4581c959bd89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_38aaffec-2567-4ffe-b769-99287ff4b84f" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_38aaffec-2567-4ffe-b769-99287ff4b84f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LoanPoolsMember_e35b8638-4e27-4f7c-8b69-5ec2139bd0d7" xlink:href="cpix-20180331.xsd#cpix_LoanPoolsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:to="loc_cpix_LoanPoolsMember_e35b8638-4e27-4f7c-8b69-5ec2139bd0d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_4e2bc80f-0e00-43f8-8a8a-28e54d7137f5" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:to="loc_us-gaap_MunicipalBondsMember_4e2bc80f-0e00-43f8-8a8a-28e54d7137f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_c60cc649-b5c3-4292-9564-350eff5e1db2" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_97ae5a12-59d4-457d-9759-ceb6d9ee866c" xlink:to="loc_us-gaap_TradingSecurities_c60cc649-b5c3-4292-9564-350eff5e1db2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20180331.xsd#EarningsLossPerShare"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended" id="i0089c9c0943742b8877c667067468860_4a749619-4326-42c6-8768-7631e34d3fdb"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20180331.xsd#EarningsLossPerShareTables"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended" id="ie6fb5d7ebe364f52af088d29a66b1bfe_923fd1db-aa42-4314-a210-708bb9db79a4"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#EarningsLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended" id="ia4f8629b969e420cad658ae81cd14544_e5fda1da-d954-4bb4-82b2-d025488ea588"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/EarningsLossPerShareTextualDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#EarningsLossPerShareTextualDetails"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/EarningsLossPerShareTextualDetails" xlink:type="extended" id="i667a446ab4644316a3bf0d1783acb513_b929d2bd-893e-41fc-88e7-c2dd4a9c1403"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20180331.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/Revenues" xlink:type="extended" id="ic7b922b5f0114daab42d2c3e65bf8f45_fedcb292-9e9e-4b87-aa00-f80cb18fb9ab"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20180331.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/RevenuesTables" xlink:type="extended" id="i922b43e8e4fd4b0b855058d603ecceff_9443d600-d819-4cfe-8622-05e5864ac5fd"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#RevenuesDetails"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended" id="ie8c659151d97421482c4efb3fdac098f_cda144a0-af4d-4276-b448-e2f157b2218e">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_79e085ea-10ed-40a8-a901-5f503324e123" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_77ff7643-7443-4c5b-b736-9267286a5d06" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_79e085ea-10ed-40a8-a901-5f503324e123" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_77ff7643-7443-4c5b-b736-9267286a5d06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductOrServiceAxis_542fcd1a-8fb0-4a45-bab7-d2ea5df0acc3" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_77ff7643-7443-4c5b-b736-9267286a5d06" xlink:to="loc_us-gaap_ProductOrServiceAxis_542fcd1a-8fb0-4a45-bab7-d2ea5df0acc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074_default" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_542fcd1a-8fb0-4a45-bab7-d2ea5df0acc3" xlink:to="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_542fcd1a-8fb0-4a45-bab7-d2ea5df0acc3" xlink:to="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_113d4fcc-1adc-4d0e-a665-db9e9b052dd6" xlink:href="cpix-20180331.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_AcetadoteMember_113d4fcc-1adc-4d0e-a665-db9e9b052dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_abc35174-9082-45f6-accb-aecda112e178" xlink:href="cpix-20180331.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_OmeclamoxPakMember_abc35174-9082-45f6-accb-aecda112e178" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_44af31b2-29d8-4266-9fd8-9832fca53b96" xlink:href="cpix-20180331.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_KristaloseMember_44af31b2-29d8-4266-9fd8-9832fca53b96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_bd415d69-5c86-4c24-868b-c8f60300a829" xlink:href="cpix-20180331.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_VaprisolMember_bd415d69-5c86-4c24-868b-c8f60300a829" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_d8fb8d41-385a-4a02-bb2b-6270dc8f5742" xlink:href="cpix-20180331.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_CaldolorMember_d8fb8d41-385a-4a02-bb2b-6270dc8f5742" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EthyolMember_a365d9cc-2a9c-4350-b2c0-7effb013c4c8" xlink:href="cpix-20180331.xsd#cpix_EthyolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_EthyolMember_a365d9cc-2a9c-4350-b2c0-7effb013c4c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TotectMember_581ef155-f4e4-4456-8995-e1a07e61a706" xlink:href="cpix-20180331.xsd#cpix_TotectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_TotectMember_581ef155-f4e4-4456-8995-e1a07e61a706" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_b186bddd-506d-47c6-ae9c-012c93c850a2" xlink:href="cpix-20180331.xsd#cpix_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_OtherProductsMember_b186bddd-506d-47c6-ae9c-012c93c850a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GenericAcetadoteMember_f2896de5-5e81-4c3e-90ee-9f9f35d8d064" xlink:href="cpix-20180331.xsd#cpix_GenericAcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_GenericAcetadoteMember_f2896de5-5e81-4c3e-90ee-9f9f35d8d064" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetAbstract_0babf943-0e82-4e7e-8379-088b9af98945" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_79e085ea-10ed-40a8-a901-5f503324e123" xlink:to="loc_us-gaap_SalesRevenueNetAbstract_0babf943-0e82-4e7e-8379-088b9af98945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_113458a4-de40-450b-ae6a-7e214fa3b9e5" xlink:href="cpix-20180331.xsd#cpix_ProductsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SalesRevenueNetAbstract_0babf943-0e82-4e7e-8379-088b9af98945" xlink:to="loc_cpix_ProductsAbstract_113458a4-de40-450b-ae6a-7e214fa3b9e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNet_3c8743cd-0729-4994-bf85-c1cd99e4a1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductsAbstract_113458a4-de40-450b-ae6a-7e214fa3b9e5" xlink:to="loc_us-gaap_SalesRevenueNet_3c8743cd-0729-4994-bf85-c1cd99e4a1b5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20180331.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/Inventories" xlink:type="extended" id="i7e85d955affb43fdb6fe86c729aeedbb_6bcefdd0-9f62-4f24-b30b-2bcb34cc4719"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20180331.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/InventoriesTables" xlink:type="extended" id="ibf55654a6f33477cae12a3ed31d01639_5c678f17-8b2f-4bec-b305-aab6d861d095"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/InventoriesDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#InventoriesDetails"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/InventoriesDetails" xlink:type="extended" id="if91142f1dd034160a4d7336174b7bcb4_512a0447-559e-4926-beae-2720e58508a9"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/InventoriesTextualDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#InventoriesTextualDetails"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/InventoriesTextualDetails" xlink:type="extended" id="i2d02fd3c15484fc689b852373ad2d316_e1b2ad98-e499-496d-a64e-a6b2cc953f00"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20180331.xsd#ShareholdersEquityandDebt"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended" id="if205a3676f824daa81f72954551aefbf_d95d78b7-5bae-48ec-9473-fb28845f1662"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended" id="i46012cf7f115480a8734c6c923e27d04_51a38d12-2ef2-4146-86e8-072a337d362a">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bab5ea3f-f87b-4314-b745-de41113dab1a" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf7e8e59-9a84-473f-8291-18d21630e795" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bab5ea3f-f87b-4314-b745-de41113dab1a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf7e8e59-9a84-473f-8291-18d21630e795" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a3b1beb5-ef39-46c3-9cc0-3af7d9146ece" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf7e8e59-9a84-473f-8291-18d21630e795" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a3b1beb5-ef39-46c3-9cc0-3af7d9146ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5d948d1f-bc7f-44e2-881b-1ff4b52f2c3f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3b1beb5-ef39-46c3-9cc0-3af7d9146ece" xlink:to="loc_us-gaap_EquityComponentDomain_5d948d1f-bc7f-44e2-881b-1ff4b52f2c3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5d948d1f-bc7f-44e2-881b-1ff4b52f2c3f" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3b1beb5-ef39-46c3-9cc0-3af7d9146ece" xlink:to="loc_us-gaap_EquityComponentDomain_5d948d1f-bc7f-44e2-881b-1ff4b52f2c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_75539f24-68c0-4a77-b4f7-204d001af913" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5d948d1f-bc7f-44e2-881b-1ff4b52f2c3f" xlink:to="loc_us-gaap_CommonStockMember_75539f24-68c0-4a77-b4f7-204d001af913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_ff8d6f5c-d267-474c-b164-aebda1718f66" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf7e8e59-9a84-473f-8291-18d21630e795" xlink:to="loc_us-gaap_TitleOfIndividualAxis_ff8d6f5c-d267-474c-b164-aebda1718f66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_63dd2e1c-40ed-46e7-9f79-604bb214a395_default" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_ff8d6f5c-d267-474c-b164-aebda1718f66" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_63dd2e1c-40ed-46e7-9f79-604bb214a395_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_63dd2e1c-40ed-46e7-9f79-604bb214a395" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_ff8d6f5c-d267-474c-b164-aebda1718f66" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_63dd2e1c-40ed-46e7-9f79-604bb214a395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember_d72a0a80-8e22-404f-b3c3-2bf1ee408e23" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_63dd2e1c-40ed-46e7-9f79-604bb214a395" xlink:to="loc_us-gaap_DirectorMember_d72a0a80-8e22-404f-b3c3-2bf1ee408e23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e9835b38-b89a-413c-9f9f-51ad36c42a02" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf7e8e59-9a84-473f-8291-18d21630e795" xlink:to="loc_us-gaap_AwardTypeAxis_e9835b38-b89a-413c-9f9f-51ad36c42a02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5f2ddab-ff9c-49a7-a7da-a04d66df158e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e9835b38-b89a-413c-9f9f-51ad36c42a02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5f2ddab-ff9c-49a7-a7da-a04d66df158e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5f2ddab-ff9c-49a7-a7da-a04d66df158e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e9835b38-b89a-413c-9f9f-51ad36c42a02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5f2ddab-ff9c-49a7-a7da-a04d66df158e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_62283149-2352-4061-b719-17d3c278c640" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5f2ddab-ff9c-49a7-a7da-a04d66df158e" xlink:to="loc_us-gaap_RestrictedStockMember_62283149-2352-4061-b719-17d3c278c640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:href="cpix-20180331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bab5ea3f-f87b-4314-b745-de41113dab1a" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_637db0e7-d1b8-4fb7-bc41-afff356925ce" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_637db0e7-d1b8-4fb7-bc41-afff356925ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_d13a9004-7988-4930-a2c2-f115f42fe9ac" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_d13a9004-7988-4930-a2c2-f115f42fe9ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_e8fca253-93d9-41fd-882c-bd837fda8085" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_e8fca253-93d9-41fd-882c-bd837fda8085" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities_fb682e75-84a0-40f1-8ce0-9ad405bffaed" xlink:href="cpix-20180331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities_fb682e75-84a0-40f1-8ce0-9ad405bffaed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e89b3960-a55b-4ef9-a50a-7b2cfa173010" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e89b3960-a55b-4ef9-a50a-7b2cfa173010" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4009047e-322d-4d8b-bef5-e4bcce997159" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4009047e-322d-4d8b-bef5-e4bcce997159" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a87adbf0-38d9-4553-b873-29296d30144c" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a87adbf0-38d9-4553-b873-29296d30144c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_490aa76a-b8ce-4f9c-b098-6dde78e6a909" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_490aa76a-b8ce-4f9c-b098-6dde78e6a909" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended" id="iab1e503869cb46bfb35916dee15d2feb_637c91c1-4fda-480d-9a86-2862454618ed">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_e3aaaf8f-1e68-4ae0-ace3-859bd5d6c12e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_e3aaaf8f-1e68-4ae0-ace3-859bd5d6c12e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_6e2d9643-c585-444d-aec7-c10133b96579" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_e3aaaf8f-1e68-4ae0-ace3-859bd5d6c12e" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_6e2d9643-c585-444d-aec7-c10133b96579" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_40df7bb5-6e3e-4686-ad09-fec7c6432564_default" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_6e2d9643-c585-444d-aec7-c10133b96579" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_40df7bb5-6e3e-4686-ad09-fec7c6432564_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_40df7bb5-6e3e-4686-ad09-fec7c6432564" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_6e2d9643-c585-444d-aec7-c10133b96579" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_40df7bb5-6e3e-4686-ad09-fec7c6432564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_02a5d42b-5524-489b-88d7-108ed701aae4" xlink:href="cpix-20180331.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_40df7bb5-6e3e-4686-ad09-fec7c6432564" xlink:to="loc_cpix_PinnacleBankMember_02a5d42b-5524-489b-88d7-108ed701aae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SunTrustBankMember_590d5481-4133-4882-ad46-c83e070187d0" xlink:href="cpix-20180331.xsd#cpix_SunTrustBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_40df7bb5-6e3e-4686-ad09-fec7c6432564" xlink:to="loc_cpix_SunTrustBankMember_590d5481-4133-4882-ad46-c83e070187d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d7543798-78a3-4331-a3ab-1687f422dc97" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_e3aaaf8f-1e68-4ae0-ace3-859bd5d6c12e" xlink:to="loc_us-gaap_DebtInstrumentAxis_d7543798-78a3-4331-a3ab-1687f422dc97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b45619d-d303-43c6-8277-db026d3163d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d7543798-78a3-4331-a3ab-1687f422dc97" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b45619d-d303-43c6-8277-db026d3163d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b45619d-d303-43c6-8277-db026d3163d9" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d7543798-78a3-4331-a3ab-1687f422dc97" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b45619d-d303-43c6-8277-db026d3163d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_eb2ad641-f853-40a6-bf2f-f7174b68392e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3b45619d-d303-43c6-8277-db026d3163d9" xlink:to="loc_us-gaap_LineOfCreditMember_eb2ad641-f853-40a6-bf2f-f7174b68392e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_56971712-83aa-4e09-8f4c-6a317563759f" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_e3aaaf8f-1e68-4ae0-ace3-859bd5d6c12e" xlink:to="loc_us-gaap_CreditFacilityAxis_56971712-83aa-4e09-8f4c-6a317563759f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d407a933-8f92-4ed6-aca6-341ad8933b35_default" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_56971712-83aa-4e09-8f4c-6a317563759f" xlink:to="loc_us-gaap_CreditFacilityDomain_d407a933-8f92-4ed6-aca6-341ad8933b35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d407a933-8f92-4ed6-aca6-341ad8933b35" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_56971712-83aa-4e09-8f4c-6a317563759f" xlink:to="loc_us-gaap_CreditFacilityDomain_d407a933-8f92-4ed6-aca6-341ad8933b35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_b90a3405-d695-40db-991c-69188eeb69cf" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d407a933-8f92-4ed6-aca6-341ad8933b35" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_b90a3405-d695-40db-991c-69188eeb69cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RangeAxis_55b14deb-ada7-48a3-9601-6d4bc007c2bf" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_e3aaaf8f-1e68-4ae0-ace3-859bd5d6c12e" xlink:to="loc_us-gaap_RangeAxis_55b14deb-ada7-48a3-9601-6d4bc007c2bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RangeMember_3bc64de0-7cf0-41af-924d-39031471118d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_55b14deb-ada7-48a3-9601-6d4bc007c2bf" xlink:to="loc_us-gaap_RangeMember_3bc64de0-7cf0-41af-924d-39031471118d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RangeMember_3bc64de0-7cf0-41af-924d-39031471118d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_55b14deb-ada7-48a3-9601-6d4bc007c2bf" xlink:to="loc_us-gaap_RangeMember_3bc64de0-7cf0-41af-924d-39031471118d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinimumMember_444dda62-761d-4fbd-8a75-16c6e48a8b93" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3bc64de0-7cf0-41af-924d-39031471118d" xlink:to="loc_us-gaap_MinimumMember_444dda62-761d-4fbd-8a75-16c6e48a8b93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumMember_15c3a472-4ee5-4964-ab0e-6960c1f3c1a5" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3bc64de0-7cf0-41af-924d-39031471118d" xlink:to="loc_us-gaap_MaximumMember_15c3a472-4ee5-4964-ab0e-6960c1f3c1a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_5f5cd25a-141d-483e-b8fd-3cb07a2b930c" xlink:href="cpix-20180331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_5f5cd25a-141d-483e-b8fd-3cb07a2b930c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_62059e05-e5a8-41fd-9737-44883dde720e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_62059e05-e5a8-41fd-9737-44883dde720e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2b39946d-39f1-4644-b826-293c5a9c702e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2b39946d-39f1-4644-b826-293c5a9c702e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e36c044-368f-473a-b895-8c3f4eb48eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e36c044-368f-473a-b895-8c3f4eb48eb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_832ca96a-8b78-4ce5-8f63-6e2fff0bf5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_832ca96a-8b78-4ce5-8f63-6e2fff0bf5e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_f51c0e03-11ab-4f91-8752-08bef8caabfb" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_us-gaap_LongTermLineOfCredit_f51c0e03-11ab-4f91-8752-08bef8caabfb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_62f97296-124b-45a6-ad15-3c5b56454b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_62f97296-124b-45a6-ad15-3c5b56454b2a" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20180331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended" id="i6a69ba8298fa440884db0dd327698ef2_9a5afd4e-6997-4eca-b0b8-c340dc3879ef"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/IncomeTaxesTextualDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#IncomeTaxesTextualDetails"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/IncomeTaxesTextualDetails" xlink:type="extended" id="i375c3f61338b47d3b939b1c30ff8030d_1589c17f-5779-4c28-933c-6d5bbba33a87"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20180331.xsd#CollaborativeAgreements"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended" id="i0cce667459514da390e3768190374622_dbfb4645-7a5e-4c7c-9ced-a2216108d0ba"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cpix-20180331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="extended" id="id8ec85103d974af9b53622bf82b954f8_11ad5a5c-5ec2-4fc2-ba6a-b42c04cef41d"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cpix-20180331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:6f9d426d-7cdf-4d24-852c-1304a591467b,g:9b882308-6c8b-47b4-823c-512a5c520540-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CommonStockMember_80a4a833-095b-4568-a544-060892ddd5e1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range values are not currently supported</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5fc697b1-9ac6-40a9-9e5a-4e4eed86e4e2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RangeMember_f3cf4a3a-a982-43e0-9fb8-5d7564d3199f_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_label_en-US" xlink:label="lab_us-gaap_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RangeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember" xlink:to="lab_us-gaap_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9670f175-1d0f-4443-9f1f-bf0c24e3e4dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_c8830e5b-366c-4814-b491-c2b49c619b9f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_7108520c-cfd5-4873-82a8-367c9fcd36ba_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_478fcf9e-5924-46ed-a5ae-16321f0bc1a9_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8e41dcb2-baed-49a0-b35e-31bd85851436_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1f21c0c7-4239-41d7-984b-d08d127c6b37_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_19ddbd32-61cf-497c-adb2-b13229b1a612_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c6591b47-0565-4bd6-825d-569890a40df9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_76825498-b007-4bde-ad77-27f097eaa5e6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa2985a2-140e-467b-abca-b098f1f458eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_55ac0c24-157f-4a91-8940-46fb1f92b401_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f54cb64f-bfaa-482b-b2a1-94b2f8151864_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of marketable securities, by type</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_99d7bb7b-e9d2-486f-a1fa-8b5f4b8cfe12_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investment gains</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNet_2f9e711b-c2d2-4dcd-9c69-2ac9183100ba_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNet_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNet" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet" xlink:to="lab_us-gaap_SalesRevenueNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_65e6eb3d-6282-409d-95a8-7e701ae9cc5e_verboseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20180331.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_98701aff-3f02-4701-9240-588c14d8abf7_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_58c39bb1-00dc-49cd-b33d-66be32e53722_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d69036d9-9567-48c4-a0ba-2961283f9f0e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bab900e8-f9c6-44fd-916e-838496f0738e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_178ea1e9-305a-435b-9c6b-e150aa015da9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_357edb83-0ac9-4d72-849e-86a56894d5cc_verboseLabel_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_label_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations Excluding Current Portion</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_documentation_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations, excluding current portion.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:href="cpix-20180331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:to="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b3e03706-bd35-4be7-a722-96daf95e5074_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_e0ee804d-f177-49b2-9449-6d9355e67f21_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_979727f6-b351-4391-bca1-8423978b6c58_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net, Items Net of Reserve Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:to="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_f648eb91-019c-4c7f-9f8d-e8fd5660ba56_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_54e0433c-582a-4af6-b1bd-b88158c0df20_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b7ecbdea-87a4-4b4e-bb45-e1384fca40b1_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_cd9150d2-7a8a-49d7-a569-6ddcf6109268_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_c9c39196-68fb-4ea4-9bab-c94f56f66e14_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d79f1a15-b286-45ba-a56f-aca07658637e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_aed1d934-3c91-4c27-a234-71d17f165fc0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_50dbd6f3-2f3b-4021-8cfb-89ebe8b4344f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_fc61f5ec-6955-4977-8bf3-7a3d97025532_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsSold_2144dab2-fcc4-405a-b9ca-0a1ed49f2cd4_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsSold" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold" xlink:to="lab_us-gaap_CostOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_51786262-ba20-4d0f-8a0a-c456ada45cab_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetAbstract_3e35669b-208d-4bf0-bd63-45a4d71b0e1c_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetAbstract_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetAbstract" xlink:to="lab_us-gaap_SalesRevenueNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_7efea5ea-e4a9-4b9f-8d4b-34090e2ed4af_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Agency issued mortgage-backed securities &#8211; variable rate</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed Securities, Issued by Private Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2cb79106-8550-4e29-acf8-f7d3426b2b0d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_71a3f897-23da-417f-b3eb-5b765c7e63df_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_30fed3fc-4c99-4957-8d8e-d6af1de3c01e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ffb54af3-8e55-4169-9ac4-667310cfbe6c_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_b0cb3b50-e05e-4d2c-84f5-1885da786ea3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7884fa71-daf1-42df-a109-5cee403eb622_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_35c2378e-29ed-40f6-b47f-71a31021aeb3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_79d3b364-eba5-46e5-aaea-abc30a9f7891_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_1c0d206c-80ea-4933-bc2d-e0d5b6cafc9b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_332dd54a-042d-4d45-b8aa-a39b2beabf6d_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_8312739a-9a91-4476-8a89-b117cdd0f52a_verboseLabel_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_label_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_documentation_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract" xlink:href="cpix-20180331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract" xlink:to="lab_cpix_ShareholdersEquityTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_eb2f5711-7759-472b-9bc1-0e20e64748fa_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_GenericAcetadoteMember_e9197f39-a9bc-48fc-a619-a7bbca43330e_terseLabel_en-US" xlink:label="lab_cpix_GenericAcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generic Acetadote</link:label>
    <link:label id="lab_cpix_GenericAcetadoteMember_label_en-US" xlink:label="lab_cpix_GenericAcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generic Acetadote [Member]</link:label>
    <link:label id="lab_cpix_GenericAcetadoteMember_documentation_en-US" xlink:label="lab_cpix_GenericAcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized Generic Acetadote [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GenericAcetadoteMember" xlink:href="cpix-20180331.xsd#cpix_GenericAcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_GenericAcetadoteMember" xlink:to="lab_cpix_GenericAcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_UsTreasuryNotesAndBondsSecuritiesDomain_a97bfac3-1c31-4a72-9b8a-1342756e476e_terseLabel_en-US" xlink:label="lab_cpix_UsTreasuryNotesAndBondsSecuritiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes and bonds</link:label>
    <link:label id="lab_cpix_UsTreasuryNotesAndBondsSecuritiesDomain_label_en-US" xlink:label="lab_cpix_UsTreasuryNotesAndBondsSecuritiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Us Treasury Notes and Bonds Securities [Domain]</link:label>
    <link:label id="lab_cpix_UsTreasuryNotesAndBondsSecuritiesDomain_documentation_en-US" xlink:label="lab_cpix_UsTreasuryNotesAndBondsSecuritiesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_UsTreasuryNotesAndBondsSecuritiesDomain" xlink:href="cpix-20180331.xsd#cpix_UsTreasuryNotesAndBondsSecuritiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_UsTreasuryNotesAndBondsSecuritiesDomain" xlink:to="lab_cpix_UsTreasuryNotesAndBondsSecuritiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0b23326a-6313-44e2-bc19-f85d3d687477_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14b6a65c-c607-4816-821f-331af36a1cad_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_78eb011e-d7e2-4d7a-b73b-5a85566d8477_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e4c62bc1-add1-446e-9510-8ebf98defc19_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_5612fb6b-e87b-4db7-b528-7975244cf304_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f1ee39a5-6be1-4e1c-94c1-ca9ea3071762_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductsAbstract_3be2d191-eabf-4f01-b687-1ecec6be4286_verboseLabel_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_label_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_documentation_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract" xlink:href="cpix-20180331.xsd#cpix_ProductsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductsAbstract" xlink:to="lab_cpix_ProductsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_247e32d7-099c-4522-875d-4529888b0613_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2967156d-7195-4d9f-8ce9-0718d75c0120_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_5b4d64d6-6786-4a1d-ae4a-621f35ae02ec_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_038d45c6-4ab5-4033-82df-4298f8df7397_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_70718cf1-d0a4-42c4-9504-3c2364e5b794_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20180331.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_a4138f24-0f73-49a8-ba64-3d8e8a161dc8_verboseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20180331.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_13364059-eabd-44df-b939-b90f47e97547_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherProductsMember_07b9fb98-af9f-4212-8c67-0096bd1ce029_verboseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_cpix_OtherProductsMember_label_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember" xlink:href="cpix-20180331.xsd#cpix_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember" xlink:to="lab_cpix_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d6fdbed4-a712-4a47-9a29-39310e8ee2a4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,727,250 and 15,723,075 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_c52e11e3-679a-4b78-8f24-67203c2b3b45_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_07682a66-cd9f-4bc0-933f-8cca39fac386_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a803d9ad-bd16-437d-b605-81254061d8ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RangeAxis_05dd3cc5-9976-46aa-a1a6-d9d75fe1e723_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_label_en-US" xlink:label="lab_us-gaap_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis" xlink:to="lab_us-gaap_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_00a2d5c8-5df8-4706-9634-d1ae1178298b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c42f4ab5-f21a-4cd2-84b4-75aa04a9f350_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_eec9ae4c-6bcf-45a9-9ebe-4e86a287c7cf_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DirectorMember_612d63d3-0c1b-46a4-8bf1-690bdabc8b01_terseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_us-gaap_DirectorMember_label_en-US" xlink:label="lab_us-gaap_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember" xlink:to="lab_us-gaap_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_403f3c45-b662-4348-99a1-1be3d04f7ab5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_97db4fc1-cd75-4deb-8b57-1ce6d263bd7b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY AND DEBT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b845c145-7539-4d76-8e2d-08abbf3aa8f1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5331099f-a8df-4d23-9376-ed7b0b980e91_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_c8e9ef8d-e2d9-48a5-848d-80263a5854bf_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_cbcc57e5-f64d-41ce-99de-c33762d027c6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_ea5be1a7-bb9e-432e-8386-7f97da8feabf_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_7cfde404-7ed1-41d1-b45d-0f037412c02c_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_38e4598d-d2a7-4e43-a84a-6b27e6673b76_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b631a508-5b29-4ec6-9e3d-1632659aacb0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5d987407-6661-4169-8687-5e29296dd598_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8a082f5e-ace3-4563-af83-4bec94afeb7d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f92ba7a6-f7fb-4b80-9135-36eb9a9420cb_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_fea0061c-03f0-4087-8e86-6d3bb25557ff_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range values are not currently supported</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d74a865d-e465-497f-9001-abd2e78e4507_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ef917a9f-74a8-4bd8-8267-e6ffe273d36a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e18dbf28-e3c9-4de7-bf91-7afa8aea8757_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_48634d8b-8911-4d0f-b379-bf18d1fbcbe8_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LoanPoolsMember_2e430ab0-bf6b-41c8-9f43-baf92d5bdc1b_terseLabel_en-US" xlink:label="lab_cpix_LoanPoolsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:label id="lab_cpix_LoanPoolsMember_label_en-US" xlink:label="lab_cpix_LoanPoolsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Pools [Member]</link:label>
    <link:label id="lab_cpix_LoanPoolsMember_documentation_en-US" xlink:label="lab_cpix_LoanPoolsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan pools.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LoanPoolsMember" xlink:href="cpix-20180331.xsd#cpix_LoanPoolsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LoanPoolsMember" xlink:to="lab_cpix_LoanPoolsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_298a37d1-9430-4852-8617-f70d3c45451c_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_9d897bec-0fdc-4895-b1cd-91097648d5a4_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_deddd8a1-2fc0-4590-b795-f6cfc233e4b7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8b7aa9d5-7482-4290-a194-e87ccd4f0e9e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_abcd424f-8b6f-4d48-aabc-c4896b1fc505_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b3b8198a-f971-432a-abc6-7f5cc1aca48a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_8e476ecb-1ff9-4806-857c-a6f41d7f6037_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:href="cpix-20180331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_018c4398-2cfb-4d32-9789-8aa9a072fdbb_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_accb2f0b-936f-4da9-b6b1-aa9551dde569_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_fcd5921f-a197-4bf5-a7b3-91e6529b66a0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_f8a9be33-5aa7-4ffd-9bfc-4a7431eb20e3_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e4e7232f-5691-44fa-b999-0d9ec196a502_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_cf67ad9d-3be7-444e-9a24-90c0031017ae_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_4ae13155-e3e6-4e43-8ba8-dc416418e604_negatedLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess tax (benefit) expense derived from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b3dc4754-a86f-44c8-823b-b7d977e1e092_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for purchase through restricted stock awards and options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_bbd16de6-c106-4b8a-853b-7189208ee152_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_394f92c6-5b44-49c5-b2ad-9904c946cec0_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_a895204f-46fe-4e84-929a-8871a3f51951_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4a850230-1057-468e-a4b1-8caaa0862c82_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SunTrustBankMember_0199f58c-93e2-496b-9288-7a388cea6773_terseLabel_en-US" xlink:label="lab_cpix_SunTrustBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SunTrust Bank</link:label>
    <link:label id="lab_cpix_SunTrustBankMember_label_en-US" xlink:label="lab_cpix_SunTrustBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SunTrust Bank [Member]</link:label>
    <link:label id="lab_cpix_SunTrustBankMember_documentation_en-US" xlink:label="lab_cpix_SunTrustBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SunTrust Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SunTrustBankMember" xlink:href="cpix-20180331.xsd#cpix_SunTrustBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SunTrustBankMember" xlink:to="lab_cpix_SunTrustBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_67bb3bdb-4c5e-4ba8-a60c-13c53c020950_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20aaf1e7-ebf6-4f83-b301-d68f874ac8de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b6484abb-803d-45fc-8b14-3cb645220ad4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1955fde8-c2a9-4011-8b16-bdf3020114f0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_fadeb820-f232-4161-bb1a-8ef21e2feac3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3da27b78-9130-4b0f-973d-264018464de3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4199f05d-92ac-4317-a607-46e32cc2fca2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_721c367d-bcfe-477d-a2dd-5f0c5685188c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_12bed79a-9930-4b00-ab08-f02c2edf4d98_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_25c2cf21-704b-401b-84bf-edc1a22d5852_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d338b907-569c-4fa1-91f5-85a3d96f30c4_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_d3c00cf0-8e23-429a-80e0-1790ee9a500b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7f79be5a-c6e2-4034-9c06-98bb1e838645_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_d304ff61-a200-4b28-951b-da2800c2784d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bff44e76-c295-486b-9bb3-1b712ec869bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ce95fd4b-9a0b-48c7-abfd-f9a0de75a27d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fc752371-39d8-4bed-a02f-93acad457d10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted in period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_cc75eb53-be1c-4859-89bc-043acf8482cb_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_a201b543-63a9-4fef-9720-9537c11c6642_verboseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20180331.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f46c3715-ab00-479f-bebd-2ad8a5686f83_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_b1938ec5-de27-452e-b7bd-f739aeb5aec5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of shares of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8e883e45-9fe8-4401-bb71-7380089fc533_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_a0474fea-2e07-43df-be83-3ce0b1d6eecd_terseLabel_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Agency notes and bonds &#8211; fixed rate</link:label>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AgencySecuritiesMember" xlink:to="lab_us-gaap_AgencySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_ddfa68fc-c307-45e6-b9ca-799bad0c9b3a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7a50a9db-cef1-4a6e-9546-9b2c2372da9f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74891058-54fd-487c-b0a6-b2b9c8749b6a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6bbbde51-7f85-448b-92de-caa28336e59b_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_9b1b48b7-02ff-4b5f-a725-6db7ef49fab1_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term cash investments</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_68f29c9b-6541-477e-9108-0a5e195968b1_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_48085bcf-ca7c-4245-afde-389f3fe8733a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6f67e9f3-e1d6-4686-ad8a-9733edfe8b7f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_9ac8a325-b66b-40da-98bd-c0d3354eaacf_verboseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Current Operating Liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_documentation_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Current Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:href="cpix-20180331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:to="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_75e1e87e-32e0-4158-9f61-6bb8e5e769d1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for potential obsolescence of products</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_cf402b43-f89c-47c9-9f0f-209256fdfc69_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_d42ed13a-77a0-49a2-8a59-0ce4c2386fa8_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20180331.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e198a170-3dff-49f7-ba65-96b93e7bcfde_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_90f96934-3f65-4f37-b843-09709df36562_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_98aef5a9-1a24-4b5a-9422-606ab594eb1b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_079c6711-1275-497f-ba12-b898fa4d9250_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d6e37f83-7b26-4dc9-81eb-ea517b704f3a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of other securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_37a62316-a5d6-494c-be99-85837e83004d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_01200ae1-82a3-45cf-ae87-4d252c1ef2cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_666eee16-b956-4331-92c1-88f28cbef716_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range values are not currently supported</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_62d6ef83-ec9e-4ec3-bf37-1d6f3216d082_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_b4d4615c-d7a9-4a01-9888-7f6e4ae371e2_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_02a20259-00dc-40cd-be0c-6ebf88bb9345_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f55befb-20a2-4a54-bf4f-17553aa99d4a_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EthyolMember_fb04a063-c49f-47aa-a527-254163f43430_terseLabel_en-US" xlink:label="lab_cpix_EthyolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ethyol</link:label>
    <link:label id="lab_cpix_EthyolMember_label_en-US" xlink:label="lab_cpix_EthyolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ethyol [Member]</link:label>
    <link:label id="lab_cpix_EthyolMember_documentation_en-US" xlink:label="lab_cpix_EthyolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ethyol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EthyolMember" xlink:href="cpix-20180331.xsd#cpix_EthyolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EthyolMember" xlink:to="lab_cpix_EthyolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_72b4b152-4f64-484c-b5bb-47bc131b9349_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1a62d941-87b5-41c5-8a13-0fbe42194470_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_200a722c-fdad-4c25-b072-10b3da1f07d2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5ff397d4-deb0-4993-b97a-d5e3933793d5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_Denominator_6e8144c8-5b9d-4a86-99df-485ae511dece_verboseLabel_en-US" xlink:label="lab_cpix_Denominator" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_Denominator_label_en-US" xlink:label="lab_cpix_Denominator" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_cpix_Denominator_documentation_en-US" xlink:label="lab_cpix_Denominator" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Denominator" xlink:href="cpix-20180331.xsd#cpix_Denominator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_Denominator" xlink:to="lab_cpix_Denominator" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_41cced93-d0af-4310-894e-e943ae7bd366_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_67fbad24-f13a-441b-b703-49c15ad7f163_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities_b4def1cc-1836-4cb4-8aeb-3f093b252e0d_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" xlink:href="cpix-20180331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_be9bbd9c-6c0f-4f6c-93e5-833600a475f5_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_d8c84fd4-efe1-4208-98ab-54e9b6b3cc64_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_031b4907-8d81-40b4-aafd-289776775439_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_20ef7871-c8f4-4f9e-a482-c6840412c585_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis" xlink:to="lab_us-gaap_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8ef52b10-914f-4e8c-8b7a-a709e593f378_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c793e94b-a63a-48aa-a0cb-455038fdecce_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d183799d-649f-4973-99e9-3a6da1ef3396_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_ab7a7eb6-d99c-47d9-ad8e-405c8862d2bd_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EquityAndDebtAbstract_label_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:label id="lab_cpix_EquityAndDebtAbstract_documentation_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract" xlink:href="cpix-20180331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EquityAndDebtAbstract" xlink:to="lab_cpix_EquityAndDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_16d75f91-1942-4368-af1f-49e096a8892d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_5fac9e31-6229-4c8f-9d6d-fc36a9168f81_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f118069c-6022-4c0d-b88b-9d02d3a68b0d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_e1bc7e7a-6d82-45e3-85ac-0e4c31a167b5_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase outstanding common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_25ccb40a-7748-4472-aaf8-b037ea6dfccd_verboseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20180331.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_363cdf51-dcc6-4dee-9631-e1aef541a1c2_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4f8693fa-93e4-40ab-8fb2-2bd7774161a1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_fc6304c6-1ce4-4ea4-b649-705140a8c27b_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_98707488-50d6-419f-af50-2847430a6017_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_c4bda0a2-9090-4511-ab6d-37632b834ce1_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_40e577a6-32d9-4e4d-bbec-10bc31a360c5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_8d6c6e17-9530-468a-8c9c-1dd7e8c38344_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_fead4ad1-bbb8-4d03-aae2-e1f804c47e6f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_34e78b3b-56e8-42e5-8ba5-f269072f7e12_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20180331.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1510d224-7292-4a96-b2fc-e06095b458d1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_6b73dacb-c383-40bb-a295-29b494832f40_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_cad9decb-6678-4ab7-b251-94f065118c50_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cb05e2de-f118-447b-9f28-ae0a920ad732_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_29bc09ba-7e7b-43bd-bf7f-adaca9a7d912_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_35792b18-3f58-4499-9081-4dac1aa8430c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_507c2960-2107-4c59-af79-8694044a9db4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_813a928d-70e8-47c0-bfe7-3f9b6da98d96_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_59c318a4-4f1f-4cf8-a088-9704bacd90cd_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain" xlink:to="lab_us-gaap_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinimumMember_c2940a30-e4a1-4d03-b597-f179b787eda4_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_label_en-US" xlink:label="lab_us-gaap_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinimumMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember" xlink:to="lab_us-gaap_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9eb6b90a-522c-4983-ac27-71040523a31a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b740ec6a-5d74-4d47-a7d6-ccd2c7bd5fd1_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_169748a9-3093-4a06-a379-07ed2c67b760_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_31d7fe2e-5fb2-472e-8c96-c22962588c95_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_aaed6d3a-4809-45b1-ae86-46a0e81dc279_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1fe3453f-ce94-4e97-846b-e3410298873a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_06edea9d-cd20-4fa4-9c14-15ad851b3796_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_39092eae-b2a9-45a4-b4c6-96cc81a73704_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATIVE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DocumentAndEntityInformationAbstract_label_en-US" xlink:label="lab_cpix_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_cpix_DocumentAndEntityInformationAbstract_documentation_en-US" xlink:label="lab_cpix_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DocumentAndEntityInformationAbstract" xlink:href="cpix-20180331.xsd#cpix_DocumentAndEntityInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract" xlink:to="lab_cpix_DocumentAndEntityInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4c35c5af-3502-4d63-8e76-75ad39a1fe51_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_9ba4ccfa-6912-4840-823e-c6be4010724e_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_b7d83a51-53ae-48a4-8f22-d64a9b9976e3_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6db7f135-4aa0-4bee-9b27-64365375eadc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumMember_eeecaa80-c2c6-48c2-a2e5-1c34f64dbbbe_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_label_en-US" xlink:label="lab_us-gaap_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumMember" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember" xlink:to="lab_us-gaap_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TotectMember_b2049956-6fc5-4118-bbed-a85a8b3fc524_terseLabel_en-US" xlink:label="lab_cpix_TotectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Totect</link:label>
    <link:label id="lab_cpix_TotectMember_label_en-US" xlink:label="lab_cpix_TotectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Totect [Member]</link:label>
    <link:label id="lab_cpix_TotectMember_documentation_en-US" xlink:label="lab_cpix_TotectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Totect [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TotectMember" xlink:href="cpix-20180331.xsd#cpix_TotectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TotectMember" xlink:to="lab_cpix_TotectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9c36f49-5074-4439-a96f-3d6eb2dd2391_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cpix-20180331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:6f9d426d-7cdf-4d24-852c-1304a591467b,g:9b882308-6c8b-47b4-823c-512a5c520540-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="cpix-20180331.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DocumentAndEntityInformationAbstract_e9f2cc27-fea6-4f3b-b9e8-9b3c83538e43" xlink:href="cpix-20180331.xsd#cpix_DocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d1190cce-66c6-4308-894a-6d80fcf0d817" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e9f2cc27-fea6-4f3b-b9e8-9b3c83538e43" xlink:to="loc_dei_EntityRegistrantName_d1190cce-66c6-4308-894a-6d80fcf0d817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_43740706-ef73-4298-8f01-33c63999c46f" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e9f2cc27-fea6-4f3b-b9e8-9b3c83538e43" xlink:to="loc_dei_EntityCentralIndexKey_43740706-ef73-4298-8f01-33c63999c46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_866db956-7697-4e76-8d19-fae901e7b3c7" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e9f2cc27-fea6-4f3b-b9e8-9b3c83538e43" xlink:to="loc_dei_CurrentFiscalYearEndDate_866db956-7697-4e76-8d19-fae901e7b3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ae9091eb-9a65-4658-b6ef-314aa4d67197" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e9f2cc27-fea6-4f3b-b9e8-9b3c83538e43" xlink:to="loc_dei_DocumentType_ae9091eb-9a65-4658-b6ef-314aa4d67197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7ad1d9c3-b400-4b6a-998c-63845a225d83" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e9f2cc27-fea6-4f3b-b9e8-9b3c83538e43" xlink:to="loc_dei_EntityFilerCategory_7ad1d9c3-b400-4b6a-998c-63845a225d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_94d7b78e-b4df-4012-a52f-19bf2206f8d2" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e9f2cc27-fea6-4f3b-b9e8-9b3c83538e43" xlink:to="loc_dei_DocumentPeriodEndDate_94d7b78e-b4df-4012-a52f-19bf2206f8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a579eef7-3db2-4f9a-8cb3-49986828039f" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e9f2cc27-fea6-4f3b-b9e8-9b3c83538e43" xlink:to="loc_dei_DocumentFiscalYearFocus_a579eef7-3db2-4f9a-8cb3-49986828039f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1e591974-369a-4d66-bbf9-88a41b1ad4b1" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e9f2cc27-fea6-4f3b-b9e8-9b3c83538e43" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1e591974-369a-4d66-bbf9-88a41b1ad4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d1850145-d079-4dd0-b7f4-7317f9f15d5a" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e9f2cc27-fea6-4f3b-b9e8-9b3c83538e43" xlink:to="loc_dei_AmendmentFlag_d1850145-d079-4dd0-b7f4-7317f9f15d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4d977e6d-b822-4295-8696-a29af802e4a8" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e9f2cc27-fea6-4f3b-b9e8-9b3c83538e43" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4d977e6d-b822-4295-8696-a29af802e4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5b4537d2-df95-42bb-9c9a-c7aded631fef" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_95b14357-940d-40b6-8c3b-277a890a7a80" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5b4537d2-df95-42bb-9c9a-c7aded631fef" xlink:to="loc_us-gaap_AssetsAbstract_95b14357-940d-40b6-8c3b-277a890a7a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_683f491d-45a4-4a0e-b3a4-0c8a29d2ccff" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95b14357-940d-40b6-8c3b-277a890a7a80" xlink:to="loc_us-gaap_AssetsCurrentAbstract_683f491d-45a4-4a0e-b3a4-0c8a29d2ccff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1987fdb-af20-4759-96aa-0434132fbff8" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_683f491d-45a4-4a0e-b3a4-0c8a29d2ccff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1987fdb-af20-4759-96aa-0434132fbff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_d2f76c2c-f18a-4aa3-938d-a8fd65f41dca" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_683f491d-45a4-4a0e-b3a4-0c8a29d2ccff" xlink:to="loc_us-gaap_MarketableSecurities_d2f76c2c-f18a-4aa3-938d-a8fd65f41dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bd6fc9d9-a4d4-4ed0-811f-69f57ca814bd" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_683f491d-45a4-4a0e-b3a4-0c8a29d2ccff" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bd6fc9d9-a4d4-4ed0-811f-69f57ca814bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1fda6d22-b9c6-4337-8bfd-30e98e8ebb1d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_683f491d-45a4-4a0e-b3a4-0c8a29d2ccff" xlink:to="loc_us-gaap_InventoryNet_1fda6d22-b9c6-4337-8bfd-30e98e8ebb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0d4428e8-a131-478b-be6d-d6713d45a431" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_683f491d-45a4-4a0e-b3a4-0c8a29d2ccff" xlink:to="loc_us-gaap_OtherAssetsCurrent_0d4428e8-a131-478b-be6d-d6713d45a431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9ef4a200-14dc-4589-b9bf-84964f784b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_683f491d-45a4-4a0e-b3a4-0c8a29d2ccff" xlink:to="loc_us-gaap_AssetsCurrent_9ef4a200-14dc-4589-b9bf-84964f784b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_69327733-6bfa-40ba-82a0-3db50337af25" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95b14357-940d-40b6-8c3b-277a890a7a80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_69327733-6bfa-40ba-82a0-3db50337af25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4c3551d5-671f-4fe1-a664-90bd3a9470b8" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95b14357-940d-40b6-8c3b-277a890a7a80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4c3551d5-671f-4fe1-a664-90bd3a9470b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_a98fac0f-7a53-474d-b002-3d148c28e2d2" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95b14357-940d-40b6-8c3b-277a890a7a80" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_a98fac0f-7a53-474d-b002-3d148c28e2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7323424c-1603-4eb0-b01b-f48d5d75f32e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95b14357-940d-40b6-8c3b-277a890a7a80" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7323424c-1603-4eb0-b01b-f48d5d75f32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_97ad66e8-a3a3-4ef1-b001-49255bdbf6a4" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95b14357-940d-40b6-8c3b-277a890a7a80" xlink:to="loc_us-gaap_Assets_97ad66e8-a3a3-4ef1-b001-49255bdbf6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8cb23145-b964-4fc9-a110-11c03b2dcfcf" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5b4537d2-df95-42bb-9c9a-c7aded631fef" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8cb23145-b964-4fc9-a110-11c03b2dcfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_286766f7-1791-40c4-9e7b-2aaf9ea64591" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8cb23145-b964-4fc9-a110-11c03b2dcfcf" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_286766f7-1791-40c4-9e7b-2aaf9ea64591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7dac82ba-c062-4b36-8f03-07947c871368" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_286766f7-1791-40c4-9e7b-2aaf9ea64591" xlink:to="loc_us-gaap_AccountsPayableCurrent_7dac82ba-c062-4b36-8f03-07947c871368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e5155030-dff3-49c3-a9e9-8be92396f6ab" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_286766f7-1791-40c4-9e7b-2aaf9ea64591" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e5155030-dff3-49c3-a9e9-8be92396f6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8e3baf4a-a87f-4d66-9eac-7e4826acad5f" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_286766f7-1791-40c4-9e7b-2aaf9ea64591" xlink:to="loc_us-gaap_LiabilitiesCurrent_8e3baf4a-a87f-4d66-9eac-7e4826acad5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_420f2c64-6cf1-4f89-b94d-b4a159f0d889" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8cb23145-b964-4fc9-a110-11c03b2dcfcf" xlink:to="loc_us-gaap_LongTermLineOfCredit_420f2c64-6cf1-4f89-b94d-b4a159f0d889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_f44474c0-1529-4a96-8a54-f7645b656ada" xlink:href="cpix-20180331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8cb23145-b964-4fc9-a110-11c03b2dcfcf" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_f44474c0-1529-4a96-8a54-f7645b656ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2276762c-51d8-40a1-9082-73a08c478d37" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8cb23145-b964-4fc9-a110-11c03b2dcfcf" xlink:to="loc_us-gaap_Liabilities_2276762c-51d8-40a1-9082-73a08c478d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5300cfc9-6539-42bb-bc9b-a49fe7bd6eab" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8cb23145-b964-4fc9-a110-11c03b2dcfcf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5300cfc9-6539-42bb-bc9b-a49fe7bd6eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b20cfb5a-8677-470b-a302-f56657099a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8cb23145-b964-4fc9-a110-11c03b2dcfcf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b20cfb5a-8677-470b-a302-f56657099a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b81d5f8d-6ac0-48cb-bd55-6dbd8afcb267" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b20cfb5a-8677-470b-a302-f56657099a9d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b81d5f8d-6ac0-48cb-bd55-6dbd8afcb267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5c384870-3ef7-4159-a02e-4987f29e0a96" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b81d5f8d-6ac0-48cb-bd55-6dbd8afcb267" xlink:to="loc_us-gaap_CommonStockValue_5c384870-3ef7-4159-a02e-4987f29e0a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d831ad9e-f7cc-439e-a4df-d61e5990f569" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b81d5f8d-6ac0-48cb-bd55-6dbd8afcb267" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d831ad9e-f7cc-439e-a4df-d61e5990f569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bf671170-076e-4735-9720-67d582d0286e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b81d5f8d-6ac0-48cb-bd55-6dbd8afcb267" xlink:to="loc_us-gaap_StockholdersEquity_bf671170-076e-4735-9720-67d582d0286e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c4bfdc5a-781a-4b8b-9a95-41aeabbc5aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b20cfb5a-8677-470b-a302-f56657099a9d" xlink:to="loc_us-gaap_MinorityInterest_c4bfdc5a-781a-4b8b-9a95-41aeabbc5aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1edabe78-4724-4ec9-824f-9a2f6c8c34d0" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b20cfb5a-8677-470b-a302-f56657099a9d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1edabe78-4724-4ec9-824f-9a2f6c8c34d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9290a1bf-2aa0-40cc-982f-e0a1ecb52d72" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8cb23145-b964-4fc9-a110-11c03b2dcfcf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9290a1bf-2aa0-40cc-982f-e0a1ecb52d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_dde14783-ddee-46f4-85ab-6ae6ab0e1449" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_90a1e76a-c42c-4c60-820f-ce19454d0c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dde14783-ddee-46f4-85ab-6ae6ab0e1449" xlink:to="loc_us-gaap_CommonStockNoParValue_90a1e76a-c42c-4c60-820f-ce19454d0c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ffd3e26d-14a0-4d27-8fe9-d31060b22a24" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dde14783-ddee-46f4-85ab-6ae6ab0e1449" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ffd3e26d-14a0-4d27-8fe9-d31060b22a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_31f9d9e2-e64c-4581-852a-8167a6322818" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dde14783-ddee-46f4-85ab-6ae6ab0e1449" xlink:to="loc_us-gaap_CommonStockSharesIssued_31f9d9e2-e64c-4581-852a-8167a6322818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_eb25f7df-f86c-46b0-8599-bc46658dff59" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dde14783-ddee-46f4-85ab-6ae6ab0e1449" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_eb25f7df-f86c-46b0-8599-bc46658dff59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNet_4bb1207e-d8f9-432b-892c-5276d102e643" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_SalesRevenueNet_4bb1207e-d8f9-432b-892c-5276d102e643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_fe5569e7-f794-4ea3-bff3-290a62a1bf22" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_fe5569e7-f794-4ea3-bff3-290a62a1bf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsSold_7e386f1f-07ec-4566-952a-241f04424b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fe5569e7-f794-4ea3-bff3-290a62a1bf22" xlink:to="loc_us-gaap_CostOfGoodsSold_7e386f1f-07ec-4566-952a-241f04424b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_2b2de2d8-dbe5-4c1f-b890-64d227f96138" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fe5569e7-f794-4ea3-bff3-290a62a1bf22" xlink:to="loc_us-gaap_SellingAndMarketingExpense_2b2de2d8-dbe5-4c1f-b890-64d227f96138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a659a735-8d13-49f2-bed8-44aac53b250e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fe5569e7-f794-4ea3-bff3-290a62a1bf22" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a659a735-8d13-49f2-bed8-44aac53b250e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8a23a36f-042d-4424-ae2c-39f968559638" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fe5569e7-f794-4ea3-bff3-290a62a1bf22" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8a23a36f-042d-4424-ae2c-39f968559638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f9cb74f4-0c61-4129-ae94-1d03c76d45d6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fe5569e7-f794-4ea3-bff3-290a62a1bf22" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f9cb74f4-0c61-4129-ae94-1d03c76d45d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a535a933-d019-461a-ab60-7d17f0e8bbe6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fe5569e7-f794-4ea3-bff3-290a62a1bf22" xlink:to="loc_us-gaap_CostsAndExpenses_a535a933-d019-461a-ab60-7d17f0e8bbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_675a8e76-467d-4bb1-86bb-324a01cac7f6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fe5569e7-f794-4ea3-bff3-290a62a1bf22" xlink:to="loc_us-gaap_OperatingIncomeLoss_675a8e76-467d-4bb1-86bb-324a01cac7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4d11d266-eb08-4c1a-a935-2224fa8ff054" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4d11d266-eb08-4c1a-a935-2224fa8ff054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a1530719-36fb-407d-a8c0-b6c55bcb169b" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_InterestExpense_a1530719-36fb-407d-a8c0-b6c55bcb169b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c7cb966a-1865-4a72-97af-a2f905525ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c7cb966a-1865-4a72-97af-a2f905525ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cc80f9ba-da8a-4045-b10e-8f4ca3169b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cc80f9ba-da8a-4045-b10e-8f4ca3169b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4042839f-6a1a-4125-82af-0125a70d711d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_ProfitLoss_4042839f-6a1a-4125-82af-0125a70d711d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cde44c68-3f3a-457a-ad15-7da8e5d46409" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cde44c68-3f3a-457a-ad15-7da8e5d46409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_88bae913-cf56-4632-80cc-9e2c0beb397b" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_NetIncomeLoss_88bae913-cf56-4632-80cc-9e2c0beb397b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b5f4a767-b900-42be-ac77-251cac397662" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_EarningsPerShareAbstract_b5f4a767-b900-42be-ac77-251cac397662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6201cc44-b1ab-4e50-a2aa-ab56e3641785" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b5f4a767-b900-42be-ac77-251cac397662" xlink:to="loc_us-gaap_EarningsPerShareBasic_6201cc44-b1ab-4e50-a2aa-ab56e3641785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0e379b57-d9cf-43d0-831e-47dd67546ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b5f4a767-b900-42be-ac77-251cac397662" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0e379b57-d9cf-43d0-831e-47dd67546ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_439386ff-5e10-4240-bfdd-3a05b2f05a96" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_439386ff-5e10-4240-bfdd-3a05b2f05a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ae547bbf-c892-48bf-ae3a-c89370e7bf66" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_439386ff-5e10-4240-bfdd-3a05b2f05a96" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ae547bbf-c892-48bf-ae3a-c89370e7bf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5c2ad17b-dccf-4462-962c-dbfcabc13900" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_439386ff-5e10-4240-bfdd-3a05b2f05a96" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5c2ad17b-dccf-4462-962c-dbfcabc13900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c298706b-c645-47ef-8bf9-1917fbd9e0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c298706b-c645-47ef-8bf9-1917fbd9e0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_537fb931-b6a2-437c-a3c4-26939b0a88b0" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_537fb931-b6a2-437c-a3c4-26939b0a88b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_860f680b-178f-4dce-b63a-7a998af29f61" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53597655-e831-4027-ab6f-211f61955466" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_860f680b-178f-4dce-b63a-7a998af29f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7fcd387d-ce21-4685-a48e-8251a2f9a683" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fb7833fb-f986-4c82-9956-732f4706e200" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7fcd387d-ce21-4685-a48e-8251a2f9a683" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fb7833fb-f986-4c82-9956-732f4706e200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_526180ac-04b1-412b-94be-f0da7e929be5" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fb7833fb-f986-4c82-9956-732f4706e200" xlink:to="loc_us-gaap_ProfitLoss_526180ac-04b1-412b-94be-f0da7e929be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12d46fa5-e490-4b9f-8a60-3095e4cb23b2" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fb7833fb-f986-4c82-9956-732f4706e200" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12d46fa5-e490-4b9f-8a60-3095e4cb23b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f319d8bf-a668-441a-8fbd-9e61c4026575" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12d46fa5-e490-4b9f-8a60-3095e4cb23b2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f319d8bf-a668-441a-8fbd-9e61c4026575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f7a0d95b-b309-4e77-98ed-c95edfb4c6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12d46fa5-e490-4b9f-8a60-3095e4cb23b2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f7a0d95b-b309-4e77-98ed-c95edfb4c6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4c6a2287-1d20-496f-a4b4-8f522fc49af2" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12d46fa5-e490-4b9f-8a60-3095e4cb23b2" xlink:to="loc_us-gaap_ShareBasedCompensation_4c6a2287-1d20-496f-a4b4-8f522fc49af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_aa93b271-aa18-48bf-b3a6-c0269c17e362" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12d46fa5-e490-4b9f-8a60-3095e4cb23b2" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_aa93b271-aa18-48bf-b3a6-c0269c17e362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ace614a3-227a-4253-b6af-9eb1142ba440" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12d46fa5-e490-4b9f-8a60-3095e4cb23b2" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ace614a3-227a-4253-b6af-9eb1142ba440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_ca4fcdfb-52dd-447c-9bfb-9fd4cd4bbcd4" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12d46fa5-e490-4b9f-8a60-3095e4cb23b2" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_ca4fcdfb-52dd-447c-9bfb-9fd4cd4bbcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfa90ea0-78b1-41c6-b452-c37c680e1442" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12d46fa5-e490-4b9f-8a60-3095e4cb23b2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfa90ea0-78b1-41c6-b452-c37c680e1442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0c0106fa-08ba-4ee2-83b7-94b4bc65e973" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfa90ea0-78b1-41c6-b452-c37c680e1442" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0c0106fa-08ba-4ee2-83b7-94b4bc65e973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_91b4ebcf-faf6-4e34-a0bf-aca0f2915d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfa90ea0-78b1-41c6-b452-c37c680e1442" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_91b4ebcf-faf6-4e34-a0bf-aca0f2915d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_16bd7d5a-659a-404f-83dd-2387d0f939e2" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfa90ea0-78b1-41c6-b452-c37c680e1442" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_16bd7d5a-659a-404f-83dd-2387d0f939e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_a35c8558-0bac-49da-acbd-c0fe8cb3957f" xlink:href="cpix-20180331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfa90ea0-78b1-41c6-b452-c37c680e1442" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_a35c8558-0bac-49da-acbd-c0fe8cb3957f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_6133d7df-144f-4cc7-acb7-8152a32c7cff" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfa90ea0-78b1-41c6-b452-c37c680e1442" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_6133d7df-144f-4cc7-acb7-8152a32c7cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0ae6d09-3a52-4d5c-8ebc-0cfc1f25b1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fb7833fb-f986-4c82-9956-732f4706e200" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0ae6d09-3a52-4d5c-8ebc-0cfc1f25b1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d0545d6-d50a-4ecf-9569-9f899290025e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7fcd387d-ce21-4685-a48e-8251a2f9a683" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d0545d6-d50a-4ecf-9569-9f899290025e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5b2e5fcd-df59-466c-9a17-dbea579d7921" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d0545d6-d50a-4ecf-9569-9f899290025e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5b2e5fcd-df59-466c-9a17-dbea579d7921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2a275387-b078-4908-93b1-260f9b7948ef" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d0545d6-d50a-4ecf-9569-9f899290025e" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2a275387-b078-4908-93b1-260f9b7948ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_703d52e6-a003-45e4-a931-1caf8d7836fb" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d0545d6-d50a-4ecf-9569-9f899290025e" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_703d52e6-a003-45e4-a931-1caf8d7836fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6aafd636-658a-4021-a15b-0ebcd786b38c" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d0545d6-d50a-4ecf-9569-9f899290025e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6aafd636-658a-4021-a15b-0ebcd786b38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17879117-67c8-4744-ada5-3921a009cbe7" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d0545d6-d50a-4ecf-9569-9f899290025e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17879117-67c8-4744-ada5-3921a009cbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_82e5e34f-1149-41c3-a3e2-a899684e42f5" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7fcd387d-ce21-4685-a48e-8251a2f9a683" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_82e5e34f-1149-41c3-a3e2-a899684e42f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_c409cab4-2521-417f-8d03-eaea4668af4d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_82e5e34f-1149-41c3-a3e2-a899684e42f5" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_c409cab4-2521-417f-8d03-eaea4668af4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_8082f48b-0b51-4276-8903-fdd47a6e4664" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_82e5e34f-1149-41c3-a3e2-a899684e42f5" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_8082f48b-0b51-4276-8903-fdd47a6e4664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_63b3eb7a-3ce8-4026-98d5-c76e7c67787b" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_82e5e34f-1149-41c3-a3e2-a899684e42f5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_63b3eb7a-3ce8-4026-98d5-c76e7c67787b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_411c0f18-2ad4-46df-8e13-759e5933d22b" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_82e5e34f-1149-41c3-a3e2-a899684e42f5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_411c0f18-2ad4-46df-8e13-759e5933d22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a91c33bc-951a-46f8-80f5-c98c3b624d53" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_82e5e34f-1149-41c3-a3e2-a899684e42f5" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a91c33bc-951a-46f8-80f5-c98c3b624d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b1bd797-cb35-4189-8bdb-c2267eb6d388" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_82e5e34f-1149-41c3-a3e2-a899684e42f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b1bd797-cb35-4189-8bdb-c2267eb6d388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9291871c-4a8c-4c82-bc16-00bcdf3df5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_82e5e34f-1149-41c3-a3e2-a899684e42f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9291871c-4a8c-4c82-bc16-00bcdf3df5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5a5334fc-d18f-497c-a510-d3047178c3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_82e5e34f-1149-41c3-a3e2-a899684e42f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5a5334fc-d18f-497c-a510-d3047178c3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1ae9f8e1-e1da-45ed-ab68-608bdfe0d705" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_82e5e34f-1149-41c3-a3e2-a899684e42f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1ae9f8e1-e1da-45ed-ab68-608bdfe0d705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited" xlink:type="simple" xlink:href="cpix-20180331.xsd#CondensedConsolidatedStatementofEquityUnaudited"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4f5bc5cd-644f-4019-9af1-1a668f6ebfee" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7b399b50-c422-4f10-8a21-864dd183cc26" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4f5bc5cd-644f-4019-9af1-1a668f6ebfee" xlink:to="loc_us-gaap_StatementTable_7b399b50-c422-4f10-8a21-864dd183cc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0ab30c2d-47a1-4688-a400-dac7902b39a6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7b399b50-c422-4f10-8a21-864dd183cc26" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0ab30c2d-47a1-4688-a400-dac7902b39a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3965654f-0d17-41fc-93db-005b2e1e8326" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0ab30c2d-47a1-4688-a400-dac7902b39a6" xlink:to="loc_us-gaap_EquityComponentDomain_3965654f-0d17-41fc-93db-005b2e1e8326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_adc7178c-caf1-4f52-b5b6-3cd980ddc18d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3965654f-0d17-41fc-93db-005b2e1e8326" xlink:to="loc_us-gaap_CommonStockMember_adc7178c-caf1-4f52-b5b6-3cd980ddc18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bbcff47a-a10a-4efa-81eb-f55f4385dbe7" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3965654f-0d17-41fc-93db-005b2e1e8326" xlink:to="loc_us-gaap_RetainedEarningsMember_bbcff47a-a10a-4efa-81eb-f55f4385dbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d6fa5a67-3ee5-40c8-9394-b4d600e0255d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3965654f-0d17-41fc-93db-005b2e1e8326" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d6fa5a67-3ee5-40c8-9394-b4d600e0255d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c948b4d-e048-4456-b767-fa1ea6089b66" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7b399b50-c422-4f10-8a21-864dd183cc26" xlink:to="loc_us-gaap_StatementLineItems_0c948b4d-e048-4456-b767-fa1ea6089b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c948b4d-e048-4456-b767-fa1ea6089b66" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81c5a663-0f02-455c-9cc0-4b74fd1b0096" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81c5a663-0f02-455c-9cc0-4b74fd1b0096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_19d9be05-476a-4bb7-978a-57f87a618b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_19d9be05-476a-4bb7-978a-57f87a618b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6c56f8cd-e5f5-43bb-a6b8-4815a61cc4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6c56f8cd-e5f5-43bb-a6b8-4815a61cc4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_79408b8c-74ec-4768-b938-c50355f6db99" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_79408b8c-74ec-4768-b938-c50355f6db99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2f88c0f9-69c1-4357-90da-21a1943e2db8" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2f88c0f9-69c1-4357-90da-21a1943e2db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72736815-fe3b-48db-b51e-85bc8fe46deb" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72736815-fe3b-48db-b51e-85bc8fe46deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f0ffe988-cf84-4794-972e-1b68a68c8e84" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f0ffe988-cf84-4794-972e-1b68a68c8e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_c721872b-ea53-4efa-9040-fb115edc32be" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_c721872b-ea53-4efa-9040-fb115edc32be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1977eca3-303e-415a-a3a7-2fefb61b8bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_ProfitLoss_1977eca3-303e-415a-a3a7-2fefb61b8bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_df240e3c-b679-423c-8f18-ede9e7a67d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_df240e3c-b679-423c-8f18-ede9e7a67d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_365e2bcf-405d-42a1-a70c-6b79665147c2" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_02fd07eb-3483-412f-be0b-5fa109f70d13" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_365e2bcf-405d-42a1-a70c-6b79665147c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20180331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_032975d5-3f0e-44fb-b1c5-a9206d717c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1764257d-c205-4ae3-8736-71c32eddc2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_032975d5-3f0e-44fb-b1c5-a9206d717c2f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1764257d-c205-4ae3-8736-71c32eddc2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20180331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0effdc22-7065-4983-9935-98b34f7a0da0" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7c364aaf-da23-4470-b024-4650651f5732" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0effdc22-7065-4983-9935-98b34f7a0da0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7c364aaf-da23-4470-b024-4650651f5732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_36703a4b-b387-453c-92c6-84d90d5741f6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0effdc22-7065-4983-9935-98b34f7a0da0" xlink:to="loc_us-gaap_UseOfEstimates_36703a4b-b387-453c-92c6-84d90d5741f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8b416eb0-36ac-46a1-821c-23ce39215e97" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0effdc22-7065-4983-9935-98b34f7a0da0" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8b416eb0-36ac-46a1-821c-23ce39215e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7a1c7f1d-71b4-44c2-a2db-715417ad9696" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_5705a0ae-ada2-4341-a2b0-cdf94d49366a" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7a1c7f1d-71b4-44c2-a2db-715417ad9696" xlink:to="loc_us-gaap_NumberOfOperatingSegments_5705a0ae-ada2-4341-a2b0-cdf94d49366a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/MarketableSecurities" xlink:type="simple" xlink:href="cpix-20180331.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7a95b681-bcfd-40d0-b2da-135147688ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_65619ecd-9fb8-4e51-ba37-9c4e1c2ad019" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7a95b681-bcfd-40d0-b2da-135147688ddf" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_65619ecd-9fb8-4e51-ba37-9c4e1c2ad019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20180331.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bf690087-1d28-4b04-be2c-d1a92d18d55b" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ddac8769-795a-4e3f-8cf1-fdf2d763c316" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bf690087-1d28-4b04-be2c-d1a92d18d55b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ddac8769-795a-4e3f-8cf1-fdf2d763c316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2e227913-2e74-43dd-890c-6962d70287a0" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81ce91e8-e514-4a7f-b7e6-58383f5d83b8" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2e227913-2e74-43dd-890c-6962d70287a0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81ce91e8-e514-4a7f-b7e6-58383f5d83b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06c9ee86-655d-4e62-8243-ef392bf93f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81ce91e8-e514-4a7f-b7e6-58383f5d83b8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06c9ee86-655d-4e62-8243-ef392bf93f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f15f0f57-9512-44b8-8131-564405612d23" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06c9ee86-655d-4e62-8243-ef392bf93f6d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f15f0f57-9512-44b8-8131-564405612d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_923cd94c-83d8-4b5c-8a99-04bf33ef2b04" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f15f0f57-9512-44b8-8131-564405612d23" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_923cd94c-83d8-4b5c-8a99-04bf33ef2b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_097a9cb5-8b8f-4275-ae50-f65b7fe24151" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f15f0f57-9512-44b8-8131-564405612d23" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_097a9cb5-8b8f-4275-ae50-f65b7fe24151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_12d5a003-c360-4343-b4ee-c9bc4f017ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81ce91e8-e514-4a7f-b7e6-58383f5d83b8" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_12d5a003-c360-4343-b4ee-c9bc4f017ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_12d5a003-c360-4343-b4ee-c9bc4f017ea8" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_UsTreasuryNotesAndBondsSecuritiesDomain_515c6707-1dc8-456e-b185-dce74003568c" xlink:href="cpix-20180331.xsd#cpix_UsTreasuryNotesAndBondsSecuritiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:to="loc_cpix_UsTreasuryNotesAndBondsSecuritiesDomain_515c6707-1dc8-456e-b185-dce74003568c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_e6dfd279-9807-4504-b660-515ad2ed1b75" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_e6dfd279-9807-4504-b660-515ad2ed1b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_1990a339-b8bb-42f7-8be0-4581c959bd89" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:to="loc_us-gaap_AgencySecuritiesMember_1990a339-b8bb-42f7-8be0-4581c959bd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_38aaffec-2567-4ffe-b769-99287ff4b84f" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_38aaffec-2567-4ffe-b769-99287ff4b84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LoanPoolsMember_e35b8638-4e27-4f7c-8b69-5ec2139bd0d7" xlink:href="cpix-20180331.xsd#cpix_LoanPoolsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:to="loc_cpix_LoanPoolsMember_e35b8638-4e27-4f7c-8b69-5ec2139bd0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_4e2bc80f-0e00-43f8-8a8a-28e54d7137f5" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_d624c7fa-3f16-4726-a2c5-2bfb910ef2bf" xlink:to="loc_us-gaap_MunicipalBondsMember_4e2bc80f-0e00-43f8-8a8a-28e54d7137f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_97ae5a12-59d4-457d-9759-ceb6d9ee866c" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81ce91e8-e514-4a7f-b7e6-58383f5d83b8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_97ae5a12-59d4-457d-9759-ceb6d9ee866c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_c60cc649-b5c3-4292-9564-350eff5e1db2" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_97ae5a12-59d4-457d-9759-ceb6d9ee866c" xlink:to="loc_us-gaap_TradingSecurities_c60cc649-b5c3-4292-9564-350eff5e1db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20180331.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_78cda75f-2b4e-4e31-84e9-5a70272641d1" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c9d87210-4ad9-4599-86f7-db6df4c3cfba" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_78cda75f-2b4e-4e31-84e9-5a70272641d1" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c9d87210-4ad9-4599-86f7-db6df4c3cfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20180331.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fbc3fc76-14f2-4c0a-a609-bfdff8b0c06b" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_623c6a06-45a4-4d7d-9fcf-014d066c6977" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fbc3fc76-14f2-4c0a-a609-bfdff8b0c06b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_623c6a06-45a4-4d7d-9fcf-014d066c6977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#EarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a374c43e-46f5-44a8-b129-630ab25c2fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_6ada6ec1-09b2-497c-859d-c26b65a24c5f" xlink:href="cpix-20180331.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a374c43e-46f5-44a8-b129-630ab25c2fc2" xlink:to="loc_cpix_NumeratorAbstract_6ada6ec1-09b2-497c-859d-c26b65a24c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_73e0ce0c-80bb-4e0c-8a5c-63491e58a69f" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_6ada6ec1-09b2-497c-859d-c26b65a24c5f" xlink:to="loc_us-gaap_NetIncomeLoss_73e0ce0c-80bb-4e0c-8a5c-63491e58a69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Denominator_6fa2c9f5-3d1b-4839-ad29-a549109995a2" xlink:href="cpix-20180331.xsd#cpix_Denominator"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a374c43e-46f5-44a8-b129-630ab25c2fc2" xlink:to="loc_cpix_Denominator_6fa2c9f5-3d1b-4839-ad29-a549109995a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9691ccc3-7a6f-400c-8e96-944634683c83" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_Denominator_6fa2c9f5-3d1b-4839-ad29-a549109995a2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9691ccc3-7a6f-400c-8e96-944634683c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6ea61d93-069e-4e49-9625-505bef00d2bf" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_Denominator_6fa2c9f5-3d1b-4839-ad29-a549109995a2" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6ea61d93-069e-4e49-9625-505bef00d2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_17cac1b8-16c9-40cc-b012-dff55ad9c56f" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_Denominator_6fa2c9f5-3d1b-4839-ad29-a549109995a2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_17cac1b8-16c9-40cc-b012-dff55ad9c56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/EarningsLossPerShareTextualDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#EarningsLossPerShareTextualDetails"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/EarningsLossPerShareTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f717b16a-1f69-4284-a868-77af9793ec9b" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b292b181-cc1e-40c9-807c-4ab91b0eb015" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f717b16a-1f69-4284-a868-77af9793ec9b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b292b181-cc1e-40c9-807c-4ab91b0eb015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20180331.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2be5390f-53f4-4d02-9782-fe9d5bf9a9bb" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_8ab76e1e-ad06-4342-bb98-577c8a41c3d3" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2be5390f-53f4-4d02-9782-fe9d5bf9a9bb" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_8ab76e1e-ad06-4342-bb98-577c8a41c3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20180331.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ddbf11fa-d771-4516-b97d-826bd61a76a5" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_7f63f9f9-63f1-45ed-9449-4cdad814b795" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ddbf11fa-d771-4516-b97d-826bd61a76a5" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_7f63f9f9-63f1-45ed-9449-4cdad814b795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#RevenuesDetails"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e6e2845d-1730-4be3-9244-27dd9a7ea97c" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_77ff7643-7443-4c5b-b736-9267286a5d06" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e6e2845d-1730-4be3-9244-27dd9a7ea97c" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_77ff7643-7443-4c5b-b736-9267286a5d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductOrServiceAxis_542fcd1a-8fb0-4a45-bab7-d2ea5df0acc3" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_77ff7643-7443-4c5b-b736-9267286a5d06" xlink:to="loc_us-gaap_ProductOrServiceAxis_542fcd1a-8fb0-4a45-bab7-d2ea5df0acc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_542fcd1a-8fb0-4a45-bab7-d2ea5df0acc3" xlink:to="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_113d4fcc-1adc-4d0e-a665-db9e9b052dd6" xlink:href="cpix-20180331.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_AcetadoteMember_113d4fcc-1adc-4d0e-a665-db9e9b052dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_abc35174-9082-45f6-accb-aecda112e178" xlink:href="cpix-20180331.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_OmeclamoxPakMember_abc35174-9082-45f6-accb-aecda112e178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_44af31b2-29d8-4266-9fd8-9832fca53b96" xlink:href="cpix-20180331.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_KristaloseMember_44af31b2-29d8-4266-9fd8-9832fca53b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_bd415d69-5c86-4c24-868b-c8f60300a829" xlink:href="cpix-20180331.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_VaprisolMember_bd415d69-5c86-4c24-868b-c8f60300a829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_d8fb8d41-385a-4a02-bb2b-6270dc8f5742" xlink:href="cpix-20180331.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_CaldolorMember_d8fb8d41-385a-4a02-bb2b-6270dc8f5742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EthyolMember_a365d9cc-2a9c-4350-b2c0-7effb013c4c8" xlink:href="cpix-20180331.xsd#cpix_EthyolMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_EthyolMember_a365d9cc-2a9c-4350-b2c0-7effb013c4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TotectMember_581ef155-f4e4-4456-8995-e1a07e61a706" xlink:href="cpix-20180331.xsd#cpix_TotectMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_TotectMember_581ef155-f4e4-4456-8995-e1a07e61a706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_b186bddd-506d-47c6-ae9c-012c93c850a2" xlink:href="cpix-20180331.xsd#cpix_OtherProductsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_OtherProductsMember_b186bddd-506d-47c6-ae9c-012c93c850a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GenericAcetadoteMember_f2896de5-5e81-4c3e-90ee-9f9f35d8d064" xlink:href="cpix-20180331.xsd#cpix_GenericAcetadoteMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_eef6ec60-cb55-4279-8dd7-0e7f02d06074" xlink:to="loc_cpix_GenericAcetadoteMember_f2896de5-5e81-4c3e-90ee-9f9f35d8d064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_79e085ea-10ed-40a8-a901-5f503324e123" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_77ff7643-7443-4c5b-b736-9267286a5d06" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_79e085ea-10ed-40a8-a901-5f503324e123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetAbstract_0babf943-0e82-4e7e-8379-088b9af98945" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_79e085ea-10ed-40a8-a901-5f503324e123" xlink:to="loc_us-gaap_SalesRevenueNetAbstract_0babf943-0e82-4e7e-8379-088b9af98945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_113458a4-de40-450b-ae6a-7e214fa3b9e5" xlink:href="cpix-20180331.xsd#cpix_ProductsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesRevenueNetAbstract_0babf943-0e82-4e7e-8379-088b9af98945" xlink:to="loc_cpix_ProductsAbstract_113458a4-de40-450b-ae6a-7e214fa3b9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNet_3c8743cd-0729-4994-bf85-c1cd99e4a1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductsAbstract_113458a4-de40-450b-ae6a-7e214fa3b9e5" xlink:to="loc_us-gaap_SalesRevenueNet_3c8743cd-0729-4994-bf85-c1cd99e4a1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20180331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8cdf26af-9763-4a18-9a4d-8ea29adbe3b2" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_9b92aab3-dd48-4596-a130-edb7313978b0" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8cdf26af-9763-4a18-9a4d-8ea29adbe3b2" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_9b92aab3-dd48-4596-a130-edb7313978b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20180331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1cf0e87e-a591-4398-8768-595c8c84330f" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_84c1f6ff-7bb3-4239-b428-54fc9669c34b" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1cf0e87e-a591-4398-8768-595c8c84330f" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_84c1f6ff-7bb3-4239-b428-54fc9669c34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/InventoriesDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c3a34d8c-0355-49ba-8cbc-63d2bfb3930e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_7fa97a70-7222-449c-a85b-0bd9858dfb32" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c3a34d8c-0355-49ba-8cbc-63d2bfb3930e" xlink:to="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_7fa97a70-7222-449c-a85b-0bd9858dfb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3a82a8ba-a799-461d-a3d4-ecf4b3a1a38b" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_7fa97a70-7222-449c-a85b-0bd9858dfb32" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3a82a8ba-a799-461d-a3d4-ecf4b3a1a38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_523d4cc6-65e5-415a-8cbf-8be64f09bf29" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_7fa97a70-7222-449c-a85b-0bd9858dfb32" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_523d4cc6-65e5-415a-8cbf-8be64f09bf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_274e92b3-08f3-47cd-8122-8083f34b7020" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_7fa97a70-7222-449c-a85b-0bd9858dfb32" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_274e92b3-08f3-47cd-8122-8083f34b7020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_98424b46-3a3f-4202-9bbe-2749a930cec6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_7fa97a70-7222-449c-a85b-0bd9858dfb32" xlink:to="loc_us-gaap_InventoryNet_98424b46-3a3f-4202-9bbe-2749a930cec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/InventoriesTextualDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#InventoriesTextualDetails"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/InventoriesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6b17853a-2d42-49c3-854f-e6322126320a" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_8fac3b9a-6958-4414-a550-4da446d05e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6b17853a-2d42-49c3-854f-e6322126320a" xlink:to="loc_us-gaap_InventoryValuationReserves_8fac3b9a-6958-4414-a550-4da446d05e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20180331.xsd#ShareholdersEquityandDebt"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_da11542e-6cb0-406f-a0d8-33d29cc6d438" xlink:href="cpix-20180331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b1d98396-2035-457d-9100-061589c4d8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_da11542e-6cb0-406f-a0d8-33d29cc6d438" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b1d98396-2035-457d-9100-061589c4d8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_a146fbd2-39c9-4da7-a2a5-2a666bf95025" xlink:href="cpix-20180331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf7e8e59-9a84-473f-8291-18d21630e795" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_a146fbd2-39c9-4da7-a2a5-2a666bf95025" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf7e8e59-9a84-473f-8291-18d21630e795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a3b1beb5-ef39-46c3-9cc0-3af7d9146ece" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf7e8e59-9a84-473f-8291-18d21630e795" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a3b1beb5-ef39-46c3-9cc0-3af7d9146ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5d948d1f-bc7f-44e2-881b-1ff4b52f2c3f" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3b1beb5-ef39-46c3-9cc0-3af7d9146ece" xlink:to="loc_us-gaap_EquityComponentDomain_5d948d1f-bc7f-44e2-881b-1ff4b52f2c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_75539f24-68c0-4a77-b4f7-204d001af913" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5d948d1f-bc7f-44e2-881b-1ff4b52f2c3f" xlink:to="loc_us-gaap_CommonStockMember_75539f24-68c0-4a77-b4f7-204d001af913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_ff8d6f5c-d267-474c-b164-aebda1718f66" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf7e8e59-9a84-473f-8291-18d21630e795" xlink:to="loc_us-gaap_TitleOfIndividualAxis_ff8d6f5c-d267-474c-b164-aebda1718f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_63dd2e1c-40ed-46e7-9f79-604bb214a395" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_ff8d6f5c-d267-474c-b164-aebda1718f66" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_63dd2e1c-40ed-46e7-9f79-604bb214a395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember_d72a0a80-8e22-404f-b3c3-2bf1ee408e23" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_63dd2e1c-40ed-46e7-9f79-604bb214a395" xlink:to="loc_us-gaap_DirectorMember_d72a0a80-8e22-404f-b3c3-2bf1ee408e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e9835b38-b89a-413c-9f9f-51ad36c42a02" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf7e8e59-9a84-473f-8291-18d21630e795" xlink:to="loc_us-gaap_AwardTypeAxis_e9835b38-b89a-413c-9f9f-51ad36c42a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5f2ddab-ff9c-49a7-a7da-a04d66df158e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e9835b38-b89a-413c-9f9f-51ad36c42a02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5f2ddab-ff9c-49a7-a7da-a04d66df158e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_62283149-2352-4061-b719-17d3c278c640" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5f2ddab-ff9c-49a7-a7da-a04d66df158e" xlink:to="loc_us-gaap_RestrictedStockMember_62283149-2352-4061-b719-17d3c278c640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bab5ea3f-f87b-4314-b745-de41113dab1a" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf7e8e59-9a84-473f-8291-18d21630e795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bab5ea3f-f87b-4314-b745-de41113dab1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:href="cpix-20180331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bab5ea3f-f87b-4314-b745-de41113dab1a" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_637db0e7-d1b8-4fb7-bc41-afff356925ce" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_637db0e7-d1b8-4fb7-bc41-afff356925ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_d13a9004-7988-4930-a2c2-f115f42fe9ac" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_d13a9004-7988-4930-a2c2-f115f42fe9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_e8fca253-93d9-41fd-882c-bd837fda8085" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_e8fca253-93d9-41fd-882c-bd837fda8085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities_fb682e75-84a0-40f1-8ce0-9ad405bffaed" xlink:href="cpix-20180331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities_fb682e75-84a0-40f1-8ce0-9ad405bffaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e89b3960-a55b-4ef9-a50a-7b2cfa173010" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e89b3960-a55b-4ef9-a50a-7b2cfa173010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4009047e-322d-4d8b-bef5-e4bcce997159" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4009047e-322d-4d8b-bef5-e4bcce997159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a87adbf0-38d9-4553-b873-29296d30144c" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a87adbf0-38d9-4553-b873-29296d30144c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_490aa76a-b8ce-4f9c-b098-6dde78e6a909" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_cc1cedc4-6706-4e3c-89fd-9d7ab3b3c67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_490aa76a-b8ce-4f9c-b098-6dde78e6a909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_9b4fde4b-043e-43f5-b0a7-1f18ba260b4d" xlink:href="cpix-20180331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_e3aaaf8f-1e68-4ae0-ace3-859bd5d6c12e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_9b4fde4b-043e-43f5-b0a7-1f18ba260b4d" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_e3aaaf8f-1e68-4ae0-ace3-859bd5d6c12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_6e2d9643-c585-444d-aec7-c10133b96579" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_e3aaaf8f-1e68-4ae0-ace3-859bd5d6c12e" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_6e2d9643-c585-444d-aec7-c10133b96579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_40df7bb5-6e3e-4686-ad09-fec7c6432564" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_6e2d9643-c585-444d-aec7-c10133b96579" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_40df7bb5-6e3e-4686-ad09-fec7c6432564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_02a5d42b-5524-489b-88d7-108ed701aae4" xlink:href="cpix-20180331.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_40df7bb5-6e3e-4686-ad09-fec7c6432564" xlink:to="loc_cpix_PinnacleBankMember_02a5d42b-5524-489b-88d7-108ed701aae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SunTrustBankMember_590d5481-4133-4882-ad46-c83e070187d0" xlink:href="cpix-20180331.xsd#cpix_SunTrustBankMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_40df7bb5-6e3e-4686-ad09-fec7c6432564" xlink:to="loc_cpix_SunTrustBankMember_590d5481-4133-4882-ad46-c83e070187d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d7543798-78a3-4331-a3ab-1687f422dc97" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_e3aaaf8f-1e68-4ae0-ace3-859bd5d6c12e" xlink:to="loc_us-gaap_DebtInstrumentAxis_d7543798-78a3-4331-a3ab-1687f422dc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b45619d-d303-43c6-8277-db026d3163d9" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d7543798-78a3-4331-a3ab-1687f422dc97" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b45619d-d303-43c6-8277-db026d3163d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_eb2ad641-f853-40a6-bf2f-f7174b68392e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3b45619d-d303-43c6-8277-db026d3163d9" xlink:to="loc_us-gaap_LineOfCreditMember_eb2ad641-f853-40a6-bf2f-f7174b68392e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_56971712-83aa-4e09-8f4c-6a317563759f" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_e3aaaf8f-1e68-4ae0-ace3-859bd5d6c12e" xlink:to="loc_us-gaap_CreditFacilityAxis_56971712-83aa-4e09-8f4c-6a317563759f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d407a933-8f92-4ed6-aca6-341ad8933b35" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_56971712-83aa-4e09-8f4c-6a317563759f" xlink:to="loc_us-gaap_CreditFacilityDomain_d407a933-8f92-4ed6-aca6-341ad8933b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_b90a3405-d695-40db-991c-69188eeb69cf" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d407a933-8f92-4ed6-aca6-341ad8933b35" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_b90a3405-d695-40db-991c-69188eeb69cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RangeAxis_55b14deb-ada7-48a3-9601-6d4bc007c2bf" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_e3aaaf8f-1e68-4ae0-ace3-859bd5d6c12e" xlink:to="loc_us-gaap_RangeAxis_55b14deb-ada7-48a3-9601-6d4bc007c2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RangeMember_3bc64de0-7cf0-41af-924d-39031471118d" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_55b14deb-ada7-48a3-9601-6d4bc007c2bf" xlink:to="loc_us-gaap_RangeMember_3bc64de0-7cf0-41af-924d-39031471118d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinimumMember_444dda62-761d-4fbd-8a75-16c6e48a8b93" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3bc64de0-7cf0-41af-924d-39031471118d" xlink:to="loc_us-gaap_MinimumMember_444dda62-761d-4fbd-8a75-16c6e48a8b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumMember_15c3a472-4ee5-4964-ab0e-6960c1f3c1a5" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3bc64de0-7cf0-41af-924d-39031471118d" xlink:to="loc_us-gaap_MaximumMember_15c3a472-4ee5-4964-ab0e-6960c1f3c1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_e3aaaf8f-1e68-4ae0-ace3-859bd5d6c12e" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_5f5cd25a-141d-483e-b8fd-3cb07a2b930c" xlink:href="cpix-20180331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_5f5cd25a-141d-483e-b8fd-3cb07a2b930c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_62059e05-e5a8-41fd-9737-44883dde720e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_62059e05-e5a8-41fd-9737-44883dde720e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2b39946d-39f1-4644-b826-293c5a9c702e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2b39946d-39f1-4644-b826-293c5a9c702e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e36c044-368f-473a-b895-8c3f4eb48eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e36c044-368f-473a-b895-8c3f4eb48eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_832ca96a-8b78-4ce5-8f63-6e2fff0bf5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_832ca96a-8b78-4ce5-8f63-6e2fff0bf5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_f51c0e03-11ab-4f91-8752-08bef8caabfb" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_us-gaap_LongTermLineOfCredit_f51c0e03-11ab-4f91-8752-08bef8caabfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_62f97296-124b-45a6-ad15-3c5b56454b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_83c6d009-6928-4055-870b-d0086d89e3b0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_62f97296-124b-45a6-ad15-3c5b56454b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20180331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d649826b-d05e-4c44-9cb1-5199394ca383" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_b0879ff8-90c5-49da-9974-1c4e1704d491" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d649826b-d05e-4c44-9cb1-5199394ca383" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_b0879ff8-90c5-49da-9974-1c4e1704d491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/IncomeTaxesTextualDetails" xlink:type="simple" xlink:href="cpix-20180331.xsd#IncomeTaxesTextualDetails"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/IncomeTaxesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_59b01739-71a4-4c7b-8a04-c95124f77a56" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9cc096ff-40e6-49ed-a80e-531958028ca9" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_59b01739-71a4-4c7b-8a04-c95124f77a56" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9cc096ff-40e6-49ed-a80e-531958028ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20180331.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7130fb26-492b-439e-b55c-3af656e64d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_58e2b5c9-7f3c-49a4-804e-9af23c718aa2" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7130fb26-492b-439e-b55c-3af656e64d6e" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_58e2b5c9-7f3c-49a4-804e-9af23c718aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cpix-20180331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aacf475a-dfd4-4c91-aad6-89826b023e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_714627f5-8b49-425a-9e72-757fe9b4eb50" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aacf475a-dfd4-4c91-aad6-89826b023e9e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_714627f5-8b49-425a-9e72-757fe9b4eb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>cpix-20180331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://cumberlandpharma.com/20180331"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cpix-20180331.xsd" xlink:type="simple"/>
    <context id="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i0dd9dd6ff2ca40c88619dd5d86f0eafb_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="i097d668a5f1047f0be37d4b8f2dd8771_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0fd3da4e3c75411aa04652f12b8f13df_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0420ad95a0194945bfcbfd1dbc3b688f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ied2c88c7a3e94ca69560e97f372df5eb_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i895db0703de048cb8eb76978269e35a6_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ic602d02dff724990b5feb87e55fbb783_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i26a1fb7ff6bd4d2085da7c1c604620e1_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i5909472559854a45a161ee9683451710_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i91ee759fede74a44afc15799417026fc_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i4184f63683bf45109fe4a49c88baafbc_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i4572e5a71c344688b9efe5e38ee4a0e8_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="iac05f8bde425448ea4955ae4d2988a48_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i43d4a46326a24d6caca1fac6793144ce_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i51f8d7b7f57f4d7388487c437f5ab518_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i4c6551d700a840f38a0908ea87bf44cf_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i9d63d8a95b20480d99100f9855f3f288_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i0aea36d855cf456e880b35e2dc2c0505_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i56a7cfadcc3c4eee8a5d550fa4eb8f26_I20180504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-05-04</instant>
        </period>
    </context>
    <context id="i740c45d85a2942c196e262b2964e237b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i996d7d1b56cb43219465772f1f7597fe_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie54bf1c8e2d14928a9a06a734dfd7c6c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i439c1bc3ca8e4e5b9ea4d7bdb13d6991_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i01938b90ab854812b8ec66565464d607_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i5149372296b940a2aa525db6faa8f3c4_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id5a2b34ed5004b8fa2acfe953a3cc3c4_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2830ebd535c84a6496a304acfc539e9a_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ic4dd4eb6277e4ca19f808c8a63b5fd3e_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i18a7c5c9ec3446ddad8bd6afcd563cf6_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i6aae0fc592af4b14936eced6617fdc55_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0d02d8434f0641b9a2539c9d2707cf7b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i863ba3e77c42420dbba1bfa4d84f2196_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia15f718fd7ee4613bd4f49589b3d8fdc_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ibe82cbc40bcb489390a75fce71b8b80f_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="id8ae969ed44e419f8fc0f2099a9510cd_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i5ed094dbab104669b5bce32fe7460a28_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i84d27aa248d24ab8b554e59624c79428_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ieed830091dab43ba8375cdfb0f7f2a8c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="idde5b053a5b6476bb846c88390de0bc5_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="id98aa82685604140986e94a71f9d1936_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i5c8ca872cb5c4f4596ce2fd08ca9aa5e_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ib5c0c160863d4cceb26f484a2325fb1d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i381dc586d9494541bcf340e8bda4d8d0_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ie0982f8386a84f56bf35e403d479f381_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ibb29255b0cce4beabad9c0ef7e86504e_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iffcc23dd7a9944139daf9824e5b8eac5_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i6809c3be77f6432d9076c460384fbb07_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="ib2cf28a7f39c448f96b2e5671107943f_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i6d8502d751864f05a59b40ecc159972b_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i66977d80365d404296229eb847d696f2_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic700e54bd9e84fe38825f0e668b5fc38_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i4c5e9f1b87044a0da9566dff708f6520_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="icf73e673b6164c78ab232ce6f110e7d1_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i088036779adb405fb051b2f6ea583979_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i302d2057998b42f88bce95c8b68a0dca_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="iafc0d050afaf4677960684f8f326d0a1_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i666c2dae486e4b1eac47ec35b708938f_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ib034705aa5544216b55c469279e3eaba_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i17303c3256e5493faf87462aef420fab_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i2d39aea30fbc46889b6cfa872b2b6fb7_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="id74555dabd6a4ff2ad0bdc7e28c863bc_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i654f0cb0d52e49d39635e4e808fc2055_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i73e54bcae66640ebbb1fffa211e276c6_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:GenericAcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i4eb22c1d61c749ddac462523b2b31161_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:GenericAcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i3fd8c1a5a34842988819ab52812dc1e7_I20100513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2010-05-13</instant>
        </period>
    </context>
    <context id="ib436aa4112784a5bb575f9ce9fe4fb53_I20120430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2012-04-30</instant>
        </period>
    </context>
    <context id="i0a9e1ab5b93d4567815cacdf06859be8_I20130131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2013-01-31</instant>
        </period>
    </context>
    <context id="i47407fdc5afa40749b77a0412daf8956_I20110131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2011-01-31</instant>
        </period>
    </context>
    <context id="iebdcd0b9547b443b8727649905bdb07b_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="if5236a3131db4202b5eaec29f686e679_I20150131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2015-01-31</instant>
        </period>
    </context>
    <context id="id199b2eba45a4883a99f8420607fac40_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="ic6b3a2fc1ae64e68a3298edf95187fcd_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i61a9610b573b4e75a7c8f0f35d1cb4d8_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i653bf892b8c94a22be15b4bc51db3a05_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="id15e3d5e3e57462dba32d88ff64f623d_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i2b744dac368c4c3eb91bc9bb77c5cf97_I20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="ifb8bca4936ff40e2b30ed5d20dc32c4f_D20170731-20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-31</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="i55c284425d4448d79d408df2a3a756f9_I20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="i288af4ef515f4257be46413b7b9d94ee_I20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="i1e981a44ed99406590f2ed76af33aa59_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:SunTrustBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i8bf8f59dc7274cd6980319cc241a28f2_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="segment">
        <measure>cpix:segment</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityFilerCategory
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGFibGU6NDRmODBmMGRhMWRjNGUwMzljZWM3MTI1Yjc3ZDRmYmQvdGFibGVyYW5nZTo0NGY4MGYwZGExZGM0ZTAzOWNlYzcxMjViNzdkNGZiZF8wMjExQUFBQUJBQUFBQVFBQUFBQkFBQUFBUUFBQUFBQUFCU1dBQUElM0Q_23f9fbef-a9e2-4367-bf69-ebb39464c70e">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentPeriodEndDate
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGFibGU6NDRmODBmMGRhMWRjNGUwMzljZWM3MTI1Yjc3ZDRmYmQvdGFibGVyYW5nZTo0NGY4MGYwZGExZGM0ZTAzOWNlYzcxMjViNzdkNGZiZF8wMjE3QUFBQUJnQUFBQVlBQUFBQkFBQUFBUUFBQUFBQUFCT3NBQUElM0Q_2beb0383-0a8d-4dbf-bf86-d57c0927b03c">2018-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGFibGU6NDRmODBmMGRhMWRjNGUwMzljZWM3MTI1Yjc3ZDRmYmQvdGFibGVyYW5nZTo0NGY4MGYwZGExZGM0ZTAzOWNlYzcxMjViNzdkNGZiZF8wMjE2QUFBQUJ3QUFBQWNBQUFBQkFBQUFBUUFBQUFBQUFCT3RBQUElM0Q_14d92678-eb3c-49f7-8e76-44e426f8dd88">2018</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGFibGU6NDRmODBmMGRhMWRjNGUwMzljZWM3MTI1Yjc3ZDRmYmQvdGFibGVyYW5nZTo0NGY4MGYwZGExZGM0ZTAzOWNlYzcxMjViNzdkNGZiZF8wMmU5QUFBQUNBQUFBQWdBQUFBQkFBQUFBUUFBQUFBQUFCT3VBQUElM0Q_f50ee0f8-2087-471f-9b4e-38a91e79ad32">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGFibGU6NDRmODBmMGRhMWRjNGUwMzljZWM3MTI1Yjc3ZDRmYmQvdGFibGVyYW5nZTo0NGY4MGYwZGExZGM0ZTAzOWNlYzcxMjViNzdkNGZiZF8wMmU4QUFBQUNRQUFBQWtBQUFBQkFBQUFBUUFBQUFBQUFCT3ZBQUElM0Q_64fe1dff-1f50-4e1c-87ef-da006dc90e48">false</dei:AmendmentFlag>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i56a7cfadcc3c4eee8a5d550fa4eb8f26_I20180504"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGFibGU6NDRmODBmMGRhMWRjNGUwMzljZWM3MTI1Yjc3ZDRmYmQvdGFibGVyYW5nZTo0NGY4MGYwZGExZGM0ZTAzOWNlYzcxMjViNzdkNGZiZF8wMmUyQUFBQUNnQUFBQW9BQUFBQ0FBQUFBZ0FBQUFBQUFCaiUyRkFBQSUzRA_f0ade8d3-2c2e-47ee-9ae8-7f8cd4e05519"
      unitRef="shares">15710953</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGV4dHJlZ2lvbjpjMGRjYTk1MGFjMGQ1ODdmYTU4YmE1ZGZhOGYwNTRhN18xMDk5NTExNjI3ODYz_99cf5869-85b3-412c-a643-dd1dcf7f6b6e">0001087294</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4MTk5L2ZyYWc6YzBkY2E5NTBhYzBkNTg3ZmE1OGJhNWRmYThmMDU0YTcvdGV4dHJlZ2lvbjpjMGRjYTk1MGFjMGQ1ODdmYTU4YmE1ZGZhOGYwNTRhN18xMDk5NTExNjI3ODYy_963b0e87-cea7-4a84-be1d-31c02e08bcf6">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommonStockNoParValue
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMTJBQUFBQVFBQUFBRUFBQUFCQUFBQUFRQUFBQUFBQUJPMUFBQSUzRA_c358da0d-7bdd-4267-a286-6dcd572a8078"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMTdBQUFBQVFBQUFBRUFBQUFDQUFBQUFnQUFBQUFBQUJPNUFBQSUzRA_774a6cfc-cec1-4807-a47d-e07753742ac9"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMWRBQUFBQWdBQUFBSUFBQUFCQUFBQUFRQUFBQUFBQUJPMkFBQSUzRA_380eac0e-f879-4159-9336-550f5dd8c6cd"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMThBQUFBQWdBQUFBSUFBQUFDQUFBQUFnQUFBQUFBQUJPNkFBQSUzRA_01a19461-238c-471b-8bd2-d79b4685cf9e"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMWNBQUFBQXdBQUFBTUFBQUFCQUFBQUFRQUFBQUFBQUJPM0FBQSUzRA_baa80b31-0d2d-469f-a57c-97f5f835b0d9"
      unitRef="shares">15727250</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMWJBQUFBQXdBQUFBTUFBQUFDQUFBQUFnQUFBQUFBQUJPN0FBQSUzRA_eb70433b-a3f6-487f-9db6-06a820f02fc5"
      unitRef="shares">15723075</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMjExQUFBQUJBQUFBQVFBQUFBQkFBQUFBUUFBQUFBQUFCTzRBQUElM0Q_e4814efb-47ff-4fc8-9d99-eec7cbf59f0c"
      unitRef="shares">15727250</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDk5NTExNjI4Mzg0L2ZyYWc6MjdhZTcyOGIxZmU1NDlhNDk2ZWFiYzljOTFhNjU1MmQvdGFibGU6OWQwYTk4N2YwNWQyNGMyOWE2MTY1YmVmMzZjNTEwOTkvdGFibGVyYW5nZTo5ZDBhOTg3ZjA1ZDI0YzI5YTYxNjViZWYzNmM1MTA5OV8wMjFlQUFBQUJBQUFBQVFBQUFBQ0FBQUFBZ0FBQUFBQUFCTzhBQUElM0Q_3c470d2b-573f-406e-bd7b-0f035c4decc8"
      unitRef="shares">15723075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id15e3d5e3e57462dba32d88ff64f623d_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyNjE_3db38b5b-b57e-4753-bab2-0401c4da4aa8">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="ifb8bca4936ff40e2b30ed5d20dc32c4f_D20170731-20170731"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzNDI_faa1036d-aac4-495e-970e-7d7605ba1f7c">P3Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <dei:DocumentType
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xL2ZyYWc6OWE1ODVhZGNhZWMxNGFjNzg1MTJlYzgzNTQ0NTU4N2MvdGV4dHJlZ2lvbjo5YTU4NWFkY2FlYzE0YWM3ODUxMmVjODM1NDQ1NTg3Y18xMDk5NTExNjMxODAz_ee75a1cc-8425-4e23-a6a9-4749ef9f1551">10-Q</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xL2ZyYWc6OWE1ODVhZGNhZWMxNGFjNzg1MTJlYzgzNTQ0NTU4N2MvdGV4dHJlZ2lvbjo5YTU4NWFkY2FlYzE0YWM3ODUxMmVjODM1NDQ1NTg3Y18xMDk5NTExNjMxODA0_f7a9993b-c85a-41b3-90c5-2772ac0fbc3d">Cumberland Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i56a7cfadcc3c4eee8a5d550fa4eb8f26_I20180504"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xL2ZyYWc6OWE1ODVhZGNhZWMxNGFjNzg1MTJlYzgzNTQ0NTU4N2MvdGFibGU6ZDc3MWIyZGRjNzNjNDdhYzlkMTA3NjYwMTA4MTllYTgvdGFibGVyYW5nZTpkNzcxYjJkZGM3M2M0N2FjOWQxMDc2NjAxMDgxOWVhOF8wMTdBQUFBQVFBQUFBRUFBQUFDQUFBQUFnQUFBQUFBQUJSRUFBQSUzRA_c50198af-26a6-4a3c-961d-649e54b52c46"
      unitRef="shares">15710953</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMy0xLTEtMS0yMw_f4891eef-48fb-4cc3-915f-8417f823ef1d"
      unitRef="usd">35262976</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMy0zLTEtMS0yMw_ffa0c0c3-74ea-4a52-a8e8-f0fee11bb598"
      unitRef="usd">45412868</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNC0xLTEtMS0yMw_3cbf7f49-4c46-41a1-b65b-4e341406f954"
      unitRef="usd">15610105</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNC0zLTEtMS0yMw_ff60a054-59ec-44d8-86b5-835953b0fb0b"
      unitRef="usd">4672476</us-gaap:MarketableSecurities>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNS0xLTEtMS0yMw_0c53f282-a1cf-488b-89e9-90fb2d6e9adb"
      unitRef="usd">6301162</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNS0zLTEtMS0yMw_ce687acf-d6fb-4fef-8871-ed000770395c"
      unitRef="usd">8395112</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNi0xLTEtMS0yMw_601ecf43-692e-4e58-a1f3-33b3773827cf"
      unitRef="usd">6661525</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNi0zLTEtMS0yMw_507d818f-8096-4263-93de-da83810707f9"
      unitRef="usd">6737848</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNy0xLTEtMS0yMw_ce03fb66-8afa-46fe-9b52-45aec974c9fc"
      unitRef="usd">2987404</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfNy0zLTEtMS0yMw_d0a2144f-d14a-438c-bd50-f99dcd07ef93"
      unitRef="usd">3466541</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfOC0xLTEtMS0yMw_3c9165ed-4c5e-4e7a-a7fd-cf6e9f1555be"
      unitRef="usd">66823172</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfOC0zLTEtMS0yMw_5143ffa2-2bda-4bb0-a134-6bd590c30a6a"
      unitRef="usd">68684845</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfOS0xLTEtMS0yMw_579011df-dbeb-45fa-b2d6-f98d99adda1a"
      unitRef="usd">566907</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfOS0zLTEtMS0yMw_07b46f27-993f-4aea-8ee4-1de7798daf9a"
      unitRef="usd">528882</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTAtMS0xLTEtMjM_16808d3a-4af7-4b80-b372-da3672478332"
      unitRef="usd">21052197</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTAtMy0xLTEtMjM_beaafc70-572a-40c3-b81d-425df09c5a89"
      unitRef="usd">21444545</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTEtMS0xLTEtMjM_15b9d4fd-db67-4cb8-b0cb-9028eb2c9c34"
      unitRef="usd">87210</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTEtMy0xLTEtMjM_07295245-0fd1-496b-9abb-c32fb5dc8894"
      unitRef="usd">87210</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTItMS0xLTEtMjM_71556888-7456-4c55-8f6c-0177626438e7"
      unitRef="usd">2565354</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTItMy0xLTEtMjM_266faa81-67fc-4368-9e1e-5cba64b2c847"
      unitRef="usd">2486830</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTMtMS0xLTEtMjM_9ea60236-9da2-4091-8685-c0eed74a7315"
      unitRef="usd">91094840</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTMtMy0xLTEtMjM_7f71037f-942b-4794-898a-e53067b6196f"
      unitRef="usd">93232312</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTYtMS0xLTEtMjM_92164262-f223-4194-ab76-b99a7ecf38ec"
      unitRef="usd">8518879</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTYtMy0xLTEtMjM_f84cd7ef-7fde-44ce-904d-3aedacfcc3d5"
      unitRef="usd">8979929</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTctMS0xLTEtMjM_65775db3-8775-4d76-8a06-2dab0e5ef6f1"
      unitRef="usd">7770977</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTctMy0xLTEtMjM_6216c867-a98b-45d9-ad4e-9169b4edada4"
      unitRef="usd">8714814</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTgtMS0xLTEtMjM_e64df72a-7cd7-4f5f-817a-09f221dc6bb3"
      unitRef="usd">16289856</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTgtMy0xLTEtMjM_af1f566d-861c-4fd2-a0a2-a498565c32f1"
      unitRef="usd">17694743</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTktMS0xLTEtMjM_efaa2422-0a83-4cab-9ea5-bbee6727d67e"
      unitRef="usd">12000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMTktMy0xLTEtMjM_0ff6d434-b54c-460b-ad16-c2eea59b439b"
      unitRef="usd">9800000</us-gaap:LongTermLineOfCredit>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjAtMS0xLTEtMjM_d6713ead-9952-4ac3-b552-d78ae972296f"
      unitRef="usd">1930679</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjAtMy0xLTEtMjM_1b0f3c54-ef32-44b1-80b1-b9652d0f1f44"
      unitRef="usd">1815968</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <us-gaap:Liabilities
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjEtMS0xLTEtMjM_87ad3b6d-046b-41b7-bc5d-16ee902d5ef9"
      unitRef="usd">30220535</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjEtMy0xLTEtMjM_28ce9a8b-07bb-4cd6-9476-cd40fecd941b"
      unitRef="usd">29310711</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjUtMS0xLTEtMjY_8bf6b50d-3982-439d-a94a-9fbf74dc7607"
      unitRef="usd">51755834</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjUtMy0xLTEtMjg_78cd6883-988b-4dca-9d8c-3b8b2ccff0a2"
      unitRef="usd">52410941</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjYtMS0xLTEtMjY_23f8301a-d73b-4f34-b86f-a0e9f2165ada"
      unitRef="usd">9329983</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjYtMy0xLTEtMjg_bbcc4497-7b9e-4ff0-9ac9-64f21daf8a6f"
      unitRef="usd">11709222</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjctMS0xLTEtMjY_f84d3243-908c-418e-a971-bfa9babbdf40"
      unitRef="usd">61085817</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjctMy0xLTEtMjg_21892930-8ee9-4a68-b8fb-1cf778a8917d"
      unitRef="usd">64120163</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjgtMS0xLTEtMjY_4c6adb89-afba-4caf-aa09-21db57467986"
      unitRef="usd">-211512</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjgtMy0xLTEtMjg_76041745-e250-4015-ad11-7490d094af49"
      unitRef="usd">-198562</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjktMS0xLTEtMjY_63a2c0cc-e85f-4c1e-88e1-e1b071ef9a59"
      unitRef="usd">60874305</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMjktMy0xLTEtMjg_e7abc7d0-7136-44c9-989c-333171177589"
      unitRef="usd">63921601</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMzAtMS0xLTEtMjY_72699e43-a310-41dd-a69b-be59cc0fa590"
      unitRef="usd">91094840</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N180NC9mcmFnOjAzYjQ2ZTYyZmM4ZTRmZTBiNGY5MGQ1YzA3ZDJkZjVkL3RhYmxlOjVlOTRlOGRjNDU4OTQwMzk4MDc0N2MzZWJhOTQxZjlhL3RhYmxlcmFuZ2U6NWU5NGU4ZGM0NTg5NDAzOTgwNzQ3YzNlYmE5NDFmOWFfMzAtMy0xLTEtMjg_de7daab5-1256-4581-aae2-93b8b4efbfc5"
      unitRef="usd">93232312</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SalesRevenueNet
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMi01LTEtMS01MjE0_43f0d38b-0695-44ff-a199-99dc003b375b"
      unitRef="usd">8587605</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMi03LTEtMS01MjE0_fdc9afaf-3b92-4be6-b0c2-beeca9b3f603"
      unitRef="usd">9636755</us-gaap:SalesRevenueNet>
    <us-gaap:CostOfGoodsSold
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNC01LTEtMS01MjE0_636cc67f-1b5b-4345-9d18-5b4d6756361a"
      unitRef="usd">1527961</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNC03LTEtMS01MjE0_2bed7e87-ea12-48db-ba4a-b9ecef266bab"
      unitRef="usd">1381497</us-gaap:CostOfGoodsSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNS01LTEtMS01MjE0_1046ccbf-27d5-4b2e-810b-04e8ee88b2d6"
      unitRef="usd">4670511</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNS03LTEtMS01MjE0_71f7cd7b-5bcb-4583-b0ea-c86e9c3a92e8"
      unitRef="usd">5293020</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNi01LTEtMS01MjE0_2bec1ccd-0ca9-4457-a5da-cdabb6ef3de4"
      unitRef="usd">1874939</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNi03LTEtMS01MjE0_dde4f306-d981-413f-9eea-05a7965d3141"
      unitRef="usd">898363</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNy01LTEtMS01MjE0_20e52fd7-0f5b-430b-9b9a-dde97e9baecc"
      unitRef="usd">2330281</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfNy03LTEtMS01MjE0_be9cb784-a292-4091-9c9a-c3ccf7a838ac"
      unitRef="usd">2110233</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfOC01LTEtMS01MjE0_70f16a4f-69f7-40f5-8462-e80638538db0"
      unitRef="usd">636135</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfOC03LTEtMS01MjE0_3f6d93af-ba22-4ed9-9e8e-24ceb638d1f8"
      unitRef="usd">611444</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfOS01LTEtMS01MjE0_a4395b88-1f8b-4661-a249-a17351693a96"
      unitRef="usd">11039827</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfOS03LTEtMS01MjE0_1e4352bf-7bb8-4722-b714-f72f9ed23055"
      unitRef="usd">10294557</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTAtNS0xLTEtNTIxNA_dbfd9fa6-29ce-44a2-93c5-40839d75bc43"
      unitRef="usd">-2452222</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTAtNy0xLTEtNTIxNA_e2b0630f-1613-4436-802f-2dd030d58551"
      unitRef="usd">-657802</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTEtNS0xLTEtNTIxNA_54861f66-cb21-4b14-853f-df3007c610d2"
      unitRef="usd">82494</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTEtNy0xLTEtNTIxNA_84fd8f82-270e-4151-9c4a-411e1c5065e5"
      unitRef="usd">52535</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTItNS0xLTEtNTIxNA_10a18eeb-26c4-4ee2-96e3-d75752bb63a8"
      unitRef="usd">18302</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTItNy0xLTEtNTIxNA_29e28b19-a7a1-4f30-9459-4300ce40ec9b"
      unitRef="usd">31715</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTMtNS0xLTEtNTIxNA_d8fa958e-fcea-4d50-9391-b7c4f75776cb"
      unitRef="usd">-2388030</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTMtNy0xLTEtNTIxNA_fd9bf5de-aa8c-47c8-b41b-1d431299a5d6"
      unitRef="usd">-636982</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTQtNS0xLTEtNTIxNA_34785651-6c39-4261-a221-b621f609b306"
      unitRef="usd">-4159</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTQtNy0xLTEtNTIxNA_6aea0200-200b-4fda-97f7-f0080e6a1f1e"
      unitRef="usd">-656587</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTUtNS0xLTEtNTIxNA_9fcfccbe-8f90-4318-99ae-4147c1b18f72"
      unitRef="usd">-2392189</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTUtNy0xLTEtNTIxNA_87cbcef2-92df-4724-b453-8dc6ab5212ac"
      unitRef="usd">-1293569</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTYtNS0xLTEtNTIxNA_f53614b9-7a25-4a8d-9630-9513d8547835"
      unitRef="usd">12950</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTYtNy0xLTEtNTIxNA_dedd24bc-c7e1-4167-8081-9beedf09a256"
      unitRef="usd">19123</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTctNS0xLTEtNTIxNA_c90515c6-e5f0-4684-960d-1287c77d8a03"
      unitRef="usd">-2379239</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTctNy0xLTEtNTIxNA_51fb11d8-8287-48da-98d5-ceb821b961d3"
      unitRef="usd">-1274446</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTktNS0xLTEtNTIxNA_48eac73e-7ef6-4caa-b92a-3cdaf7489ec2"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMTktNy0xLTEtNTIxNA_dd4783aa-9b4a-42a0-b516-9dd90d9c2f40"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMjAtNS0xLTEtNTIxNA_56d0ad3b-7c95-41d1-b5ed-767b4f0281e7"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMjAtNy0xLTEtNTIxNA_b92f23e4-9d13-43dd-aa5a-4ff2c1a55d69"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMjItNS0xLTEtNTIxNA_d6159259-601f-43a2-b3f5-7ee055363086"
      unitRef="shares">15689240</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMjItNy0xLTEtNTIxNA_469701ca-0a98-47c0-af28-728d0135325d"
      unitRef="shares">16042219</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMjMtNS0xLTEtNTIxNA_fbd96162-d6a3-4892-9341-6feeeba568df"
      unitRef="shares">15689240</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMjMtNy0xLTEtNTIxNA_02e434d3-0706-45e9-8291-bf0e0d137ee5"
      unitRef="shares">16042219</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMDMxNzhBQUFBR1FBQUFCa0FBQUFGQUFBQUJRQUFBQUFBQUJSbkFBQSUzRA_eec7fca7-cf7b-4d00-85f3-d4289ccac721"
      unitRef="usd">-2379239</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMDMxN2VBQUFBR1FBQUFCa0FBQUFIQUFBQUJ3QUFBQUFBQUJScUFBQSUzRA_c2ec9815-28e8-4f0d-8873-574a10623fca"
      unitRef="usd">-1274446</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMDMxNzdBQUFBR2dBQUFCb0FBQUFGQUFBQUJRQUFBQUFBQUJSb0FBQSUzRA_929d418d-7f6d-4a6a-888c-eeeb6adbf783"
      unitRef="usd">12950</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMDMxNzFBQUFBR2dBQUFCb0FBQUFIQUFBQUJ3QUFBQUFBQUJSckFBQSUzRA_29e994f9-5594-4f78-a854-67e2247e76b6"
      unitRef="usd">19123</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMDMxNzRBQUFBR3dBQUFCc0FBQUFGQUFBQUJRQUFBQUFBQUJScEFBQSUzRA_456afc42-993b-4b69-a367-084844901df5"
      unitRef="usd">-2392189</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N181NC9mcmFnOjA1YTliMzZiYWU1YTRlZTk4OWZjM2I2YjZlZGFhM2ZlL3RhYmxlOjY3YzA1MzQ3MWNiYjRiMzQ4Y2Q1MzljNGM0YmNkMmYyL3RhYmxlcmFuZ2U6NjdjMDUzNDcxY2JiNGIzNDhjZDUzOWM0YzRiY2QyZjJfMDMxNzBBQUFBR3dBQUFCc0FBQUFIQUFBQUJ3QUFBQUFBQUJSc0FBQSUzRA_38f9d2c3-311f-43fe-9341-866b14cfff68"
      unitRef="usd">-1293569</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMy0xLTEtMS0yOTM_b6f4e98b-4e4d-489c-9c7a-f10995055a01"
      unitRef="usd">-2392189</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMy0zLTEtMS0yOTM_d069f32d-d884-43d0-adb2-67ce27defdc9"
      unitRef="usd">-1293569</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfNS0xLTEtMS0yOTM_4a130545-32cc-42a5-8207-9bfa84bff941"
      unitRef="usd">692991</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfNS0zLTEtMS0yOTM_b0568cf0-354f-48a3-baa2-2807ef9c6394"
      unitRef="usd">661485</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfNi0xLTEtMS0yOTM_7236d89f-ea85-4e42-a257-a9bf2fdfe9a9"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfNi0zLTEtMS0yOTM_36983131-5cbf-4ec4-a0fa-b1389fd0063f"
      unitRef="usd">758112</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfNy0xLTEtMS0yOTM_920273f5-ef02-4452-bc84-0f8e41874287"
      unitRef="usd">339209</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfNy0zLTEtMS0yOTM_79fdf85f-b0d6-4f35-8794-7a7e03336720"
      unitRef="usd">254585</us-gaap:ShareBasedCompensation>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfOC0zLTEtMS0yOTM_bbbfadbf-69e6-4f44-aae8-3273a85527aa"
      unitRef="usd">92741</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfOS0xLTEtMS0yOTM_58166d59-69b5-44f1-b446-ff84f2060532"
      unitRef="usd">18303</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfOS0zLTEtMS0yOTM_11688785-ede5-4c0f-ba76-ec8011777df5"
      unitRef="usd">26778</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTAtMS0xLTEtMjkz_4b4093f2-9be8-40b8-a18d-51ee3bfe7976"
      unitRef="usd">-43338</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTAtMy0xLTEtMjkz_cdefcc8c-aea9-4a32-af48-ddedc32d004d"
      unitRef="usd">-4807</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTItMS0xLTEtMjkz_33cf1dd9-eed8-4f66-a5d9-ae5069f90c6b"
      unitRef="usd">2093950</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTItMy0xLTEtMjkz_5018784c-833f-45f8-a4f8-d978b924f166"
      unitRef="usd">2395348</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTMtMS0xLTEtMjkz_03661edf-e75a-47ce-955a-874cf6b1b472"
      unitRef="usd">76323</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTMtMy0xLTEtMjkz_cde0ad6d-0746-46c7-8c39-e44906e7e4b5"
      unitRef="usd">-275175</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTQtMS0xLTEtMjkz_13d0d4e5-9382-49d9-90ed-ad1254c1c3f0"
      unitRef="usd">600884</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTQtMy0xLTEtMjkz_cf7a5941-1447-452a-bcac-81b6877e2841"
      unitRef="usd">132819</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTUtMS0xLTEtMjkz_b5a4b6f4-e559-4ebd-ae9c-d74f930a0966"
      unitRef="usd">-1254535</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTUtMy0xLTEtMjkz_db305cd1-d420-49c3-88b6-c900b5c63a42"
      unitRef="usd">-1216345</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTYtMS0xLTEtMjkz_63341d00-dbe0-44f2-98d8-2d9cd529ae8e"
      unitRef="usd">103991</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTYtMy0xLTEtMjkz_5742a76b-4945-4c4f-8f73-8599a1c16bb4"
      unitRef="usd">92881</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTctMS0xLTEtMjkz_3c91d6da-f9e8-4a20-92a2-30010bc89104"
      unitRef="usd">235589</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTctMy0xLTEtMjkz_541501c1-7615-44c9-a596-f421d7c708b5"
      unitRef="usd">1439371</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTktMS0xLTEtMjkz_4de914f7-76c4-420d-bd66-070a307c2361"
      unitRef="usd">94881</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMTktMy0xLTEtMjkz_07839bb5-527c-4ad8-8469-b701d4bca32d"
      unitRef="usd">123945</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjAtMS0xLTEtMjkz_f4b96057-c430-4bea-a694-e7025fb58e22"
      unitRef="usd">15151948</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjAtMy0xLTEtMjkz_6b5f223d-13cf-4a7a-b5bb-f4e21ef9fc5d"
      unitRef="usd">792716</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjEtMS0xLTEtMjkz_1ec1d424-cf85-4d0f-998a-ec0e9a3e0c0f"
      unitRef="usd">4257657</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjEtMy0xLTEtMjkz_0c9edd71-9ca2-4a74-a043-a680371687aa"
      unitRef="usd">941087</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjMtMS0xLTEtMjkz_c40c22ae-968a-4367-975b-27d4ea14d061"
      unitRef="usd">532954</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjMtMy0xLTEtMjkz_8f6ec09e-f8be-414e-9430-720e98b84a54"
      unitRef="usd">453961</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjQtMS0xLTEtMjkz_74388b97-6b98-4251-8953-115424f81c38"
      unitRef="usd">-11522126</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjQtMy0xLTEtMjkz_8bb47f79-fb63-4ee0-8dd3-4bd406851f07"
      unitRef="usd">-429535</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjctMS0xLTEtMjkz_03461dcc-a659-4a56-969e-ba7c9314a272"
      unitRef="usd">12000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMjctMy0xLTEtMjkz_72e78167-a83c-4dd3-bb8c-2b6fe7c9ab1c"
      unitRef="usd">0</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMDMxNTFBQUFBSEFBQUFCd0FBQUFCQUFBQUFRQUFBQUFBQUJpSEFBQSUzRA_56157e38-0dda-4acf-8bbb-717e5c278e83"
      unitRef="usd">9800000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMDMxNWZBQUFBSEFBQUFCd0FBQUFEQUFBQUF3QUFBQUFBQUJpR0FBQSUzRA_fa22cd34-87fb-41aa-98a7-67cc0fbb2753"
      unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMDMxNTJBQUFBSFFBQUFCMEFBQUFCQUFBQUFRQUFBQUFBQUJqY0FBQSUzRA_be013311-28ec-4176-a5b5-edfdddaf3b3e"
      unitRef="usd">200909</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMDMxNWNBQUFBSFFBQUFCMEFBQUFEQUFBQUF3QUFBQUFBQUJqZEFBQSUzRA_6267f0e5-2ce4-4eb6-9f15-cd889a919013"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMDMxNTdBQUFBSGdBQUFCNEFBQUFCQUFBQUFRQUFBQUFBQUJqVUFBQSUzRA_642564b7-39be-4d2c-a1d7-b7fba36e8279"
      unitRef="usd">248108</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMDMxNWJBQUFBSGdBQUFCNEFBQUFEQUFBQUF3QUFBQUFBQUJqVkFBQSUzRA_009ba1d5-d624-47c2-abe8-209a16cb5b65"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzItMS0xLTEtMjkz_cb1e6ed6-1a06-4c09-8e64-9609a7102536"
      unitRef="usd">1016156</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzItMy0xLTEtMjkz_4dddd682-2270-45c2-8b72-4a77c475f9e5"
      unitRef="usd">545924</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzMtMS0xLTEtMjkz_8c2f83e9-4833-48fc-a15e-1ab5e59d3d96"
      unitRef="usd">1136645</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzMtMy0xLTEtMjkz_8c9182ab-94de-4e87-883f-ba7d7a343b3d"
      unitRef="usd">-545924</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzQtMS0xLTEtMjkz_5e7b54c9-8eb7-493c-b7fe-46fb675b7591"
      unitRef="usd">-10149892</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzQtMy0xLTEtMjkz_e713253b-c73b-406b-a4f5-b49a1c3ae345"
      unitRef="usd">463912</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzUtMS0xLTEtMjkz_93c81e29-7036-4948-ab50-c9d01a3c37a1"
      unitRef="usd">45412868</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8bf8f59dc7274cd6980319cc241a28f2_I20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzUtMy0xLTEtMjkz_111df818-f773-4700-8d09-a89c2e771639"
      unitRef="usd">34510330</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzYtMS0xLTEtMjkz_baeb7beb-cd50-42b5-9aed-ba2833d9b494"
      unitRef="usd">35262976</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0dd9dd6ff2ca40c88619dd5d86f0eafb_I20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N182Ni9mcmFnOmE0NTJkMjA5MGQ3MTQ4ODQ5MzBkNzI3NzYyOTVhZmI0L3RhYmxlOmMxZDk3YTE2M2I1ZTQ3NTA4MDEwNWE1NmZhODhkM2NlL3RhYmxlcmFuZ2U6YzFkOTdhMTYzYjVlNDc1MDgwMTA1YTU2ZmE4OGQzY2VfMzYtMy0xLTEtMjkz_adc71879-d5ff-4594-94b3-bf444aea51d0"
      unitRef="usd">34974242</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i097d668a5f1047f0be37d4b8f2dd8771_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMy0xLTEtMS0zMDA_99706fe8-758b-4edc-affb-d114b49b4632"
      unitRef="shares">15723075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i097d668a5f1047f0be37d4b8f2dd8771_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMy0zLTEtMS0zMDA_8fb685e7-c918-4e4d-9cde-c6811b8460db"
      unitRef="usd">52410941</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0fd3da4e3c75411aa04652f12b8f13df_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMy01LTEtMS0zMDA_bfd5e0a5-bd41-4738-9b4e-490d39825bce"
      unitRef="usd">11709222</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0420ad95a0194945bfcbfd1dbc3b688f_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMy03LTEtMS0zMDA_bae95abe-fdb4-4947-ad21-3f98c96df9a1"
      unitRef="usd">-198562</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMy05LTEtMS0zMDA_19012b83-666e-4df3-8cd0-3a6b699dfc0f"
      unitRef="usd">63921601</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMDIxMUFBQUFCQUFBQUFRQUFBQUJBQUFBQVFBQUFBQUFBQmpmQUFBJTNE_ec02ceae-7ab4-4b70-abce-6b736d42423b"
      unitRef="shares">30704</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMDIxZkFBQUFCQUFBQUFRQUFBQURBQUFBQXdBQUFBQUFBQmpnQUFBJTNE_fa457348-5c8e-49cd-8a90-88c2612abe12"
      unitRef="usd">200909</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMDI3OUFBQUFCQUFBQUFRQUFBQUpBQUFBQ1FBQUFBQUFBQmpoQUFBJTNE_2d4fa339-9ce0-483a-8d2b-a25506d81320"
      unitRef="usd">200909</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfNS0xLTEtMS0zMDA_d3e5967e-2ebd-4719-8c38-c95e12a924bd"
      unitRef="shares">145550</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfNS0zLTEtMS0zMDA_356e405b-3f7b-4a57-8107-1bc60944ec6c"
      unitRef="usd">339209</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfNS05LTEtMS0zMDA_a2f26eea-ceb3-400d-8379-5a075e13dcf6"
      unitRef="usd">339209</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfOC0xLTEtMS0zMDA_9a788407-af2e-4389-aa5e-ce5a6bd22f10"
      unitRef="shares">172079</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfOC0zLTEtMS0zMDA_645d82db-4ea0-496e-ad2b-b1e7f4206446"
      unitRef="usd">1195225</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfOC05LTEtMS0zMDA_efbc4edb-c638-4c15-9e1d-b5f04cb45737"
      unitRef="usd">1195225</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="ied2c88c7a3e94ca69560e97f372df5eb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfOS01LTEtMS0zMDA_32a14ae8-94e9-4578-86f8-5f11dbcfd313"
      unitRef="usd">-2379239</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i895db0703de048cb8eb76978269e35a6_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfOS03LTEtMS0zMDA_455aa193-9635-4525-933d-33b61ce6ce16"
      unitRef="usd">-12950</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfOS05LTEtMS0zMDA_62e472bf-3567-4740-b1ba-496dea0394d4"
      unitRef="usd">-2392189</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic602d02dff724990b5feb87e55fbb783_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMTAtMS0xLTEtMzAw_6c3a311e-84d3-449e-9759-78fac3ebc8e6"
      unitRef="shares">15727250</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic602d02dff724990b5feb87e55fbb783_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMTAtMy0xLTEtMzAw_4b8fd5c5-eda9-4db7-9bf1-2b701d6b03d3"
      unitRef="usd">51755834</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i26a1fb7ff6bd4d2085da7c1c604620e1_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMTAtNS0xLTEtMzAw_6c49c6a7-2528-43b8-80ae-da44c3ad1fd4"
      unitRef="usd">9329983</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5909472559854a45a161ee9683451710_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMTAtNy0xLTEtMzAw_c664ec5b-a4ed-49df-9931-bdbdfbf31c6e"
      unitRef="usd">-211512</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N183OC9mcmFnOjdmNzM4YjQ2NjNhZjRlODBiYTRkNzc2ZGFlNzU0YzM4L3RhYmxlOmEyZTc1YTk3MWVmZDQ4ZGM5ODlkNmFmNjQyY2FlYjlmL3RhYmxlcmFuZ2U6YTJlNzVhOTcxZWZkNDhkYzk4OWQ2YWY2NDJjYWViOWZfMTAtOS0xLTEtMzAw_740ebd61-bdee-4f4b-bc38-fa9685a71381"
      unitRef="usd">60874305</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDEvZnJhZzo2MjFjNzE1Y2FiOTQ0Y2I1OGFiMWNkMGMxYmU2OWE2MC90ZXh0cmVnaW9uOjYyMWM3MTVjYWI5NDRjYjU4YWIxY2QwYzFiZTY5YTYwXzIxOTkwMjMyNzkwMjU_d1eae438-5d29-42b0-acf0-9d0de76cd6c3">ORGANIZATION AND&#160;BASIS OF PRESENTATION&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December&#160;31, 2017 audited consolidated financial statements, with the exception of the impacts of adopting accounting pronouncements during 2018, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2017 (the &#x201c;2017 Annual Report on Form 10-K&#x201d;). The results of operations for the three months ended March&#160;31, 2018 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;Total comprehensive income (loss) consisted solely of net income (loss) for the three months ended March&#160;31, 2018 and 2017.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;vertical-align:bottom;"&gt;Adoption of Revenue Accounting Standard&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) amended guidance in the form of Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 45 days from date of shipment. The Company&#x2019;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;"&gt;Sales Rebates and Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;"&gt;Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#x2019;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other tactor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;vertical-align:bottom;"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;"&gt;Recent Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, &#x201c;Revenue from Contracts with Customers.&#x201d; (&#x201c;ASC 606&#x201d;)  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018.  As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. The Company is currently applying the standard in its current practices. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In November 2016, the FASB issued ASU No. 2016-18, &#x201c;Statement of Cash Flows: Restricted Cash.&#x201d; This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the &#x201c;beginning-of-period&#x201d; and &#x201c;end-of-period&#x201d; total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, &#x201c;Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.&#x201d; The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;"&gt;Recent Accounting Pronouncements - Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard&#x2019;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-12, &#x201c;Leases.&#x201d; The new standard establishes a right-of-use (&#x201c;ROU&#x201d;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients available. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;its current lease agreements for the impact of its pending adoption of the new standard on its consolidated financial statements and disclosures. The Company&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of office and wet laboratory space in Nashville, Tennessee by Cumberland Emerging Technologies (&#x201c;CET&#x201d;), our majority-owned subsidiary, in which it operates the CET Life Sciences Center.  This lease currently expires in April 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;vertical-align:bottom;"&gt;Accounting Policies:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;text-decoration: underline;vertical-align:bottom;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the allowances for obsolescent or unmarketable inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;vertical-align:bottom;"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;The Company has&#160;one&#160;operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDEvZnJhZzo2MjFjNzE1Y2FiOTQ0Y2I1OGFiMWNkMGMxYmU2OWE2MC90ZXh0cmVnaW9uOjYyMWM3MTVjYWI5NDRjYjU4YWIxY2QwYzFiZTY5YTYwXzEwNDQ1MzYwNjI0NTM2_214a318d-b78a-407e-8f6f-d9ea65e78300">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;"&gt;Recent Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, &#x201c;Revenue from Contracts with Customers.&#x201d; (&#x201c;ASC 606&#x201d;)  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018.  As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. The Company is currently applying the standard in its current practices. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In November 2016, the FASB issued ASU No. 2016-18, &#x201c;Statement of Cash Flows: Restricted Cash.&#x201d; This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the &#x201c;beginning-of-period&#x201d; and &#x201c;end-of-period&#x201d; total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, &#x201c;Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.&#x201d; The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;"&gt;Recent Accounting Pronouncements - Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard&#x2019;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-12, &#x201c;Leases.&#x201d; The new standard establishes a right-of-use (&#x201c;ROU&#x201d;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients available. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating &lt;/span&gt;&lt;/div&gt;its current lease agreements for the impact of its pending adoption of the new standard on its consolidated financial statements and disclosures. The Company&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of office and wet laboratory space in Nashville, Tennessee by Cumberland Emerging Technologies (&#x201c;CET&#x201d;), our majority-owned subsidiary, in which it operates the CET Life Sciences Center.  This lease currently expires in April 2023.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDEvZnJhZzo2MjFjNzE1Y2FiOTQ0Y2I1OGFiMWNkMGMxYmU2OWE2MC90ZXh0cmVnaW9uOjYyMWM3MTVjYWI5NDRjYjU4YWIxY2QwYzFiZTY5YTYwXzEwNDQ1MzYwNjI0NTM1_3ce7a717-f273-4fbd-9ddc-344f69f374a2">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;text-decoration: underline;vertical-align:bottom;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the allowances for obsolescent or unmarketable inventory.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDEvZnJhZzo2MjFjNzE1Y2FiOTQ0Y2I1OGFiMWNkMGMxYmU2OWE2MC90ZXh0cmVnaW9uOjYyMWM3MTVjYWI5NDRjYjU4YWIxY2QwYzFiZTY5YTYwXzIxOTkwMjMyNzkwMjI_4cc3b3ec-711f-47eb-8c26-6ee192a7feb5">Operating SegmentsThe Company has&#160;one&#160;operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMDEvZnJhZzo2MjFjNzE1Y2FiOTQ0Y2I1OGFiMWNkMGMxYmU2OWE2MC90ZXh0cmVnaW9uOjYyMWM3MTVjYWI5NDRjYjU4YWIxY2QwYzFiZTY5YTYwXzEwOTk1MTE2NTEyMzI_59824400-253f-4afc-97b4-72a8eb8a55e7"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90ZXh0cmVnaW9uOjc5MTYyOTJkZjVhMDQwYmViMDZkMDVlNDFmYWMwZTczXzEwOTk1MTE2MzQ0Njg_62fafb61-4077-4589-83d1-d0317e8ea720">MARKETABLE SECURITIES&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency issued mortgage-backed securities, U.S. government agency notes and bonds, Small Business Administration (&#x201c;SBA&#x201d;) loan pools, and corporate bonds.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of March 31, 2018&#160;and December 31, 2017,&#160;the marketable securities are comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the condensed consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;Level 1 -&#160;Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;Level 2 -&#160;Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;Level 3 -&#160;Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;vertical-align:bottom;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/span&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.368576%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2017&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury notes and bonds&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;6,486,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;6,486,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Agency issued mortgage-backed securities &#x2013; variable rate&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;1,569,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;1,569,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,539,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,539,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Agency notes and bonds &#x2013; fixed rate&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;198,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;198,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2,502,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2,502,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;SBA loan pools &#x2013; variable rate&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;548,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;548,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;935,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;935,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term cash investments&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;4,502,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;4,502,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of marketable  securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;6,486,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;9,123,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;15,610,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;4,672,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;4,672,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90ZXh0cmVnaW9uOjc5MTYyOTJkZjVhMDQwYmViMDZkMDVlNDFmYWMwZTczXzEwOTk1MTE2MzQ0Njc_644507d4-5a9a-4ca7-bd69-570e27b03bae">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/span&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.368576%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2017&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury notes and bonds&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;6,486,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;6,486,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Agency issued mortgage-backed securities &#x2013; variable rate&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;1,569,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;1,569,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,539,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,539,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Agency notes and bonds &#x2013; fixed rate&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;198,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;198,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2,502,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2,502,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;SBA loan pools &#x2013; variable rate&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;548,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;548,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;935,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;935,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term cash investments&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;4,502,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;4,502,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of marketable  securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;6,486,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;9,123,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;15,610,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;4,672,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;4,672,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:TradingSecurities
      contextRef="i91ee759fede74a44afc15799417026fc_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAxY0FBQUFBd0FBQUFNQUFBQUJBQUFBQVFBQUFBQUFBQmpzQUFBJTNE_0da431b3-b3cf-4824-9b4e-02f69c4c0171"
      unitRef="usd">6486345</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i4184f63683bf45109fe4a49c88baafbc_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAxYUFBQUFBd0FBQUFNQUFBQURBQUFBQXdBQUFBQUFBQmp0QUFBJTNE_7373a3b6-4498-4b5f-b856-262f3b4c3803"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i4572e5a71c344688b9efe5e38ee4a0e8_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMzRBQUFBQXdBQUFBTUFBQUFGQUFBQUJRQUFBQUFBQUJqd0FBQSUzRA_ca10405f-815e-4391-b5f5-20f0412980fb"
      unitRef="usd">6486345</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="iac05f8bde425448ea4955ae4d2988a48_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMzBBQUFBQXdBQUFBTUFBQUFIQUFBQUJ3QUFBQUFBQUJqeUFBQSUzRA_91b3a8d1-2789-4504-b377-1ab3dc402bd8"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i43d4a46326a24d6caca1fac6793144ce_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyNDZBQUFBQXdBQUFBTUFBQUFKQUFBQUNRQUFBQUFBQUJqMEFBQSUzRA_d00cfea6-e92a-4100-876d-259e23a90afa"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i51f8d7b7f57f4d7388487c437f5ab518_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyNGFBQUFBQXdBQUFBTUFBQUFMQUFBQUN3QUFBQUFBQUJqMkFBQSUzRA_e02f7047-857f-4fc2-a0b7-c3204d3f76d4"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i4c6551d700a840f38a0908ea87bf44cf_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzMtMS0xLTEtMzA4_6573151a-e0ed-4ab9-9488-6a9daec3aa93"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i9d63d8a95b20480d99100f9855f3f288_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzMtMy0xLTEtMzA4_ff515aa1-d582-4baf-8a0b-e2ca7db96b22"
      unitRef="usd">1569884</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i0aea36d855cf456e880b35e2dc2c0505_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzMtNS0xLTEtMzA4_a38d56f0-bc91-402d-b03d-76f951b1a653"
      unitRef="usd">1569884</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i740c45d85a2942c196e262b2964e237b_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzMtNy0xLTEtMzE2_bd8919c3-1714-4796-ba7a-873382753c0a"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i996d7d1b56cb43219465772f1f7597fe_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzMtOS0xLTEtMzE2_1bc95a17-7bf3-4de8-b552-8dbbbdc21600"
      unitRef="usd">3539102</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ie54bf1c8e2d14928a9a06a734dfd7c6c_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzMtMTEtMS0xLTMxNg_d7375a00-43a3-4be0-a9fd-9986eaae9a6b"
      unitRef="usd">3539102</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i439c1bc3ca8e4e5b9ea4d7bdb13d6991_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzQtMS0xLTEtMzA4_1d63ccb7-3af0-4994-b5ca-0cc187873718"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i01938b90ab854812b8ec66565464d607_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzQtNy0xLTEtMzE2_1a9497ea-e8ca-40b0-b38b-aa4fe4081f55"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i5149372296b940a2aa525db6faa8f3c4_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzQtOS0xLTEtMzE2_9038d103-20bd-496b-a7f3-cc30cf3d0f19"
      unitRef="usd">198293</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="id5a2b34ed5004b8fa2acfe953a3cc3c4_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzQtMTEtMS0xLTMxNg_8ef1fca3-fc7d-4fd4-a68a-eb5b32d0d505"
      unitRef="usd">198293</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i2830ebd535c84a6496a304acfc539e9a_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMTdBQUFBQmdBQUFBWUFBQUFCQUFBQUFRQUFBQUFBQUJqNEFBQSUzRA_bcc7156d-e7f8-402d-897d-7c5b176b7e79"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ic4dd4eb6277e4ca19f808c8a63b5fd3e_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMWJBQUFBQmdBQUFBWUFBQUFEQUFBQUF3QUFBQUFBQUJqNUFBQSUzRA_57744f62-48f4-42b1-a33a-1170fee98168"
      unitRef="usd">2502977</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i18a7c5c9ec3446ddad8bd6afcd563cf6_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMjdBQUFBQmdBQUFBWUFBQUFGQUFBQUJRQUFBQUFBQUJqNkFBQSUzRA_745f70b0-3374-4a9b-8593-e69dda538517"
      unitRef="usd">2502977</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i6aae0fc592af4b14936eced6617fdc55_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMmJBQUFBQmdBQUFBWUFBQUFIQUFBQUJ3QUFBQUFBQUJqN0FBQSUzRA_175dd3bd-c584-4241-a628-1f232ec9ad4d"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i0d02d8434f0641b9a2539c9d2707cf7b_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyN2RBQUFBQmdBQUFBWUFBQUFKQUFBQUNRQUFBQUFBQUJqOEFBQSUzRA_87e76c5b-e311-4df7-b63b-c92d2a727984"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i863ba3e77c42420dbba1bfa4d84f2196_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyNzNBQUFBQmdBQUFBWUFBQUFMQUFBQUN3QUFBQUFBQUJqOUFBQSUzRA_1da23d35-098a-4fa0-82fb-ff36b936c789"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ia15f718fd7ee4613bd4f49589b3d8fdc_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzUtMS0xLTEtMzA4_9c653172-aa0c-4545-bda8-d9e8b1a31079"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ibe82cbc40bcb489390a75fce71b8b80f_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzUtMy0xLTEtMzA4_35fa2976-28bb-4de9-a8ad-1b6b4072afee"
      unitRef="usd">548641</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="id8ae969ed44e419f8fc0f2099a9510cd_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzUtNS0xLTEtMzA4_883e3ab8-1c4c-4976-aca1-4bf5b2440f69"
      unitRef="usd">548641</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i5ed094dbab104669b5bce32fe7460a28_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzUtNy0xLTEtMzE2_f6556c4e-cedc-4c04-ae9d-5c6d37536355"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i84d27aa248d24ab8b554e59624c79428_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzUtOS0xLTEtMzE2_704f6513-28d5-45c4-be70-ff024c1470ab"
      unitRef="usd">935081</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ieed830091dab43ba8375cdfb0f7f2a8c_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzUtMTEtMS0xLTMxNg_d506ce2d-f481-4272-a592-92265bbf1eda"
      unitRef="usd">935081</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="idde5b053a5b6476bb846c88390de0bc5_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzYtMS0xLTEtMzA4_e2b8d65c-87bb-492f-8299-9bfd8e613a3b"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="id98aa82685604140986e94a71f9d1936_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzYtMy0xLTEtMzA4_3cd2c97e-666c-48cd-a68d-1e2b81f4bac1"
      unitRef="usd">4502258</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i5c8ca872cb5c4f4596ce2fd08ca9aa5e_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzYtNS0xLTEtMzA4_a86ef7a7-8f69-485f-9aba-9c5e48be2b27"
      unitRef="usd">4502258</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ib5c0c160863d4cceb26f484a2325fb1d_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzYtOS0xLTEtMzE2_f6fb5afb-d9ec-41bd-a31c-a3b3ce0813b4"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i381dc586d9494541bcf340e8bda4d8d0_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMTZBQUFBQndBQUFBY0FBQUFCQUFBQUFRQUFBQUFBQUJQV0FBQSUzRA_86c6bd71-0d57-430f-911d-833344704092"
      unitRef="usd">6486345</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ie0982f8386a84f56bf35e403d479f381_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMWFBQUFBQndBQUFBY0FBQUFEQUFBQUF3QUFBQUFBQUJQWEFBQSUzRA_b95e9e56-d29a-4530-ad31-0a11ca9a65f8"
      unitRef="usd">9123760</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyMjZBQUFBQndBQUFBY0FBQUFGQUFBQUJRQUFBQUFBQUJQWUFBQSUzRA_1a704342-63e5-4733-b3d1-fcf65df60d6e"
      unitRef="usd">15610105</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ibb29255b0cce4beabad9c0ef7e86504e_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyN2VBQUFBQndBQUFBY0FBQUFKQUFBQUNRQUFBQUFBQUJQY0FBQSUzRA_d17edcc7-d42a-4f10-a46f-7b062f65395e"
      unitRef="usd">4672476</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMTQvZnJhZzo3OTE2MjkyZGY1YTA0MGJlYjA2ZDA1ZTQxZmFjMGU3My90YWJsZTpkMzgyM2UxNDUyZGY0MmU5ODBmNjQwYmJiZWM5YTgzNi90YWJsZXJhbmdlOmQzODIzZTE0NTJkZjQyZTk4MGY2NDBiYmJlYzlhODM2XzAyNzBBQUFBQndBQUFBY0FBQUFMQUFBQUN3QUFBQUFBQUJQZEFBQSUzRA_9d1529bf-6075-45df-a9a1-310f0d01ea6e"
      unitRef="usd">4672476</us-gaap:TradingSecurities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90ZXh0cmVnaW9uOmU3ZWVlOTEzM2UwNTRkOTI4MTlhMzUwZGY2Yzg3MjEwXzIxOTkwMjMyNTY2NDc_b7049524-2d2f-45ad-873e-db20700d59a2">EARNINGS (LOSS) PER SHARE&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the&#160;three&#160;months ended&#160;March 31, 2018&#160;and 2017:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"/&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.102639%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.008798%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.155425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,379,239)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,274,446)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;15,689,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;16,042,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;15,689,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;16,042,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:0pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;As of&#160;March 31, 2018&#160;and 2017, restricted stock awards and options to purchase&#160;247,530&#160;and&#160;237,875&#160;shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90ZXh0cmVnaW9uOmU3ZWVlOTEzM2UwNTRkOTI4MTlhMzUwZGY2Yzg3MjEwXzIxOTkwMjMyNTY2NDY_fe8939b5-1e4d-42a3-8c87-e55d4443967a">&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the&#160;three&#160;months ended&#160;March 31, 2018&#160;and 2017:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"/&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.102639%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.008798%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.155425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,379,239)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,274,446)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;15,689,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;16,042,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;15,689,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;16,042,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90YWJsZTplN2YyNzY3NGE4OWM0OGFlODI4Y2I2YTU3N2Q3YTkxNS90YWJsZXJhbmdlOmU3ZjI3Njc0YTg5YzQ4YWU4MjhjYjZhNTc3ZDdhOTE1XzEyLTEtMS0xLTMyMA_c90515c6-e5f0-4684-960d-1287c77d8a03"
      unitRef="usd">-2379239</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90YWJsZTplN2YyNzY3NGE4OWM0OGFlODI4Y2I2YTU3N2Q3YTkxNS90YWJsZXJhbmdlOmU3ZjI3Njc0YTg5YzQ4YWU4MjhjYjZhNTc3ZDdhOTE1XzEyLTMtMS0xLTMyMg_51fb11d8-8287-48da-98d5-ceb821b961d3"
      unitRef="usd">-1274446</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90YWJsZTplN2YyNzY3NGE4OWM0OGFlODI4Y2I2YTU3N2Q3YTkxNS90YWJsZXJhbmdlOmU3ZjI3Njc0YTg5YzQ4YWU4MjhjYjZhNTc3ZDdhOTE1XzE0LTEtMS0xLTMyNA_d6159259-601f-43a2-b3f5-7ee055363086"
      unitRef="shares">15689240</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90YWJsZTplN2YyNzY3NGE4OWM0OGFlODI4Y2I2YTU3N2Q3YTkxNS90YWJsZXJhbmdlOmU3ZjI3Njc0YTg5YzQ4YWU4MjhjYjZhNTc3ZDdhOTE1XzE0LTMtMS0xLTMyOA_469701ca-0a98-47c0-af28-728d0135325d"
      unitRef="shares">16042219</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90YWJsZTplN2YyNzY3NGE4OWM0OGFlODI4Y2I2YTU3N2Q3YTkxNS90YWJsZXJhbmdlOmU3ZjI3Njc0YTg5YzQ4YWU4MjhjYjZhNTc3ZDdhOTE1XzE2LTEtMS0xLTMyNg_fbd96162-d6a3-4892-9341-6feeeba568df"
      unitRef="shares">15689240</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90YWJsZTplN2YyNzY3NGE4OWM0OGFlODI4Y2I2YTU3N2Q3YTkxNS90YWJsZXJhbmdlOmU3ZjI3Njc0YTg5YzQ4YWU4MjhjYjZhNTc3ZDdhOTE1XzE2LTMtMS0xLTMzMA_02e434d3-0706-45e9-8291-bf0e0d137ee5"
      unitRef="shares">16042219</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90ZXh0cmVnaW9uOmU3ZWVlOTEzM2UwNTRkOTI4MTlhMzUwZGY2Yzg3MjEwXzEwOTk1MTE2Mjg3MDc_3cebe322-5c03-4c9e-b9ab-4426ab9716c9"
      unitRef="shares">247530</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xMjcvZnJhZzplN2VlZTkxMzNlMDU0ZDkyODE5YTM1MGRmNmM4NzIxMC90ZXh0cmVnaW9uOmU3ZWVlOTEzM2UwNTRkOTI4MTlhMzUwZGY2Yzg3MjEwXzEwOTk1MTE2Mjg3MTk_49501f3b-675a-43f9-b7a9-ea5fcfc4f5e3"
      unitRef="shares">237875</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90ZXh0cmVnaW9uOjg1NTkzMTdlNjM1YTRjMWZiMDU3YjczYTY4N2FkMmNhXzEwOTk1MTE2MzEzODY_1578b962-f475-4616-97f6-8022fe4d29ea">REVENUES&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605. However, no cumulative effect adjustment to historical retained earnings was necessary as no revenue recognition differences were identified when comparing the revenue recognition criteria under ASC 606 to previous requirements. See further discussion in Note 1. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The Company&#x2019;s net revenues consisted of the following for the&#160;three&#160;months ended&#160;March 31, 2018&#160;and 2017:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"/&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.742313%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.762811%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.762811%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Products:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Acetadote&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;1,273,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;1,265,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Omeclamox-Pak&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;141,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;645,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Kristalose&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,269,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2,386,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Vaprisol&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;93,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;684,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Caldolor&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;1,039,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;813,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Ethyol&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2,256,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,666,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;       Totect&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;412,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;100,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;175,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:42pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net revenues&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;8,587,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;9,636,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;Cumberland supplies Perrigo Company (&#x201c;Perrigo&#x201d;) with an Authorized Generic version of the Company's Acetadote product. The Company's revenue generated by sales of its Authorized Generic distributed by Perrigo is included in the Acetadote product revenue presented above. The Company's share of Authorized Generic revenue was&#160;$0.8 million&#160;and&#160;$0.9 million&#160;for first quarter of 2018 and 2017, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is entitled to receive non-refundable, up-front payments at the time the agreements are entered into and milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company recognizes revenue for these substantive milestones using the milestone method. The Company is also entitled to receive royalties on future sales of the products under the agreements.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90ZXh0cmVnaW9uOjg1NTkzMTdlNjM1YTRjMWZiMDU3YjczYTY4N2FkMmNhXzEwOTk1MTE2MzEzODU_4b90c663-8d41-421a-82fa-6afd6f3cf3b0">&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The Company&#x2019;s net revenues consisted of the following for the&#160;three&#160;months ended&#160;March 31, 2018&#160;and 2017:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"/&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.742313%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.762811%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.762811%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Products:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Acetadote&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;1,273,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;1,265,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Omeclamox-Pak&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;141,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;645,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Kristalose&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,269,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2,386,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Vaprisol&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;93,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;684,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Caldolor&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;1,039,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;813,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Ethyol&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2,256,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,666,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;       Totect&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;412,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;100,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;175,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:42pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net revenues&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;8,587,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;9,636,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:SalesRevenueNet
      contextRef="iffcc23dd7a9944139daf9824e5b8eac5_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzMtNS0xLTEtMzM2_422d4156-c242-4ed0-9098-c904825a0d7f"
      unitRef="usd">1273764</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="i6809c3be77f6432d9076c460384fbb07_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzMtNy0xLTEtMzM2_85a85149-e9b3-4724-a524-2c82c8df905d"
      unitRef="usd">1265440</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="ib2cf28a7f39c448f96b2e5671107943f_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzQtNS0xLTEtMzM2_72ef0dbc-af9f-4359-af51-eb4d9837207c"
      unitRef="usd">141392</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="i6d8502d751864f05a59b40ecc159972b_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzQtNy0xLTEtMzM2_b31c72ed-5374-49ce-a5ae-100efcb633da"
      unitRef="usd">645325</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="ic700e54bd9e84fe38825f0e668b5fc38_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzUtNS0xLTEtMzM2_e5d663c4-0622-4298-a212-e1e4ebb4af0a"
      unitRef="usd">3269901</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="i4c5e9f1b87044a0da9566dff708f6520_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzUtNy0xLTEtMzM2_cd6b34f5-30a2-46f1-89c3-89e3a7f87098"
      unitRef="usd">2386591</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="icf73e673b6164c78ab232ce6f110e7d1_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzYtNS0xLTEtMzM2_ab72cb2c-228b-480d-817a-25eb033d7896"
      unitRef="usd">93890</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="i088036779adb405fb051b2f6ea583979_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzYtNy0xLTEtMzM2_b5e1da2a-ca6f-4e8b-9d9d-59089375be61"
      unitRef="usd">684548</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="i302d2057998b42f88bce95c8b68a0dca_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzctNS0xLTEtMzM2_16f2b3cb-d83b-45f7-bcf3-d0af708ddc4d"
      unitRef="usd">1039747</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="iafc0d050afaf4677960684f8f326d0a1_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzctNy0xLTEtMzM2_5cf4557f-6022-44e8-af09-2ff19419d74b"
      unitRef="usd">813027</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="i666c2dae486e4b1eac47ec35b708938f_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzgtNS0xLTEtMzM2_c2bd1caa-c577-4728-8bfb-bff0467b5d4b"
      unitRef="usd">2256073</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="ib034705aa5544216b55c469279e3eaba_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzgtNy0xLTEtMzM2_ca29b4fc-3ceb-4a2a-af21-c948d1a813c6"
      unitRef="usd">3666808</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="i17303c3256e5493faf87462aef420fab_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzktNS0xLTEtMzM2_517318dc-fbb0-4669-a482-1fb295208ba4"
      unitRef="usd">412774</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="i2d39aea30fbc46889b6cfa872b2b6fb7_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzktNy0xLTEtMzM2_a13a5acb-9cb2-4adf-a27f-ee859d8f773f"
      unitRef="usd">0</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="id74555dabd6a4ff2ad0bdc7e28c863bc_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzEwLTUtMS0xLTMzNg_59fb9c43-001e-45df-a490-cc8f2eb0f8fd"
      unitRef="usd">100064</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="i654f0cb0d52e49d39635e4e808fc2055_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzEwLTctMS0xLTMzNg_f9788d0a-17ec-49db-a90f-116ba466d560"
      unitRef="usd">175016</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzExLTUtMS0xLTMzNg_08f7f0c5-39e9-4f92-9570-abaad6afb28d"
      unitRef="usd">8587605</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="id199b2eba45a4883a99f8420607fac40_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90YWJsZTphNjFkY2NhZTcwZjQ0MGQ5YTg2Y2FjN2M0ODMyZTJhMy90YWJsZXJhbmdlOmE2MWRjY2FlNzBmNDQwZDlhODZjYWM3YzQ4MzJlMmEzXzExLTctMS0xLTMzNg_554dea69-e5e6-4c62-893d-907e14e5e2f5"
      unitRef="usd">9636755</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="i73e54bcae66640ebbb1fffa211e276c6_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90ZXh0cmVnaW9uOjg1NTkzMTdlNjM1YTRjMWZiMDU3YjczYTY4N2FkMmNhXzEwOTk1MTE2MzExMzk_1ee14944-8a6a-42ad-bdb2-d20cd1643268"
      unitRef="usd">800000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet
      contextRef="i4eb22c1d61c749ddac462523b2b31161_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNDAvZnJhZzo4NTU5MzE3ZTYzNWE0YzFmYjA1N2I3M2E2ODdhZDJjYS90ZXh0cmVnaW9uOjg1NTkzMTdlNjM1YTRjMWZiMDU3YjczYTY4N2FkMmNhXzEwOTk1MTE2MzExNjA_eda9bd93-1df0-49fa-893d-869706846ae0"
      unitRef="usd">900000</us-gaap:SalesRevenueNet>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90ZXh0cmVnaW9uOmY3ZWRlNjRlODVkYzQ1ZTE4MzM5NzA3OGY4NjAzOWJlXzIxOTkwMjMyNTkxNzI_b3e910c9-968c-4585-b39d-e6e814494798">INVENTORIES&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At&#160;March 31, 2018&#160;and&#160;December 31, 2017, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately&#160;$0.1 million&#160;and $0.2 million, respectively.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total at&#160;March 31, 2018&#160;and&#160;December 31, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;As of&#160;March 31, 2018&#160;and December 31, 2017, net inventory consisted of the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:0pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"/&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:60.316716%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.475073%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.475073%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials and work in process&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2,642,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,156,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Consigned inventory&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;418,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;249,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,600,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,331,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;6,661,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;6,737,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90ZXh0cmVnaW9uOmY3ZWRlNjRlODVkYzQ1ZTE4MzM5NzA3OGY4NjAzOWJlXzEwOTk1MTE2MzExODg_91ac3cac-0776-4096-9284-d71da1dabe87"
      unitRef="usd">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90ZXh0cmVnaW9uOmY3ZWRlNjRlODVkYzQ1ZTE4MzM5NzA3OGY4NjAzOWJlXzEwOTk1MTE2MzEyMDg_d7f0138d-c160-47d2-88ed-f614a7a856bd"
      unitRef="usd">200000</us-gaap:InventoryValuationReserves>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90ZXh0cmVnaW9uOmY3ZWRlNjRlODVkYzQ1ZTE4MzM5NzA3OGY4NjAzOWJlXzIxOTkwMjMyNTkxNzE_a10c54b2-3d6a-4bc7-b23f-663d8306f805">&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;As of&#160;March 31, 2018&#160;and December 31, 2017, net inventory consisted of the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:0pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"/&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:60.316716%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.475073%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.475073%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials and work in process&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;2,642,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,156,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Consigned inventory&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;418,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;249,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,600,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;3,331,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;6,661,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"&gt;&lt;span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);"&gt;6,737,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzEtMS0xLTEtNTMwNg_e83315db-a6f9-4a00-b723-793a26e7cbc3"
      unitRef="usd">2642543</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzEtMy0xLTEtNTMwNg_d335b4a4-70c1-4a9f-9a57-f22d4a7e8949"
      unitRef="usd">3156002</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzItMS0xLTEtNTMwNg_e28383f1-cfcc-440c-9290-700138150c6e"
      unitRef="usd">418829</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzItMy0xLTEtNTMwNg_eb7c5989-3165-4efe-b45d-ef8c5e623378"
      unitRef="usd">249964</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzMtMS0xLTEtNTMwNg_1be2bac4-6cd1-4f7c-b05f-8c5941ae56ee"
      unitRef="usd">3600153</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzMtMy0xLTEtNTMwNg_e21bb61e-f334-49e9-9e6a-a3ce422dc059"
      unitRef="usd">3331882</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzAyMTFBQUFBQkFBQUFBUUFBQUFCQUFBQUFRQUFBQUFBQUJQa0FBQSUzRA_7ec3880e-bebb-4561-9d67-bd2506987106"
      unitRef="usd">6661525</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i66977d80365d404296229eb847d696f2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNTMvZnJhZzpmN2VkZTY0ZTg1ZGM0NWUxODMzOTcwNzhmODYwMzliZS90YWJsZTo1YWM5NzVkMjNlZGE0ZmFjYjY2NDc2Mjc4MGViNWU5NS90YWJsZXJhbmdlOjVhYzk3NWQyM2VkYTRmYWNiNjY0NzYyNzgwZWI1ZTk1XzAyMWZBQUFBQkFBQUFBUUFBQUFEQUFBQUF3QUFBQUFBQUJQbEFBQSUzRA_1c5a524b-e297-4dc2-a62d-22325fb97bba"
      unitRef="usd">6737848</us-gaap:InventoryNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzY1Mzc_bb0c26d8-0d59-4faa-aa0b-adb4a815022e">SHAREHOLDERS&#x2019; EQUITY AND DEBT&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The Company currently has a share repurchase program to repurchase up to&#160;$10 million&#160;of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2016, the Company's Board of Directors established the current&#160;$10 million repurchase program to replace the prior authorizations.  During the&#160;three months ended March 31, 2018&#160;and March 31, 2017, the Company repurchased&#160;172,079&#160;shares and&#160;155,150&#160;shares, respectively, of common stock for approximately&#160;$1.2 million&#160;and $1.0 million, respectively.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;"&gt;Share Sales&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to&#160;$100 million&#160;in corporate securities. The Shelf Registration was declared effective in January 2018. During the three months ended March 31, 2018, the Company issued &#160;30,704&#160;shares of common stock for gross proceeds of&#160;$0.2 million&#160;as part of its At-The-Market (&#x201c;ATM&#x201d;) sales agreement with B. Riley FBR.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;"&gt;Restricted Share Grants&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;During the&#160;three months ended March 31, 2018, the Company issued&#160;229,205&#160;shares of restricted stock to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyNjE_3db38b5b-b57e-4753-bab2-0401c4da4aa8"&gt;one&lt;/span&gt;-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;"&gt;Debt Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;On July 31, 2017,&#160;the Company entered into a Revolving Credit Loan Agreement with Pinnacle Bank ("Pinnacle Agreement").  The Pinnacle Agreement replaced the June 2014 Revolving Credit Loan Agreement with SunTrust Bank, which was to expire on June 30, 2018. The Company had&#160;$12.0 million&#160;&#160;in borrowings under that agreement at March&#160;31, 2018.&#160;The Pinnacle Agreement provides for an aggregate principal amount of up to&#160;$20 million&#160;and has a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzNDI_faa1036d-aac4-495e-970e-7d7605ba1f7c"&gt;three&lt;/span&gt;-year term expiring on July 31, 2020.  The initial revolving line of credit is up to&#160;$12 million&#160;with the ability to increase the borrowing amount up to&#160;$20 million, upon the satisfaction of certain conditions.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of&#160;1.75%&#160;to&#160;2.75%&#160;(representing an interest rate of&#160;3.3%&#160;at March 31, 2018).&#160;&#160;In addition, a fee of&#160;0.25%&#160;per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;Under the Pinnacle Agreement, Cumberland is subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.&#160; The Company achieved compliance with the Funded Debt Ratio covenant as of&#160;March 31, 2018&#160;through the utilization of the covenant cure section of the agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i3fd8c1a5a34842988819ab52812dc1e7_I20100513"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyMTk_d2a727f1-7133-4b0b-a532-f1163261e108"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ib436aa4112784a5bb575f9ce9fe4fb53_I20120430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyMzY_19a740b5-f1af-4b76-b2db-a0e2f520b492"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i0a9e1ab5b93d4567815cacdf06859be8_I20130131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyMzY_1f0a193a-fc53-4fe3-aefc-b40cc1513cc3"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i47407fdc5afa40749b77a0412daf8956_I20110131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyMzY_5160aa19-e3cc-41bc-879c-eed8cb4f5b21"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="iebdcd0b9547b443b8727649905bdb07b_I20160131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyMzY_8e01842c-d3b1-4a4c-886b-5b34a069851e"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="if5236a3131db4202b5eaec29f686e679_I20150131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyMzY_fde360d7-764f-4ecb-ab2d-ee68e11724bd"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzIxOTkwMjMyNjQzMDI_5148ad9a-c338-4d7a-b412-7de06002be71"
      unitRef="shares">172079</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ic6b3a2fc1ae64e68a3298edf95187fcd_D20170101-20170331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzU5MTA_96e7135a-c219-43ab-a02a-ad13fe8c938d"
      unitRef="shares">155150</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i83bfa1c60069472ebb3a478b77659e7b_D20180101-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzIxOTkwMjMyNjQzMDQ_02417140-e444-4731-920e-04feb32360a2"
      unitRef="usd">1200000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic6b3a2fc1ae64e68a3298edf95187fcd_D20170101-20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzU5NDU_bdb6e75c-7284-4eb2-b0cb-1f370f71baf0"
      unitRef="usd">1000000.0</us-gaap:StockRepurchasedDuringPeriodValue>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities
      contextRef="i61a9610b573b4e75a7c8f0f35d1cb4d8_D20171101-20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3Xzg3OTYwOTMwMzc5NzA_a8b5165b-331a-4ca6-bb6c-c2ff4655ca2c"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3Xzg3OTYwOTMwMzc5ODY_4fa376fd-2212-4800-b1a9-bc10cea83c43"
      unitRef="shares">30704</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3Xzg3OTYwOTMwMzc5ODY_ea8b2942-a5ee-427d-8944-2a69eb3cbc5e"
      unitRef="shares">30704</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3Xzg3OTYwOTMwMzc5OTU_a27851c6-ddac-400f-b68b-ae72f387fac1"
      unitRef="usd">200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i653bf892b8c94a22be15b4bc51db3a05_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzU5Njk_dc6c8d81-6cb8-4275-9e5a-046d351dda81"
      unitRef="shares">229205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:LongTermLineOfCredit
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzU0OTc1NTgyNTIwOQ_efaa2422-0a83-4cab-9ea5-bbee6727d67e"
      unitRef="usd">12000000.0</us-gaap:LongTermLineOfCredit>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions
      contextRef="i2b744dac368c4c3eb91bc9bb77c5cf97_I20170731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyODc_2bec098f-a91d-48e2-82a2-2832d8d6f07d"
      unitRef="usd">20000000</cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2b744dac368c4c3eb91bc9bb77c5cf97_I20170731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzMDM_bb3fd2f2-19b9-4459-864b-de17f7cdc5da"
      unitRef="usd">12000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions
      contextRef="i2b744dac368c4c3eb91bc9bb77c5cf97_I20170731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzMTk_eb9de3cc-0acc-4c54-ba06-350bd4d27300"
      unitRef="usd">20000000</cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i55c284425d4448d79d408df2a3a756f9_I20170731"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzNDY_414b703e-d751-4fcf-8963-09d44228986e"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i288af4ef515f4257be46413b7b9d94ee_I20170731"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzNTc_3ce909d9-2a7e-4e7d-91a1-5c995ece1515"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i1e981a44ed99406590f2ed76af33aa59_I20180331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzU4ODY_ba6c0a5e-942c-46da-8478-8d5997ea769a"
      unitRef="number">0.033</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="ifb8bca4936ff40e2b30ed5d20dc32c4f_D20170731-20170731"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzNjY_847745fb-6675-43e3-accd-e0f60cda60bf"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNzkvZnJhZzpkOWEyNjI5OGUyNzY0OGQ2YmQxOGExYTdkNDM0ZWMzNy90ZXh0cmVnaW9uOmQ5YTI2Mjk4ZTI3NjQ4ZDZiZDE4YTFhN2Q0MzRlYzM3XzEwOTk1MTE2MzczMDQ_ff147858-c9d0-4caf-beba-ebed9f03617b">INCOME TAXES&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#x201c;the Tax Act&#x201d;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to&#160;21% (2) eliminating the corporate alternative minimum tax ("AMT") and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;The SEC staff issued Staff Accounting Bulletin (&#x201c;SAB&#x201d;) 118 which provides guidance for the tax effects of the Tax Act.  SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.  In accordance with SAB 118, a company must reflect the income tax effects of those &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;aspects of the Tax Act for which the accounting under ASC 740 is complete.  To the extent that a company&#x2019;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements.  If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;In connection with our analysis of the impact of the Tax Act, we have a net tax benefit of&#160;$0.1 million of March&#160;31, 2018.  This net tax benefit consists entirely of the release of the valuation allowance against AMT credits that will be realizable under the Tax Act in future periods. While the Company does not expect to record further amounts related to the Tax Act, we will continue to evaluate additional guidance as it is released by the Internal Revenue Service and will record additional amounts if needed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="if9792ad3cd7e4c9d9650e51b4862ce84_I20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNzkvZnJhZzpkOWEyNjI5OGUyNzY0OGQ2YmQxOGExYTdkNDM0ZWMzNy90ZXh0cmVnaW9uOmQ5YTI2Mjk4ZTI3NjQ4ZDZiZDE4YTFhN2Q0MzRlYzM3Xzg3OTYwOTMwMzg2Mjg_9f39563b-b512-46c5-9ceb-3a871779c001"
      unitRef="usd">100000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xOTIvZnJhZzpmZjQxMTY2MDZkZjc0ZWYyOTdmMTc3MmIxMDI3ZDZlNC90ZXh0cmVnaW9uOmZmNDExNjYwNmRmNzRlZjI5N2YxNzcyYjEwMjdkNmU0XzIxOTkwMjMyNTc3MDM_a21177b2-79f0-404b-ab43-2495283480c9">COLLABORATIVE AGREEMENTSCumberland is a party to several collaborative arrangements with certain research institutions to identify and pursue promising pre-clinical pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, Collaborative Agreements. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or Federal Small Business Administration (SBIR/STTR) grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from private sector investments and grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18yMDUvZnJhZzowZGJhOTMwOGU4MDE0M2Y0OGVjMWE4OTBmYjI5Njg4Zi90ZXh0cmVnaW9uOjBkYmE5MzA4ZTgwMTQzZjQ4ZWMxYTg5MGZiMjk2ODhmXzIxOTkwMjMyNjA4ODY_37f2a2e6-ff7e-4111-9577-26976f248a95">COMMITMENTS AND CONTINGENCIES&lt;div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"&gt;The Company developed a new formulation of Acetadote (acetylcysteine) Injection as part of the Phase IV commitment in response to a request by the FDA regarding the role of EDTA in the product's formulation.  The Company has received several patents from the United States Patent and Trademark Office ("USPTO") since 2012 as well as notices that its Acetadote patents are being challenged on the basis of invalidity or non-infringement by others.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;During the third quarter of 2015, an arbitrator issued a final award in the Company&#x2019;s favor, enjoining Mylan Pharma Group Limited and Mylan Teoranta, together with all their affiliates (&#x201c;Mylan&#x201d;), from selling, delivering, or giving away any acetylcysteine injectable drug product to another entity or person until April 30, 2018.  The arbitration request was filed with the American Arbitration Association for claims against Mylan in connection with agreements which require that Mylan manufacture and supply acetylcysteine drug product, including Acetadote, for us exclusively until April 2016. As the prevailing party, the Company received reimbursement of its attorney&#x2019;s fees and related costs associated with the arbitration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;During the third quarter of 2015, the United States District Court for the Northern District of Illinois, Eastern Division ("District Court") ruled in the Company&#x2019;s favor in its lawsuit against Mylan for infringement of its U.S. Patent number 8,399,445 (the &#x201c;445 Acetadote Patent&#x201d;).  The opinion upheld&#160;our 445 Acetadote Patent and expressly rejected Mylan's validity challenge. &#160; The District Court ruled&#160;that Mylan is liable to us for infringement of the 445 Acetadote patent in light of Mylan's&#160;Abbreviated New Drug Application in which Mylan sought to market a generic version of Acetadote.  On November 17, 2015, the District Court entered an order enjoining Mylan and its affiliates from selling or using its generic version of Acetadote until August 2025, the date of expiration of the 445 Acetadote Patent. On October 30, 2015, Mylan filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the "Appeals Court").&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;"&gt;On January 26, 2017, the Appeals Court affirmed the District Court ruling in the Company's favor in its lawsuit against Mylan for infringement of the 445 Acetadote Patent. The Appeals Court opinion affirmed the District Court&#x2019;s ruling upholding Cumberland's 445 Acetadote Patent and expressly rejected Mylan's validity challenge. Additional information on these developments is included in Part 1, Item 3, Legal Proceedings in our Annual Report on Form 10-K for the year ended December 31, 2017.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749182768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>May 04, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cumberland Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,710,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749606160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,262,976<span></span>
</td>
<td class="nump">$ 45,412,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">15,610,105<span></span>
</td>
<td class="nump">4,672,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances</a></td>
<td class="nump">6,301,162<span></span>
</td>
<td class="nump">8,395,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">6,661,525<span></span>
</td>
<td class="nump">6,737,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,987,404<span></span>
</td>
<td class="nump">3,466,541<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">66,823,172<span></span>
</td>
<td class="nump">68,684,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">566,907<span></span>
</td>
<td class="nump">528,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">21,052,197<span></span>
</td>
<td class="nump">21,444,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax assets, net</a></td>
<td class="nump">87,210<span></span>
</td>
<td class="nump">87,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,565,354<span></span>
</td>
<td class="nump">2,486,830<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">91,094,840<span></span>
</td>
<td class="nump">93,232,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,518,879<span></span>
</td>
<td class="nump">8,979,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">7,770,977<span></span>
</td>
<td class="nump">8,714,814<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,289,856<span></span>
</td>
<td class="nump">17,694,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">9,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_OtherLongTermObligationsExcludingCurrentPortion', window );">Other long-term liabilities</a></td>
<td class="nump">1,930,679<span></span>
</td>
<td class="nump">1,815,968<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">30,220,535<span></span>
</td>
<td class="nump">29,310,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,727,250 and 15,723,075 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">51,755,834<span></span>
</td>
<td class="nump">52,410,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">9,329,983<span></span>
</td>
<td class="nump">11,709,222<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">61,085,817<span></span>
</td>
<td class="nump">64,120,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(211,512)<span></span>
</td>
<td class="num">(198,562)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">60,874,305<span></span>
</td>
<td class="nump">63,921,601<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 91,094,840<span></span>
</td>
<td class="nump">$ 93,232,312<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherLongTermObligationsExcludingCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other long-term obligations, excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherLongTermObligationsExcludingCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6906782528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">15,727,250<span></span>
</td>
<td class="nump">15,723,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">15,727,250<span></span>
</td>
<td class="nump">15,723,075<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751938816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
<td class="nump">$ 8,587,605<span></span>
</td>
<td class="nump">$ 9,636,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of products sold</a></td>
<td class="nump">1,527,961<span></span>
</td>
<td class="nump">1,381,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">4,670,511<span></span>
</td>
<td class="nump">5,293,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,874,939<span></span>
</td>
<td class="nump">898,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,330,281<span></span>
</td>
<td class="nump">2,110,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">636,135<span></span>
</td>
<td class="nump">611,444<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">11,039,827<span></span>
</td>
<td class="nump">10,294,557<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(2,452,222)<span></span>
</td>
<td class="num">(657,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">82,494<span></span>
</td>
<td class="nump">52,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(18,302)<span></span>
</td>
<td class="num">(31,715)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="num">(2,388,030)<span></span>
</td>
<td class="num">(636,982)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="nump">4,159<span></span>
</td>
<td class="nump">656,587<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(2,392,189)<span></span>
</td>
<td class="num">(1,293,569)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="num">(12,950)<span></span>
</td>
<td class="num">(19,123)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (2,379,239)<span></span>
</td>
<td class="num">$ (1,274,446)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">- basic (in dollars per share)</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">- diluted (in dollars per share)</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- basic (in shares)</a></td>
<td class="nump">15,689,240<span></span>
</td>
<td class="nump">16,042,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in shares)</a></td>
<td class="nump">15,689,240<span></span>
</td>
<td class="nump">16,042,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to common shareholders</a></td>
<td class="num">$ (2,379,239)<span></span>
</td>
<td class="num">$ (1,274,446)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">12,950<span></span>
</td>
<td class="nump">19,123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss)</a></td>
<td class="num">$ (2,392,189)<span></span>
</td>
<td class="num">$ (1,293,569)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4613674-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754968912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (2,392,189)<span></span>
</td>
<td class="num">$ (1,293,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">692,991<span></span>
</td>
<td class="nump">661,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">758,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">339,209<span></span>
</td>
<td class="nump">254,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Excess tax (benefit) expense derived from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
<td class="nump">18,303<span></span>
</td>
<td class="nump">26,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Noncash investment gains</a></td>
<td class="nump">43,338<span></span>
</td>
<td class="nump">4,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,093,950)<span></span>
</td>
<td class="num">(2,395,348)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(76,323)<span></span>
</td>
<td class="nump">275,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="num">(600,884)<span></span>
</td>
<td class="num">(132,819)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="num">(1,254,535)<span></span>
</td>
<td class="num">(1,216,345)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">103,991<span></span>
</td>
<td class="nump">92,881<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">235,589<span></span>
</td>
<td class="nump">1,439,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(94,881)<span></span>
</td>
<td class="num">(123,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(15,151,948)<span></span>
</td>
<td class="num">(792,716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">4,257,657<span></span>
</td>
<td class="nump">941,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(532,954)<span></span>
</td>
<td class="num">(453,961)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(11,522,126)<span></span>
</td>
<td class="num">(429,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(9,800,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sales of shares of common stock, net of offering costs</a></td>
<td class="nump">200,909<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred offering costs</a></td>
<td class="num">(248,108)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(1,016,156)<span></span>
</td>
<td class="num">(545,924)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">1,136,645<span></span>
</td>
<td class="num">(545,924)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(10,149,892)<span></span>
</td>
<td class="nump">463,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">45,412,868<span></span>
</td>
<td class="nump">34,510,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 35,262,976<span></span>
</td>
<td class="nump">$ 34,974,242<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Current Operating Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph c<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751985664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity (Unaudited) - 3 months ended Mar. 31, 2018 - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Range values are not currently supported</div></th>
<th class="th"><div>Range values are not currently supported</div></th>
<th class="th"><div>Range values are not currently supported</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2017</a></td>
<td class="nump">$ 63,921,601<span></span>
</td>
<td class="nump">$ 52,410,941<span></span>
</td>
<td class="nump">$ 11,709,222<span></span>
</td>
<td class="num">$ (198,562)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2017</a></td>
<td class="nump">15,723,075<span></span>
</td>
<td class="nump">15,723,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, net of offering costs</a></td>
<td class="nump">$ 200,909<span></span>
</td>
<td class="nump">$ 200,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, net of offering costs (in shares)</a></td>
<td class="nump">30,704<span></span>
</td>
<td class="nump">30,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 339,209<span></span>
</td>
<td class="nump">$ 339,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares</a></td>
<td class="num">(1,195,225)<span></span>
</td>
<td class="num">$ (1,195,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(172,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(2,392,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,379,239)<span></span>
</td>
<td class="num">(12,950)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2018</a></td>
<td class="nump">$ 60,874,305<span></span>
</td>
<td class="nump">$ 51,755,834<span></span>
</td>
<td class="nump">$ 9,329,983<span></span>
</td>
<td class="num">$ (211,512)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2018</a></td>
<td class="nump">15,727,250<span></span>
</td>
<td class="nump">15,727,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6636685088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND&#160;BASIS OF PRESENTATION<div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December&#160;31, 2017 audited consolidated financial statements, with the exception of the impacts of adopting accounting pronouncements during 2018, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2017 (the &#8220;2017 Annual Report on Form 10-K&#8221;). The results of operations for the three months ended March&#160;31, 2018 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Total comprehensive income (loss) consisted solely of net income (loss) for the three months ended March&#160;31, 2018 and 2017.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;vertical-align:bottom;">Adoption of Revenue Accounting Standard</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) amended guidance in the form of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Net Product Revenue</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 45 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Sales Rebates and Discounts</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Sales Returns</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other tactor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;vertical-align:bottom;">Recent Accounting Guidance</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Recent Adopted Accounting Pronouncements </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, &#8220;Revenue from Contracts with Customers.&#8221; (&#8220;ASC 606&#8221;)  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018.  As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. The Company is currently applying the standard in its current practices. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In November 2016, the FASB issued ASU No. 2016-18, &#8220;Statement of Cash Flows: Restricted Cash.&#8221; This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the &#8220;beginning-of-period&#8221; and &#8220;end-of-period&#8221; total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, &#8220;Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.&#8221; The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Recent Accounting Pronouncements - Not Yet Adopted </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-12, &#8220;Leases.&#8221; The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients available. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">its current lease agreements for the impact of its pending adoption of the new standard on its consolidated financial statements and disclosures. The Company&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of office and wet laboratory space in Nashville, Tennessee by Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary, in which it operates the CET Life Sciences Center.  This lease currently expires in April 2023.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;vertical-align:bottom;">Accounting Policies:</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;text-decoration: underline;vertical-align:bottom;">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the allowances for obsolescent or unmarketable inventory.</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;vertical-align:bottom;">Operating Segments</span></div>The Company has&#160;one&#160;operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6634865680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
<td class="text">MARKETABLE SECURITIES<div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency issued mortgage-backed securities, U.S. government agency notes and bonds, Small Business Administration (&#8220;SBA&#8221;) loan pools, and corporate bonds.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of March 31, 2018&#160;and December 31, 2017,&#160;the marketable securities are comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).&#160;</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="text-indent:-45pt;padding-left:81pt;line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Level 1 -&#160;Quoted prices for identical instruments in active markets.</span></div><div style="text-indent:-45pt;padding-left:81pt;line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Level 2 -&#160;Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="text-indent:-45pt;padding-left:81pt;line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Level 3 -&#160;Significant inputs to the valuation model are unobservable.</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with </span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;vertical-align:bottom;">&#160;</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:27.368576%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">March 31, 2018&#160;</span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Level 1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Level 2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Level 1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Level 2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury notes and bonds&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">6,486,345&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">6,486,345&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">U.S. Agency issued mortgage-backed securities &#8211; variable rate&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,569,884&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,569,884&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,539,102&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,539,102&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">U.S. Agency notes and bonds &#8211; fixed rate&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">198,293&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">198,293&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,502,977&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,502,977&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">SBA loan pools &#8211; variable rate&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">548,641&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">548,641&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">935,081&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">935,081&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Short-term cash investments&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">4,502,258&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">4,502,258&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">6,486,345&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">9,123,760&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">15,610,105&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">4,672,476&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">4,672,476&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=4738149<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2289146<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6636608096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the&#160;three&#160;months ended&#160;March 31, 2018&#160;and 2017:</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"/><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:63.102639%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.008798%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.155425%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Numerator:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(2,379,239)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(1,274,446)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Denominator:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">15,689,240&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">16,042,219&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">15,689,240&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">16,042,219&#160;</span></td></tr></table></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">As of&#160;March 31, 2018&#160;and 2017, restricted stock awards and options to purchase&#160;247,530&#160;and&#160;237,875&#160;shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6597530288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Product Revenues</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605. However, no cumulative effect adjustment to historical retained earnings was necessary as no revenue recognition differences were identified when comparing the revenue recognition criteria under ASC 606 to previous requirements. See further discussion in Note 1. </span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company&#8217;s net revenues consisted of the following for the&#160;three&#160;months ended&#160;March 31, 2018&#160;and 2017:</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"/><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:69.742313%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.762811%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.762811%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Products:&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Acetadote&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,273,764&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,265,440&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">141,392&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">645,325&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Kristalose&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,269,901&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,386,591&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Vaprisol&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">93,890&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">684,548&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Caldolor&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,039,747&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">813,027&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Ethyol&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,256,073&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,666,808&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">       Totect&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">412,774&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Other&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">100,064&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">175,016&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:42pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total net revenues&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">8,587,605&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">9,636,755&#160;</span></td></tr></table></div><div style="line-height:120%;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Cumberland supplies Perrigo Company (&#8220;Perrigo&#8221;) with an Authorized Generic version of the Company's Acetadote product. The Company's revenue generated by sales of its Authorized Generic distributed by Perrigo is included in the Acetadote product revenue presented above. The Company's share of Authorized Generic revenue was&#160;$0.8 million&#160;and&#160;$0.9 million&#160;for first quarter of 2018 and 2017, respectively. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Other Revenues</span></div>The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is entitled to receive non-refundable, up-front payments at the time the agreements are entered into and milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company recognizes revenue for these substantive milestones using the milestone method. The Company is also entitled to receive royalties on future sales of the products under the agreements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745759760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At&#160;March 31, 2018&#160;and&#160;December 31, 2017, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately&#160;$0.1 million&#160;and $0.2 million, respectively.&#160;</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total at&#160;March 31, 2018&#160;and&#160;December 31, 2017.</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">As of&#160;March 31, 2018&#160;and December 31, 2017, net inventory consisted of the following:&#160;</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"/><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:60.316716%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.475073%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.475073%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,642,543&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,156,002&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">418,829&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">249,964&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Finished goods&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,600,153&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,331,882&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">6,661,525&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">6,737,848&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749169008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#8220;the Tax Act&#8221;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to&#160;21% (2) eliminating the corporate alternative minimum tax ("AMT") and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The SEC staff issued Staff Accounting Bulletin (&#8220;SAB&#8221;) 118 which provides guidance for the tax effects of the Tax Act.  SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.  In accordance with SAB 118, a company must reflect the income tax effects of those </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">aspects of the Tax Act for which the accounting under ASC 740 is complete.  To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements.  If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In connection with our analysis of the impact of the Tax Act, we have a net tax benefit of&#160;$0.1 million of March&#160;31, 2018.  This net tax benefit consists entirely of the release of the valuation allowance against AMT credits that will be realizable under the Tax Act in future periods. While the Company does not expect to record further amounts related to the Tax Act, we will continue to evaluate additional guidance as it is released by the Internal Revenue Service and will record additional amounts if needed.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6906520336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text">COLLABORATIVE AGREEMENTSCumberland is a party to several collaborative arrangements with certain research institutions to identify and pursue promising pre-clinical pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, Collaborative Agreements. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or Federal Small Business Administration (SBIR/STTR) grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from private sector investments and grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749169008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Legal Matters</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company developed a new formulation of Acetadote (acetylcysteine) Injection as part of the Phase IV commitment in response to a request by the FDA regarding the role of EDTA in the product's formulation.  The Company has received several patents from the United States Patent and Trademark Office ("USPTO") since 2012 as well as notices that its Acetadote patents are being challenged on the basis of invalidity or non-infringement by others.&#160; </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">During the third quarter of 2015, an arbitrator issued a final award in the Company&#8217;s favor, enjoining Mylan Pharma Group Limited and Mylan Teoranta, together with all their affiliates (&#8220;Mylan&#8221;), from selling, delivering, or giving away any acetylcysteine injectable drug product to another entity or person until April 30, 2018.  The arbitration request was filed with the American Arbitration Association for claims against Mylan in connection with agreements which require that Mylan manufacture and supply acetylcysteine drug product, including Acetadote, for us exclusively until April 2016. As the prevailing party, the Company received reimbursement of its attorney&#8217;s fees and related costs associated with the arbitration.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">During the third quarter of 2015, the United States District Court for the Northern District of Illinois, Eastern Division ("District Court") ruled in the Company&#8217;s favor in its lawsuit against Mylan for infringement of its U.S. Patent number 8,399,445 (the &#8220;445 Acetadote Patent&#8221;).  The opinion upheld&#160;our 445 Acetadote Patent and expressly rejected Mylan's validity challenge. &#160; The District Court ruled&#160;that Mylan is liable to us for infringement of the 445 Acetadote patent in light of Mylan's&#160;Abbreviated New Drug Application in which Mylan sought to market a generic version of Acetadote.  On November 17, 2015, the District Court entered an order enjoining Mylan and its affiliates from selling or using its generic version of Acetadote until August 2025, the date of expiration of the 445 Acetadote Patent. On October 30, 2015, Mylan filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the "Appeals Court").</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">On January 26, 2017, the Appeals Court affirmed the District Court ruling in the Company's favor in its lawsuit against Mylan for infringement of the 445 Acetadote Patent. The Appeals Court opinion affirmed the District Court&#8217;s ruling upholding Cumberland's 445 Acetadote Patent and expressly rejected Mylan's validity challenge. Additional information on these developments is included in Part 1, Item 3, Legal Proceedings in our Annual Report on Form 10-K for the year ended December 31, 2017.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749245840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Recent Adopted Accounting Pronouncements </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, &#8220;Revenue from Contracts with Customers.&#8221; (&#8220;ASC 606&#8221;)  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018.  As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. The Company is currently applying the standard in its current practices. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In November 2016, the FASB issued ASU No. 2016-18, &#8220;Statement of Cash Flows: Restricted Cash.&#8221; This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the &#8220;beginning-of-period&#8221; and &#8220;end-of-period&#8221; total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, &#8220;Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.&#8221; The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;vertical-align:bottom;">Recent Accounting Pronouncements - Not Yet Adopted </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-12, &#8220;Leases.&#8221; The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients available. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating </span></div>its current lease agreements for the impact of its pending adoption of the new standard on its consolidated financial statements and disclosures. The Company&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of office and wet laboratory space in Nashville, Tennessee by Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary, in which it operates the CET Life Sciences Center.  This lease currently expires in April 2023.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;text-decoration: underline;vertical-align:bottom;">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the allowances for obsolescent or unmarketable inventory.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text">Operating SegmentsThe Company has&#160;one&#160;operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745125504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair value of marketable securities, by type</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:27.368576%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">March 31, 2018&#160;</span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Level 1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Level 2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Level 1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Level 2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury notes and bonds&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">6,486,345&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">6,486,345&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">U.S. Agency issued mortgage-backed securities &#8211; variable rate&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,569,884&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,569,884&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,539,102&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,539,102&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">U.S. Agency notes and bonds &#8211; fixed rate&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">198,293&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">198,293&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,502,977&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,502,977&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">SBA loan pools &#8211; variable rate&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">548,641&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">548,641&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">935,081&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">935,081&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Short-term cash investments&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">4,502,258&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">4,502,258&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">6,486,345&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">9,123,760&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">15,610,105&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">4,672,476&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">4,672,476&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745156592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of numerator and denominator</a></td>
<td class="text"><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the&#160;three&#160;months ended&#160;March 31, 2018&#160;and 2017:</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"/><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:63.102639%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.008798%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.155425%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Numerator:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(2,379,239)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">(1,274,446)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Denominator:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">15,689,240&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">16,042,219&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">15,689,240&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">16,042,219&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745134128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of net revenue</a></td>
<td class="text"><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company&#8217;s net revenues consisted of the following for the&#160;three&#160;months ended&#160;March 31, 2018&#160;and 2017:</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"/><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:69.742313%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.762811%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.762811%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:8pt;font-weight:700;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Products:&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Acetadote&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,273,764&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,265,440&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">141,392&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">645,325&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Kristalose&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,269,901&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,386,591&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Vaprisol&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">93,890&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">684,548&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Caldolor&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">1,039,747&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">813,027&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Ethyol&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,256,073&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,666,808&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">       Totect&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">412,774&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Other&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">100,064&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">175,016&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:42pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total net revenues&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">8,587,605&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">9,636,755&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6642227136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">As of&#160;March 31, 2018&#160;and December 31, 2017, net inventory consisted of the following:&#160;</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:0pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;"/><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:60.316716%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.475073%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.475073%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">2,642,543&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,156,002&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">418,829&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">249,964&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Finished goods&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,600,153&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">3,331,882&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">6,661,525&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-left:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:5pt double #000000;padding-right:1pt;"><span style="vertical-align:bottom;font-size:10pt;font-weight:400;font-family:Times New Roman;color:000000;background-color:rgb(255,255,255, 0.0);">6,737,848&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6906536224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755437136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 15,610,105<span></span>
</td>
<td class="nump">$ 4,672,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=cpix_UsTreasuryNotesAndBondsSecuritiesDomain', window );">U.S. Treasury notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">6,486,345<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember', window );">U.S. Agency issued mortgage-backed securities &#8211; variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">1,569,884<span></span>
</td>
<td class="nump">3,539,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_AgencySecuritiesMember', window );">U.S. Agency notes and bonds &#8211; fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">2,502,977<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=cpix_LoanPoolsMember', window );"></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">548,641<span></span>
</td>
<td class="nump">935,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MunicipalBondsMember', window );">Short-term cash investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">4,502,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">6,486,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Treasury notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">6,486,345<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Agency issued mortgage-backed securities &#8211; variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Agency notes and bonds &#8211; fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 |</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Short-term cash investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">9,123,760<span></span>
</td>
<td class="nump">4,672,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Agency issued mortgage-backed securities &#8211; variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">1,569,884<span></span>
</td>
<td class="nump">3,539,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Agency notes and bonds &#8211; fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">2,502,977<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 |</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">548,641<span></span>
</td>
<td class="nump">935,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term cash investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 4,502,258<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities and other forms of securities that provide ownership interests classified as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=cpix_UsTreasuryNotesAndBondsSecuritiesDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=cpix_UsTreasuryNotesAndBondsSecuritiesDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=cpix_LoanPoolsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=cpix_LoanPoolsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744173520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (2,379,239)<span></span>
</td>
<td class="num">$ (1,274,446)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_Denominator', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">15,689,240<span></span>
</td>
<td class="nump">16,042,219<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">15,689,240<span></span>
</td>
<td class="nump">16,042,219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_Denominator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_Denominator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744015232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share - Textual (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock available for purchase through restricted stock awards and options (in shares)</a></td>
<td class="nump">247,530<span></span>
</td>
<td class="nump">237,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749415600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
<td class="nump">$ 8,587,605<span></span>
</td>
<td class="nump">$ 9,636,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
<td class="nump">1,273,764<span></span>
</td>
<td class="nump">1,265,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
<td class="nump">141,392<span></span>
</td>
<td class="nump">645,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=cpix_KristaloseMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
<td class="nump">3,269,901<span></span>
</td>
<td class="nump">2,386,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=cpix_VaprisolMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
<td class="nump">93,890<span></span>
</td>
<td class="nump">684,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=cpix_CaldolorMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
<td class="nump">1,039,747<span></span>
</td>
<td class="nump">813,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=cpix_EthyolMember', window );">Ethyol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
<td class="nump">2,256,073<span></span>
</td>
<td class="nump">3,666,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=cpix_TotectMember', window );">Totect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
<td class="nump">412,774<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=cpix_OtherProductsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
<td class="nump">100,064<span></span>
</td>
<td class="nump">175,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=cpix_GenericAcetadoteMember', window );">Generic Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cpix_EthyolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cpix_EthyolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cpix_TotectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cpix_TotectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cpix_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cpix_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cpix_GenericAcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cpix_GenericAcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6906486128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 2,642,543<span></span>
</td>
<td class="nump">$ 3,156,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">418,829<span></span>
</td>
<td class="nump">249,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">3,600,153<span></span>
</td>
<td class="nump">3,331,882<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 6,661,525<span></span>
</td>
<td class="nump">$ 6,737,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.2.Q2 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745012512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Textual (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for potential obsolescence of products</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745082384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EquityAndDebtAbstract', window );"><strong>Equity and Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY AND DEBT</a></td>
<td class="text">SHAREHOLDERS&#8217; EQUITY AND DEBT<div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Share Repurchases</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company currently has a share repurchase program to repurchase up to&#160;$10 million&#160;of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2016, the Company's Board of Directors established the current&#160;$10 million repurchase program to replace the prior authorizations.  During the&#160;three months ended March 31, 2018&#160;and March 31, 2017, the Company repurchased&#160;172,079&#160;shares and&#160;155,150&#160;shares, respectively, of common stock for approximately&#160;$1.2 million&#160;and $1.0 million, respectively.&#160;</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Share Sales</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;vertical-align:bottom;">In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to&#160;$100 million&#160;in corporate securities. The Shelf Registration was declared effective in January 2018. During the three months ended March 31, 2018, the Company issued &#160;30,704&#160;shares of common stock for gross proceeds of&#160;$0.2 million&#160;as part of its At-The-Market (&#8220;ATM&#8221;) sales agreement with B. Riley FBR.</span></div><div><span><br/></span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Restricted Share Grants&#160;</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">During the&#160;three months ended March 31, 2018, the Company issued&#160;229,205&#160;shares of restricted stock to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYyNjE_3db38b5b-b57e-4753-bab2-0401c4da4aa8">one</span>-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Debt Agreement</span></div><div style="line-height:120%;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">On July 31, 2017,&#160;the Company entered into a Revolving Credit Loan Agreement with Pinnacle Bank ("Pinnacle Agreement").  The Pinnacle Agreement replaced the June 2014 Revolving Credit Loan Agreement with SunTrust Bank, which was to expire on June 30, 2018. The Company had&#160;$12.0 million&#160;&#160;in borrowings under that agreement at March&#160;31, 2018.&#160;The Pinnacle Agreement provides for an aggregate principal amount of up to&#160;$20 million&#160;and has a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiODM0ZGJmZmYwNDRlYzhiOTNlODM4MTYxMGNiNzk3L3NlYzpiYjgzNGRiZmZmMDQ0ZWM4YjkzZTgzODE2MTBjYjc5N18xNjYvZnJhZzozM2ExMWNhZjdjODc0ZDU5YTRhOTI0NGE2YjYxYTQzNy90ZXh0cmVnaW9uOjMzYTExY2FmN2M4NzRkNTlhNGE5MjQ0YTZiNjFhNDM3XzEwOTk1MTE2MzYzNDI_faa1036d-aac4-495e-970e-7d7605ba1f7c">three</span>-year term expiring on July 31, 2020.  The initial revolving line of credit is up to&#160;$12 million&#160;with the ability to increase the borrowing amount up to&#160;$20 million, upon the satisfaction of certain conditions.&#160;</span></div><div><span><br/></span></div><div style="line-height:120%;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of&#160;1.75%&#160;to&#160;2.75%&#160;(representing an interest rate of&#160;3.3%&#160;at March 31, 2018).&#160;&#160;In addition, a fee of&#160;0.25%&#160;per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. &#160;</span></div><div style="line-height:120%;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Under the Pinnacle Agreement, Cumberland is subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.&#160; The Company achieved compliance with the Funded Debt Ratio covenant as of&#160;March 31, 2018&#160;through the utilization of the covenant cure section of the agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EquityAndDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity and Debt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EquityAndDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755563840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt - Shareholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Jan. 31, 2013</div></th>
<th class="th"><div>Apr. 30, 2012</div></th>
<th class="th"><div>Jan. 31, 2011</div></th>
<th class="th"><div>May 13, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,195,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,909<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock awards, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Range values are not currently supported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,079<span></span>
</td>
<td class="nump">155,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,195,225)<span></span>
</td>
<td class="num">$ (1,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755548128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity and Debt - Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="nump">$ 9,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions', window );">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Expiration period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_SunTrustBankMember', window );">SunTrust Bank | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_SunTrustBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_SunTrustBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6906553280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Textual (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net tax benefit</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MN?[R.PL[;^S67K#Q2;"IX<]=--]02P,$%     @ N(FI3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M<SF>7QZZ^C3^]%!<?_]8_PM02P,$%     @ N(FI3+IL;<[O 0  @04  !@
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MV8QC-AH.N^D'L?D;%W\!4$L#!!0    ( +B)J4PWA(DRM@$  -(#   9
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M"_OW ,H,&4WH)? LZ\:' ,O33M3P$_RO[FC18[-**36T3IJ66*@R>I_L#[N
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MHP+G HZ[?U_ KNMV_@+<<>_=N^/(!C3/M@5PY%5);7/:.M<=&+-E"XK;*^Q
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M'VPQ)-0N'._]V4QC-AD.^_D'L>4;%W\ 4$L#!!0    ( +B)J4SI#=)BN $
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M?[#%D-"X<#SXLYG&;#(<]O,/8LLW+O\ 4$L#!!0    ( +B)J4P%SC*VM@$
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MT/AXO ]G.XW99'CLYQ_$EF]<_@%02P,$%     @ N(FI3/F"/K^X 0  T@,
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MH/;1/ 3;CFLV.AZ[Z06Q^1D7OP%02P,$%     @ N(FI3)R!+[=$!   5Q@
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MX*F]-,H$4%7VY )?07WK#T*?T,1R:AETLN5=(."\#1_CS;XP> OXWL(@9_O
M.#ER_FP.GT[;,#*"@$*M# /1RPWV0*DATC)^CISA5-(DSO>O[!^L=^WE2"3L
M.?W1GE2S#5=A<((SN5+UQ(>/,/K)PF T_QEN0#7<*-$U:DZE_0WJJU2<C2Q:
M"B,O;FT[NP[N)EN-:?X$/";@*4'7_E=",B8D;PFI->^46:OOB2)5*?@0"/=G
M]<1\$_$FT<VL3=#VSMYIMU)';U6\7I?H9HA&S,YA\!PS(9!FGTI@7XD=ODO'
M?Q;8WR.RPE\A\9I(;'XRKQ!%?H+42Y!:@G1&4*2+)CA(82&=A;S#2;'&R:);
M>P\PQD6:IKE?4>95E'DL_:7KN9<@O[.$HT7?=PZ3S:3&6;Y:XS1:>/( \RC%
M.%[[)15>285'4K*05/RO) _0+PG-G@(#<;%30P8UOW;*?'2SZ#28'K%Y2HOX
M3@\L-U_>:-RT^T+$I>UD<.1*/U3[G,Z<*] ZHP<ML=$#=CI0."NS+?1>N#'C
M#HKWXP1%TQBO?@-02P,$%     @ N(FI3 V(P@W? 0  : 0  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL?519;MLP$+V*P .$LI8J,"0!L8L@!5K
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M?*S)@+DH-J8L&[_Q"$[$G('G+:$>\U)7%>J1E:+F?*!P@RZX^RB[0A?FU,M
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M^['\D;92&K"2R9V]1IU]9'/!H35NNK%S%:Y:*(P<XRLB\U.N_@)02P,$%
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M]K]&=."E[&[\"+7^@RV&@MJ%XR=_-M.838;#?OY!;/G&Q5]02P,$%     @
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M*\SS/% R#_\=KJ 0'I5@C]8JG[ZDO?A@]<R"4K1XS5::9*=\LMG-9?<+^%S
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MXH( (]DT6"$9GRZ\@H2(G]%0[KY'S7162T!.G<(?K0#.H]5-!6H3L6IX9K%
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M^QW;N_N?)K<W_V?R<'-WJR:W[]3E9'HS57?OU:?[Z^GU[0-=^;ZGU#,I!W6
M4:+Q\$=W7T"_C'XDCC17@8O"=&LO98A&K-W#&]'ATE^)4>69)VUOEU^JPA]
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MGV:=7 ?S!N;0A!+)$P:9!E&EQ0CCEQA=7)([R,H *"9#U=>&,FA3WK7)6+'
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MO$%?96A3\WG3EYB&08^HDEJF*J\2WFR3:.<"'CO&*H:)P/9(X0'5#L08CI#
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M04T]W=WQ :R ( ])SD9R[^&Z"K#-0,*O4H/%2D5>AQOM2O]:0?4K_#H0'2A
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M6/=H'JQL#ZQ2'_NSMNN_4$L#!!0    ( +B)J4Q5H"SI; $  !\3   :
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MO*)9<ULV7)G_2+ZL7>SKD_PS;_H#4$L! A0#%     @ N(FI3!\CSP/
M$P(   L              ( !     %]R96QS+RYR96QS4$L! A0#%     @
MN(FI3&;S"V""    L0   !               ( !Z0   &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " "XB:E,R5PZ;N\    K @  $0
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M965T-"YX;6Q02P$"% ,4    " "XB:E, O;[N7T$   H%   &
M    @ $$%@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
MN(FI3.4]S!'D @  O H  !@              ( !MQH  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( +B)J4RGR.;GL@$  -(#   8
M          "  =$=  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " "XB:E,:?LH\;8!  #2 P  &               @ &Y'P  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ N(FI3+Q8<#>V 0  T@,
M !@              ( !I2$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( +B)J4PWA(DRM@$  -(#   9              "  9$C  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ N(FI3%69KI:V
M 0  T0,  !D              ( !?B4  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " "XB:E,(6K; +<!  #2 P  &0
M@ %K)P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( +B)
MJ4RT_-&.L@$  -(#   9              "  5DI  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ N(FI3"NC7/BV 0  T@,  !D
M         ( !0BL  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " "XB:E,#*V@?<\!  "<!   &0              @ $O+0  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( +B)J4R4[\91MP$  -(#
M   9              "  34O  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ N(FI3.D-TF*X 0  T@,  !D              ( !(S$
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "XB:E,!<XR
MMK8!  #2 P  &0              @ $2,P  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( +B)J4S,B1@_M@$  -(#   9
M  "  ?\T  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
MN(FI3/F"/K^X 0  T@,  !D              ( ![#8  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " "XB:E,G($OMT0$  !7&   &0
M            @ ';.   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( +B)J4QMT-TY( (  -(%   9              "  58]  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ N(FI3 V(P@W? 0
M: 0  !D              ( !K3\  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " "XB:E,GAMPJD\#   W#@  &0              @ '#
M00  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( +B)J4S'
M$M4/"@(  (D%   9              "  4E%  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ N(FI3+.0NCVR 0  U@,  !D
M     ( !BD<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +B)J4S57),\*3$  #'&   4              "
M 2M3  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( +B)J4PO#!FL
M30(  'T+   -              "  8:$  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ N(FI3(I(>U*T @  VA,   \              ( !_H8  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( +B)J4Q5H"SI; $  !\3   :
M      "  =^)  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( +B)J4QIAGLXB $  -03   3              "  8.+  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     G "< @PH  #R-      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>84</ContextCount>
  <ElementCount>123</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006006 - Statement - Condensed Consolidated Statement of Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2107101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2110102 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2113103 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2117104 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2127106 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2208201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cumberlandpharma.com/role/MarketableSecurities</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2409401 - Disclosure - Organization and Basis of Presentation Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails</Role>
      <ShortName>Organization and Basis of Presentation Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cumberlandpharma.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2416404 - Disclosure - Earnings (Loss) Per Share - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/EarningsLossPerShareTextualDetails</Role>
      <ShortName>Earnings (Loss) Per Share - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2419405 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2422406 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2423407 - Disclosure - Inventories - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/InventoriesTextualDetails</Role>
      <ShortName>Inventories - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2424408 - Disclosure - Shareholders' Equity and Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/ShareholdersEquityandDebt</Role>
      <ShortName>Shareholders' Equity and Debt</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2425409 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity and Debt - Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2426410 - Disclosure - Shareholders' Equity and Debt - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails</Role>
      <ShortName>Shareholders' Equity and Debt - Debt (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20180331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2428411 - Disclosure - Income Taxes - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/IncomeTaxesTextualDetails</Role>
      <ShortName>Income Taxes - Textual (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cpix-20180331.htm">cpix-20180331.htm</File>
    <File>cpix-20180331.xsd</File>
    <File>cpix-20180331_cal.xml</File>
    <File>cpix-20180331_def.xml</File>
    <File>cpix-20180331_lab.xml</File>
    <File>cpix-20180331_pre.xml</File>
    <File>q12018-exhibit311.htm</File>
    <File>q12018-exhibit312.htm</File>
    <File>q12018-exhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>47
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20180331.htm": {
   "axisCustom": 0,
   "axisStandard": 10,
   "contextCount": 84,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20180331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20180331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20180331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20180331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-doc-2017-01-31.xml",
      "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20180331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-ref-2017-01-31.xml",
      "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20180331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-parts-codification-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd",
      "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"
     ]
    }
   },
   "elementCount": 216,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2017-01-31": 10,
    "http://xbrl.sec.gov/dei/2014-01-31": 8,
    "total": 18
   },
   "keyCustom": 4,
   "keyStandard": 119,
   "memberCustom": 13,
   "memberStandard": 15,
   "nsprefix": "cpix",
   "nsuri": "http://cumberlandpharma.com/20180331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://cumberlandpharma.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117104 - Disclosure - Revenues",
     "role": "http://cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - Inventories",
     "role": "http://cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127106 - Disclosure - Income Taxes",
     "role": "http://cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - Collaborative Agreements",
     "role": "http://cumberlandpharma.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Commitments and Contingencies",
     "role": "http://cumberlandpharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2208201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Marketable Securities (Tables)",
     "role": "http://cumberlandpharma.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "role": "http://cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Revenues (Tables)",
     "role": "http://cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Inventories (Tables)",
     "role": "http://cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "if9792ad3cd7e4c9d9650e51b4862ce84_I20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "if9792ad3cd7e4c9d9650e51b4862ce84_I20180331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409401 - Disclosure - Organization and Basis of Presentation Organization (Details)",
     "role": "http://cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails",
     "shortName": "Organization and Basis of Presentation Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "if9792ad3cd7e4c9d9650e51b4862ce84_I20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Marketable Securities (Details)",
     "role": "http://cumberlandpharma.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "if9792ad3cd7e4c9d9650e51b4862ce84_I20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415403 - Disclosure - Earnings (Loss) Per Share (Details)",
     "role": "http://cumberlandpharma.com/role/EarningsLossPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416404 - Disclosure - Earnings (Loss) Per Share - Textual (Details)",
     "role": "http://cumberlandpharma.com/role/EarningsLossPerShareTextualDetails",
     "shortName": "Earnings (Loss) Per Share - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalesRevenueNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419405 - Disclosure - Revenues (Details)",
     "role": "http://cumberlandpharma.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "iffcc23dd7a9944139daf9824e5b8eac5_D20180101-20180331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:SalesRevenueNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "if9792ad3cd7e4c9d9650e51b4862ce84_I20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422406 - Disclosure - Inventories (Details)",
     "role": "http://cumberlandpharma.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "if9792ad3cd7e4c9d9650e51b4862ce84_I20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "if9792ad3cd7e4c9d9650e51b4862ce84_I20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423407 - Disclosure - Inventories - Textual (Details)",
     "role": "http://cumberlandpharma.com/role/InventoriesTextualDetails",
     "shortName": "Inventories - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "if9792ad3cd7e4c9d9650e51b4862ce84_I20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424408 - Disclosure - Shareholders' Equity and Debt",
     "role": "http://cumberlandpharma.com/role/ShareholdersEquityandDebt",
     "shortName": "Shareholders' Equity and Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
       "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
       "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "iebdcd0b9547b443b8727649905bdb07b_I20160131",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425409 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details)",
     "role": "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails",
     "shortName": "Shareholders' Equity and Debt - Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
       "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
       "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "iebdcd0b9547b443b8727649905bdb07b_I20160131",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "if9792ad3cd7e4c9d9650e51b4862ce84_I20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426410 - Disclosure - Shareholders' Equity and Debt - Debt (Details)",
     "role": "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
     "shortName": "Shareholders' Equity and Debt - Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2b744dac368c4c3eb91bc9bb77c5cf97_I20170731",
      "decimals": "0",
      "lang": null,
      "name": "cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "if9792ad3cd7e4c9d9650e51b4862ce84_I20180331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428411 - Disclosure - Income Taxes - Textual (Details)",
     "role": "http://cumberlandpharma.com/role/IncomeTaxesTextualDetails",
     "shortName": "Income Taxes - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "if9792ad3cd7e4c9d9650e51b4862ce84_I20180331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalesRevenueNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)",
     "role": "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i66977d80365d404296229eb847d696f2_I20171231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006006 - Statement - Condensed Consolidated Statement of Equity (Unaudited)",
     "role": "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited",
     "shortName": "Condensed Consolidated Statement of Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i097d668a5f1047f0be37d4b8f2dd8771_I20171231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://cumberlandpharma.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110102 - Disclosure - Marketable Securities",
     "role": "http://cumberlandpharma.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113103 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i1cd1a621ccb24cc78000aff0e2aade7b_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 28,
   "tag": {
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acetadote.",
        "label": "Acetadote [Member]",
        "verboseLabel": "Acetadote"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Caldolor.",
        "label": "Caldolor [Member]",
        "verboseLabel": "Caldolor"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_Denominator": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "Denominator",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Document and entity information.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "xbrltype": "stringItemType"
    },
    "cpix_EquityAndDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity and Debt [Abstract]",
        "label": "Equity and Debt [Abstract]"
       }
      }
     },
     "localname": "EquityAndDebtAbstract",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "xbrltype": "stringItemType"
    },
    "cpix_EthyolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ethyol [Member]",
        "label": "Ethyol [Member]",
        "terseLabel": "Ethyol"
       }
      }
     },
     "localname": "EthyolMember",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_GenericAcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Authorized Generic Acetadote [Member]",
        "label": "Generic Acetadote [Member]",
        "terseLabel": "Generic Acetadote"
       }
      }
     },
     "localname": "GenericAcetadoteMember",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Current Operating Liabilities",
        "label": "Increase (Decrease) in Current Operating Liabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInCurrentOperatingLiabilities",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Kristalose.",
        "label": "Kristalose [Member]",
        "verboseLabel": "Kristalose"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions",
        "terseLabel": "Line of credit, maximum borrowing capacity upon satisfaction of certain conditions"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LoanPoolsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loan pools.",
        "label": "Loan Pools [Member]",
        "terseLabel": ""
       }
      }
     },
     "localname": "LoanPoolsMember",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Omeclamox-Pak [Member]",
        "label": "Omeclamox-Pak [Member]",
        "verboseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherLongTermObligationsExcludingCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other long-term obligations, excluding current portion.",
        "label": "Other Long Term Obligations Excluding Current Portion",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLongTermObligationsExcludingCurrentPortion",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other products.",
        "label": "Other Products [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pinnacle Bank [Member]",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products.",
        "label": "Products [Abstract]",
        "verboseLabel": "Products [Abstract]"
       }
      }
     },
     "localname": "ProductsAbstract",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ShareholdersEquityTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shareholders Equity.",
        "label": "Shareholders Equity (Textual) [Abstract]",
        "verboseLabel": "Shareholders Equity [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityTextualAbstract",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SunTrustBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SunTrust Bank [Member]",
        "label": "SunTrust Bank [Member]",
        "terseLabel": "SunTrust Bank"
       }
      }
     },
     "localname": "SunTrustBankMember",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_TotectMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Totect [Member]",
        "label": "Totect [Member]",
        "terseLabel": "Totect"
       }
      }
     },
     "localname": "TotectMember",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_UsTreasuryNotesAndBondsSecuritiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Us Treasury Notes and Bonds Securities [Domain]",
        "terseLabel": "U.S. Treasury notes and bonds"
       }
      }
     },
     "localname": "UsTreasuryNotesAndBondsSecuritiesDomain",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vaprisol [Member]",
        "label": "Vaprisol [Member]",
        "terseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://cumberlandpharma.com/20180331",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r15",
      "r20"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "verboseLabel": "Accounts receivable, net of allowances"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AgencySecuritiesMember": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities issued by government sponsored entities.",
        "label": "Agency Securities [Member]",
        "terseLabel": "U.S. Agency notes and bonds \u2013 fixed rate"
       }
      }
     },
     "localname": "AgencySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r44",
      "r62",
      "r153",
      "r165"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r61",
      "r102",
      "r104"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/EarningsLossPerShareTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r156",
      "r171"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r40"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r119",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r26",
      "r63"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r57",
      "r150"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "COLLABORATIVE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r107",
      "r161",
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Range values are not currently supported"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited",
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, End of Period (in shares)",
        "periodStartLabel": "Balance, Beginning of Period (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,727,250 and 15,723,075 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r138",
      "r139",
      "r144"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r137",
      "r144"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsSold": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs related to goods produced and sold during the reporting period.",
        "label": "Cost of Goods Sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r157",
      "r158",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r33",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate spread"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r61",
      "r66",
      "r131",
      "r132"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Net tax benefit"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": {
     "auth_ref": [
      "r127",
      "r128",
      "r129"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Assets, Net, Noncurrent",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DirectorMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Person serving on the board of directors (who collectively have responsibility for governing the entity).",
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r43",
      "r73",
      "r76",
      "r77",
      "r164",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "- basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r43",
      "r73",
      "r164",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "- diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited",
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
        "negatedLabel": "Excess tax (benefit) expense derived from exercise of stock options"
       }
      }
     },
     "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r147",
      "r148",
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "verboseLabel": "Fair value of marketable securities, by type"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within the fair value hierarchy.",
        "label": "Fair Value, Hierarchy [Axis]",
        "terseLabel": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r146",
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r69",
      "r130"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r151",
      "r153",
      "r166"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r21",
      "r100"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r38",
      "r98"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://cumberlandpharma.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://cumberlandpharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r22",
      "r100"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r38",
      "r70",
      "r98",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "verboseLabel": "Reserve for potential obsolescence of products"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/InventoriesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r155",
      "r169",
      "r179",
      "r180",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r160",
      "r174"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r29",
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of Credit Facility, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r29",
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r34",
      "r109",
      "r110"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type of debt and equity security.",
        "label": "Major Types of Debt and Equity Securities [Axis]",
        "terseLabel": "Major Types of Debt and Equity Securities [Axis]"
       }
      }
     },
     "localname": "MajorTypesOfDebtAndEquitySecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain": {
     "auth_ref": [
      "r97",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions. Equity securities are ownership interests or the right to acquire or dispose of ownership interests in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock.",
        "label": "Major Types of Debt and Equity Securities [Domain]",
        "terseLabel": "Major Types of Debt and Equity Securities [Domain]"
       }
      }
     },
     "localname": "MajorTypesOfDebtAndEquitySecuritiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r89",
      "r92",
      "r162"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale.",
        "label": "Marketable Securities",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r37",
      "r159",
      "r173"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by non-governmental sponsored enterprises.",
        "label": "Mortgage-backed Securities, Issued by Private Enterprises [Member]",
        "terseLabel": "U.S. Agency issued mortgage-backed securities \u2013 variable rate"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Short-term cash investments"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r57",
      "r59"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r57",
      "r59"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r57",
      "r58",
      "r62"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r42",
      "r62",
      "r76",
      "r163",
      "r177"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to common shareholders",
        "totalLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited",
      "http://cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r140",
      "r143"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Range values are not currently supported"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r38",
      "r114"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r31"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r51",
      "r86"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Sales of shares of common stock, net of offering costs",
        "verboseLabel": "Gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [
      "r50",
      "r86"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductOrServiceAxis": {
     "auth_ref": [
      "r82",
      "r115",
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by products and services or groups of similar products and services.",
        "label": "Products and Services [Axis]",
        "terseLabel": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductsAndServicesDomain": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Products and Services [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r137",
      "r140",
      "r141",
      "r143",
      "r144"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited",
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r105",
      "r175"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by range, including, but not limited to, upper and lower bounds.",
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.",
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r126",
      "r182"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r112",
      "r172"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Range values are not currently supported"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNet": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.",
        "label": "Revenue, Net",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "SalesRevenueNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited",
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue, Net [Abstract]",
        "verboseLabel": "Net Revenues"
       }
      }
     },
     "localname": "SalesRevenueNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Available-for-sale Securities [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r93",
      "r94",
      "r95",
      "r96",
      "r167",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Reconciliation of numerator and denominator"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "verboseLabel": "Summary of net revenue"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r7",
      "r23",
      "r24",
      "r25"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r119",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "REVENUES"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Restricted stock awards, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted in period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r117",
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r36",
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited",
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r111",
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Proceeds from the sale of common stock, net of offering costs (in shares)",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited",
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r111",
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r111",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from the sale of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r112",
      "r118",
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "verboseLabel": "Repurchase outstanding common shares"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r13",
      "r14",
      "r111",
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of shares (in shares)",
        "terseLabel": "Repurchase of shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited",
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r13",
      "r14",
      "r111",
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of shares",
        "negatedTerseLabel": "Repurchase of shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited",
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r84"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r135",
      "r136",
      "r142"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, End of Period",
        "periodStartLabel": "Balance, Beginning of Period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementofEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "SHAREHOLDERS' EQUITY AND DEBT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Relationship to Entity [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r85",
      "r87",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities and other forms of securities that provide ownership interests classified as trading.",
        "label": "Trading Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Noncash investment gains"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive effect of other securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r72",
      "r74"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "- diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited",
      "http://cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r71",
      "r74"
     ],
     "calculation": {
      "http://cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "- basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited",
      "http://cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 13.A.2.Q2 Response)",
   "Topic": "605",
   "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913847&loc=SL49130545-203045"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=96862333&loc=SL49130690-203046-203046"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96864182&loc=d3e11374-113907"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4568447-111683"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4568740-111683"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4569643-111683"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4613674-111683"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "48",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=65894324&loc=d3e18349-110257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19190-110258"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04(8))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "944",
   "URI": "http://asc.fasb.org/subtopic&trid=4738149"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "954",
   "URI": "http://asc.fasb.org/subtopic&trid=2289146"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r183": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12b",
   "Subsection": "1"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e557-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3179-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "c",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3098-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1448-109256"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1505-109256"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1252-109256"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96948231&loc=d3e4984-109258"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=84177426&loc=d3e6061-108592"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=84177426&loc=d3e6132-108592"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=84177426&loc=d3e6143-108592"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82896770&loc=d3e26610-111562"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82896770&loc=d3e26853-111562"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82896770&loc=d3e26626-111562"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=SL6283291-111563"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  }
 },
 "version": "2.0"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>48
<FILENAME>0001628280-18-006417-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-18-006417-xbrl.zip
M4$L#!!0    ( +B)J4Q'\Q[K( \! !#9"P 1    8W!I>"TR,#$X,#,S,2YH
M=&WL?6E36TNR[??[*_3H=V^<$Z'"-0\^IWF!F1I?2]@@[(8OCAK1!@VT)##P
MZU_5E@0(8\R,!-71QTC:4^W*K)4KL[*R_OY_)^U6Y=CW^D6W\\\Y- _G*O]O
MX>__ \"_/VQ^JBQW[5';=P:5I9[7 ^\J/XI!L_+-^?Y!)?2Z[<JW;N^@.-8
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MNR"=DW)NX4758@@;63'NJ1CM;384_$@AOKD;%./KN6($!KV'048!21%9.PI
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M51#Y0_]Y_?S8ZY@NGEGMNWEN^.J\<+_I6ZVQ<E;^B"I7SL]&T?]V)O3/F4D
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M?:AC>BEH!J370L R(#T<D";Y%H<:,@J8\A90ZB20W# @"5.,&!@,-)%O5;G
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MUR9HJ/*:0TPX4$YC0*%"0'+)@(7>.T&U((C-+2A4A2HEXKY<D&_:LMMG<YN
M#.<9SJ>6TF<XOQ^<7^+P(@@$B0A 46P %8H"J:0&GA'(A>$H2BK".:EB@JMD
MUHNO_0KH?[5I,GS^39,O#^&?=H2&-VRB_&E]\</ZI_7&^LI6N37XRI?M]<;.
MY.;0SQ7UN01U)$*=ZQZEQ,;78GQSS.QE^^<5:U>.?]R+E8RW_VQ=S*4^8 _0
M-Y],D'LD]\@LT+E9*@!WOF'!H3Y-I:,?/4S[J(QC.OOPJ1SY1YF=FW8%G*Y
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MXF([U>D^*ROW9+J8/?@I((B757(CK'<&NK-7F)9?[/?]H)^1]P[(NW$U"U'
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M*H:(DXP*25*=#EQ5[%;;B^4@90Y2OLZ5.QF:GAR:)FFE\\YA:BRPPJ?];K@
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MQ:EV1T=QT/+CP2"'.<RYX/OE1'6@\6?]1&RK2,0L6+X(0(-SM\*Y-XNTB["
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MCZS,57FMD,A($Y&SRAM&N*5Y?RI"VS#*^;\F[.5)F<L_ R#=[TK&>1ST ]@
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M-(L&<<T8_).R9T]$H&M.1&$""Z;P,\)D6R[94>)[)7XV)*U!K"=>'*#!KGO
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MSG'12%<C78UT-=*UVJQJ13Q?#:NZ#U:U$,)F::(R1HM\= R!H 6DF3)(6*S
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MH@'SV>I $%7:("XP!V-:*42L8\%S3%W0#5UL,+'!Q*5TD04PF"6CTE(>I+=
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MH6OKLLVU;#,N5CQPHH'E!I9_'EB.V&B:--/2:IZ$=(F)R#'8ELHDP.P&EE<
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M]?]_]MZTN6UD213]*PC?[CMV!,C!3M+][HF0)=E'/99D2W)[["^. E 089$
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ML%0!EO@LR!LF:1BSZW#!C1N",GY?<6Q9XZ5"LQ7,-VP+R&;6<?,V?U- 9K6
M;,2G95ZY6$TH_9#?@0.WTYI+=77BJ@#XJL3UEE\OH1LJ[7QW(N#%\_UXOW+4
M-[4#J,/.,U*Y#O_9/?IG;_?SS8'[=+8."*P25YYGI+*19O:AE>25:WM)T*\X
M;_V<KAA\P]$JO2K53YBSE6ME0_S(G KD,?*="UX]+K\I\^8 \DO@,77@AS+A
M<B&10)HOI*6IBS91&I1Y'0!LR&&]E1XD,W"F/,/Q&NG(M3K \R"+J9-&I1N
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M[PMX2GDYZ/?*SR'S-,+:R" M.]&V?#_CYV+EJY*:I3:NSG29DOK:<9DLE@]
M7SMJ#;2J>$H@5@N#QZMEC9$4$.UGN B TV1^U5*O7<*;5,)<0 5/'%>E1J"
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M+I@_X?!O&)__Z_^C_PCJ]+/_KO4R]:,:;Q(GO#<6_,*TC#__FK+L-$Z(1WE
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M;8%K@UDRTD?&8W8?[81?AX4_B0?K]M#3W?LTP7IZ&2-/\J2'0UNWS55.D,X
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M<V@UC[*[FN=NY$U6N& GG,]^_1]02P,$%     @ N(FI3##/AXZ6"   J$X
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M5_HY]Y,P?2']'YC./_P74$L#!!0    ( +B)J4RMVC;][10  *C*   5
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M1L-4^L,S/RJF?G\$,.TW4=4:K=92V'T%.%=;>?\2P6@2+STT*L2>=,N_'/D
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MUQ13'. .'6,9.VD4NLT=&W=#NV>M\P]%H4H&JU>TL/+T^[?0#<N"5^P 8;Z
M^?\#YGQ,97^E I$QW\G%0T9.+/,^8EKE79NBW/N ;)1>G1>T7N"#YE)DX$"L
M$F@P%2,)#M%;QM$C)!$5?\CT:@7$7<HMFC%MQ7;>%A9LG<"OFK[('&1*)I.<
ME"ASHV4K>](DE7*5#,91U63#VZ9K1X^\,_*1&;:M!1]CBDASHU.BF:10[MKT
M/!"O.(Y!%"(8;JBT.S5%],C[*Q^98=M:L#7#5OG8K#68G (1GI>CY< 3RTTD
MSD9KK/29IR:'>6\Z2FY59^>3H H,I@#9)B)#$99Z26("G@-FEY(VJ1S;V4-=
M6K#DEA-?[J/_BM?<G700AS.-X/<CF*E[G"YN?1PP;DVT21&=7)E=\!ATN)A)
M=,%HJ4&;-O.'ZX#;I4'\@3A3W6;5+TV\J>1,2>&=RHEX$*HL9)6-]U:CZ<$:
MQRU+N8D_O0/7+@W3#\:A>I:J=Z[*D>_@F9^5R!T7.',JEXNA,>;$_,9254[S
MD,1&I0EXYIAS0ILVQ3&KX>S2@0@/1)8*=JG&D9=?(O0]$G;!U%G=Q$I\J[2
M2@+NRV[*4O8L<]%" DF2D@P'7(#(FSB@K5!_#W..M2GW<&9N=';'>;HSGVDO
MYTQJJ4I^4Q(JBAW&>8ZQ'I=6 $=$(K<@WFV@UN&5_K$\634;56/-QS%FW*/A
MOR']X8?CD@@<C"_NUF!924>M))F6*J  F?@8&?%2TRQ=PL2@R4[0.W"MPQWS
M@_FDFJ:JN;'FTM3-Z_'U&S\'06<=E4A$^[(\(S@*3)DM]X/XLLW<<=-D+G8=
M<.LPR?Y@3*INM(9T6MXC.BL]53%8SQ5A42'#;49?6>H2F0A1>P<IT_ P/+J
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MK2.[K;EZVED3\D4-+2*G\B7X'G[_Z3]02P,$%     @ N(FI3!2?/"6['0
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MN;P.4N<,5C)G1:[;O#+SX P3-EFD.OH8FAR_\@6*_??']^:C&\J8+9B%CU?
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M9P,F,8.I7J!,_T2H>[RUI)%'PJ+%8@[HW!'7?R+,\.]_^3]02P,$%     @
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M<I6YMZYT[,+TUIFZ#XH?A'^%M\2<K7+]0EW/^5#O[EK4V:K[U]C5:U$LR6R
MUV(C9DOEF?[%1_53(T8_J(-,*SD-=6^I*KXMQ9R+FBUW'AU,^;_^H'Z:O"[
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M)Q*G(@US:+,OTR%K=#LS6K<@ZAGIUX*EF4_I""'/=+X=EU<K>A$T@'E(ES/
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M0CQ/61C%H9-Z,QU*C,]QVZ\W(U?*.Z\WTS4V9HSG%V_/O'>BWLS:B#>J-V,
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MH>(#WF"(+>,-_(Q!=[R"8YD#QCOX06LW7L*3C)YI!?6VP+W0R:Q*<EL[%C7
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MI'XBY>]BJ;WU_8ZI>@NMCLQ\* G7B[/JE* MV"_!4.*892"E$ *(60IH3#C
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M"]Q8:1N4:W6K-BF:%<AL5ORAU^ZV#0:Z #>C8U<@>N;6-7KW6^@I37TT)#!
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MZPZ_D._5UUE_N(NJ_ !K$ENWFM):I*K9#4HWQ?@%VC/K'.GVN$H;7FL??!P
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MCU7_=5Z.QP00I]NI7?*&W5TUL/Q@L]7D'@='6":U>B=9S#.A=UT%PP) P1)
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M/&QC#1LL#III6-W<OTK+M-X0NYSS.C?A4<R9>G);^[%4R@3G' (NJ*Y!AQ-
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M2-L<B</ZV1;W]LX-4#*>U&R:?FV:$U2UV=3R=\)RG @,*2"9#HQ!NE9%R"B
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MT."RB>@8J3H-89],:9-N935X5M5C Q'/QOK;&$NAG,M1<05*+AN)HC/DJ/1
MT&=&?I3GILI0M4<I&S;_,[2=/$I/3=C(_24XHMIH2Q$F2@>T_UK@HHI. D?W
M ]>9#3[I80.:85,_)P9C)<VU&VQ?UQ]M$:1!#SEQD8%284LNC8/CB8%#.2HC
MDF"YRF6'IY/:S(#YDP3;?>FLC6#[EA_R,7U9;P;O\[OQ-.$_KY"FTO-;X()R
M7@"318I49S 1O9#DDL/8S;@L:O7-?IRZ)D/LWD#R@-_8C[X:\!5O,_)KMTAS
M=$J611R&&):%05_#2^2#:07&(A\Y1J&=2LA+E?+%700U&4'7@EHO6FG"(;R]
M:-[.YY<HKH1KI;NXZ*:?%EWX?:2XY\EK!SPD4WQ<!=9$"4&KI(/2Z&Q4#Y*W
M4M9D4'P*XW:\GAHP;!^N%]"2_"N>5L7F@M) ,C7 7!3HFD0TTHERT-(F:3F/
MC-7!W -$-1GZ5H-;7]IIP\BMN7G3S=!R7\["N9O?6SW.HGRX#QB0E?D<*ALP
M)./JL29PKYB(LDKEZN.D-1GEUL9=3YIJ GW[BW#$/?516PW!<XFB,Q:,CQX"
M8THGKS!>J](I?'\2A[V><F(T5M)< SF7PM;+:2S_E(/'KVY25MV'-!N7B6AW
MBXU&EEEJ- T@G FK&A$?J )"?(B9QRSKM$]Y"I'#WD0Y,2ZK::]99+Y$^<YF
MWU&4?W>3RS223G(47H!(2V= 6]I,2DH@<B(TU;@3A"H.XE[4#3MAJ@DL'J.O
M@T'X9;D /BW<;'%"*%*7;$;_%Q*-9996BJ7YI0%%< /(B41-JN2B^X-BM2%5
M34+Q*?HZ$HH_3V][D"=O+-KEU:#3BDU%-U]QHH:BC_#6?S/19?!QWDUPQ<Q7
MK[[I@8];:) A@EH67!-JP;I,@9;635DEGU.5TL^]J#NZ@\[52SXO$YS:<VN]
M)! $8R RVG#C6!EI+R+:=AX"JS+DXRX9S;0%[0D5&RUP#A=Z ZF]:^I7$BE]
M3KKITA1_&\]'Q'E. HL@M%L>.QIP@J KX(*VA"&KKBZ"ME'5"* .4/<NY!PM
M^P: =(^'U]V%&T]'W"JI)*XI$E'1@J)7:3F&VJ1,'$DT&5['!&VEIA'@'*_M
M^ZV+CA9] _BYE3;\)14_8^1B6(8;$(HI1A.-P;#T"GB(UI 8 S6U)JC<I63@
M*8[':W>SC?\1HFZBWN-C6J 44KP:)KCFP_N0LR@3DNFR:"L[,#1YR%)FP8V,
ME>K@MI,S\/#&WG'3@]"; ,_V<2AK;F)I*..4!IZ21%<PE%)Z*\"+J A)A$E9
MQ>H\1-2PI^?] ZDW!30!I^N-'>/F]!:_Q=T\6&&08$A$E(; 4H$OXU*SH\DI
M8JRO,UYQDY1&+A#VZ"P?)N4&/)S-B^&;$>E'7!)ONMD?;A9'A.5(-!I2+@PO
M\P R^$0\2.2/V*QQX9VH0=.#=#;B51\(BT<O[_>GHP8@N,G,01/O# UHH14'
MD@FN8RG1]H=0.K!ID2/UA-099-P/^:TU%^L181LV\^3J;N= Z";(V9Q.2FVT
M*,4RK5&AR^I+0S5M'$B=C7:*HOFHD@5^B*C6NI#5@V5OJFD&;->%=RF^OIR5
MY;5\P?(0Z]?TQ_(W\Y$*4F43<&.2&?GCWH-3OK2+IKB^: BB3HN>O:AKK1=9
M9:O8J[):V=DWF5JMKQNNM!7$>!- BQ3*$C/@+3<0).$8KJOHK3TA!.^1UUK'
MLI-C\!AUM0O"Y<K:,2F"96,"R19*FWQ<9A+-/8D.&'74"IY8]%6J*)].:FO-
MRX8QD#VHL9&DS0,+< >3FFFNT/Q#3MSC1A ]>$D3&.F#R4FHF*H4LAU Z["E
MOPV M3=%MF)6;TKL-Q?E*).<DS6X,60C<)^P IUFEH!Z99PRP213Y8+AHY0-
M6^I[<ASVIJ0F+D,\Q-)J?8V"9M1HYB$YR5=G/Y8( ME3*E,,G/E*Y52/D39L
M86\KR#M 34U []987&JU3L%QX(0G%(UTX+C3P'+*7E%OO*_37^=I XFK%>:>
M$DH'BKV5/?+X5&?,3)#$ WBE+0B&WYER>S+%9)-V2D=9!6RGS&R3?P6D#J#O
M7@O,*R6VN9*)E3D.@LB(_#@*3I, RFNKE*1"ASK7OXY-;--_B0.7WG33^F6&
M][,S-UV/G\-?8X@UGG?YPZTW'')_88^G]G9EX:D<]'1+X?9K;RY+K&9*WW[Y
M]4P_-[D^XKZY>4,XLUI&"3P3W)Q%Q@"6!@G.,J*BIHBD*B<)O5!_K $\BHC7
MXWF8=//+6?J,&OUI4FZI4ZT$DZ6Y%BOG3BYQ,)HKT!0=XQ1C8+[*K;"^&1GV
M8/OTR+YO?0<%1H]9S4'L]0>45BA- ZK8[>NGG]!^;^>H+3N><D84,=!$(< L
M.AS6<@G6>"Z6X]M=E4&[3=CQ7],?ZX%WQ6F?=5/\-JQ>L53=]]77F^6H U?"
MN0S1,5[FAQ+PA)6N-A+%1[/4O(IS^U1"_R7L\!.0N=F*HZ)B&\@U_%;:W/P\
M7XPO4&QS].LUX4[@1E4ZL N),:1E08$1T9(HM:"Y2C7<73*&+1\:'G1'**4!
M2'U*9T44'].7DKPH.8QMZ\1X057R!+@J$\P41I"&T0",AU0:!I=IH%6R4_M0
M-VP!T?  [%^%S]VEO/V)U^7NT*22=[GM12=T-!_ELRF?4SL:=*81HQB/6ZP(
M#!R+'O]3"JI=M*I.\78;/N=2S>_S]=RS]:J=CZ0FTA&72OMU!H(+BF+!=1IB
MMB(*RY5R59S+713]*WB13\':AA?9BZIZV]LK6-"MTV,.,)"[I]#T8?\>I[(G
M\[8:C[!*QB1_-6=K\?WFM;=P9:57AH(/.8(@$0,&%AU07M+HRI@8*PT[W9?$
MXR^+7;_I[73]KAM-;+QU&E^E6;F=^WGFXO50Y6TY+245M2E$L+E4,R>)0G1<
M@PTBT<!<)+1*!7 MAH:^S5,%LYO7TAI 0]ONZ#8SM;QUVIM)73^MJF'=1O'I
MS:O/RA*"<3.-#%'AB0"?6&D(Z"R+U$0IJQ2ZGLZ\OG'CV;(J;[4T?DFNK(OX
M?OJQO*K43^'+?^VFLZO_7+K]2^W<+)X873!:6=!6EL8'/(,)F4*.F46M>."T
MBB?=!_'/QFP^!8OWS>;)M?S\3.01<?E#CZMJ)&O&V$] )DN,:4LYL*0QN.$Q
MEODA 3"F06 09G2=PYO36<E/X3S%RTEZGU]^18D7+;SI9F7.X[T=JUP13I8F
M ^A!H"R<SN!U4B --SS+:'BE:SS[4OAL[-U34+61@JRBKP;2X]>&_*?OU]_^
MWW&:(5'GW]^EKVFR:J*F@DW)E!&/I<(J*0:&"0XI<\M\MCRK*KU[]B-OX$89
M=;"Q:\?M3U$MP6_M0:S&7FSPM^Z,E*G,))<;<)(R$ (#*T,Y!:F$(!AOL<BJ
M]&UY$I7#@K$&3'8AL7>=M03(M],OEXOY4F)TW3_+LM*U3P0P/!:'6>)WSEH@
MPF?.4V;H0E>%WR9-C8"M?R3LPMR1:FD486S-"K':V> E&%\&!# MP25)("OI
M=4Y,4$E/A3#60JO%81%VB%H:0-@O[K^[V6?\\/Q]WN44ETT Y2&7L^(#5Z2<
M]G#P(B4(U@>1$2G)50DM]J1OX 9[)_'J:JCJ>2!PO62C8B+H[(!GJD!HIL"Q
M( &=$&\I*=:[RGG3WA0.N\-6P<?3,7B L@9$84FHC7Z;?YXM]XSOR]&TR-1/
MW33.-WB25 :E2<F"EC'Q4B7PU$B((6F!1$EE[MU+W,S7/>6%S>/I$%UWE07?
M@DGK9HLS=Y9^<N'W%&^X637(^.G[A]GXJUNDG\O]QR^S\3Q=-7%.*N;(M 5K
M2*F7+&EVA8L4^7>1I4B]KG('YE""A]UVZP+TI,IL +0OS](TW!+=F@MJ+7&<
M6RAWS=&?S1H]VX3[AD1?QDKKHZE2J;"=G&'+6T\#N!X4T0"<7G6S+]T,%T:Q
MZ!O,<.-<SBD DPK7!GY;N@/C4K',Z)PQ&A-57+D'J1JV\=UIP-6?6H9VVMYU
M;OJAZR;7YI9+;Q0O]3.LT*X#K@^D7:; *,?E0:+>RSF[]^!A.\Z=P D[1I -
M&)I?+J?C,/[B)DO7<<V#*'?\#<E $BDQ3AEY[8P#9I(445.N<QU':@LQPW:!
M.Y&3=*P2&@#2/EF<=]?][:UV23K*0-HH<!/6$:R6%D(97;T\+U%U>M0\A<IA
MW:73I,7JJ:T!3*Y+1V\X&05%0E "W4 9.+J!EH&52@"7Y=J43#36&2V^04G[
M!^D':KWK4P4MWWRXFB!5.HU]2+-EKYQ#2M"V/J>WVK/'J>RIZ.SJ15<ON:D9
M-R$Z+3/NA"*5VD,*1B1TB)PF#+=)06.5D[9=!!T])/+><V^J+(.-1C.*F[6+
M%M>)M6 4!IH1ETD6@8?LJUR_VDG1P$/_^D#$QIS(7J3?=HWKMC5[^#6 !YY6
MU<I4O :P$UG9!YZ#5D!%9B "<> 4P:TFQYR-)X&H*D7_M6S-S3Y]_PVERCM@
M-/)Z/+E<I'BOWELQ'I0C&(=(ASMV+#MV#AA*4!$)[M;*ZCJ7[ ^CMU$[]10T
M[?:KZVGN^5FQ(RKU'WI<53M6LU)_)_0<UR*(TK16E<DMPAGPE%E0G#C/9&"Y
M3@_,O@W9,D7VZ^5%N?[<S:[94RXZE0(%8CVN+%N29!A<0&#**^F8"#(_!HCM
MCV[4E#Q%GW?2B\?)KHDQ%;^FQ=LI+K&T[,FL>2(!_P>&E(.8Y7=.!I2$L#1)
MXY2M<G9QAXIA4-*'0C?:5!TJVZ$/(%ZG:7<QGI:/C%1V+%A<&#S2,LN"6W 1
M5X>32#>QUJ(4]C('MQXZ\.#JW@W!H?)JP@3\(XW/SM'9>8D/=6?IJBW&1G_A
MI6\TLLK2$ ('[53I-%Q@G*P"*P0B61D>3)7+!T^B<D 3<C 4NE-II8'<[U;F
MUC[W!H<OXW]?KNZVC51RBD;+@2A;DA/"@E5,@B32ITQ(K%0F>2"]PYBY^C#L
M65.M O)]WL7HB.K@ O4&J JVS) /X EE@+&GE"[:,MOQA%9P%YW#')*=P@[V
MHIG#@=<MW&2 /"-&MI=NTG.@?N^I=?..#W!0/?^HJ?94.:!9E5$<1H SRH#6
M+EMM>0KV6>4?7TX7XUB6P?CKK9/!G[^5*24IOL'E6&;275ZU4=L@XZ(TT!UY
M9IFGAD((-)7U8C% P2A'.&^I)PD73Y5RDEZH;S2A\!2D;91(GERK;6<J/Z:O
M:7IYV.G*]=_V9M.V4].3Y;K?X/6F98-/DEN20?)<\LZ$E9'E#'*R4?ILG?5U
MYH+N(*CO9L3;&H<9Y[5*M/1@+ EW+AAX;PU(K8-Q@@8>J\29>] V<'E('RAY
MK+?PL1IY'C;E\'/;>T_HW;Y4/)_=B9\8?:8T.XA:4Q"2*O!61S!,^:BHT\I5
M\02J69F;4S[<4Q??_S&.Z>TT=RCPHIRUJ,N.^C-*=C9UDU<8O787&%26JR]=
MO R+<F_K4YI]'0?4R<TX@:QXMF48-<]%4BF61 ON]"&Z:*CPVM:15"V.&K5H
M3T'D V>\ VK_>=C!(P+*^X_HW1+6#!5W B^IA$Z[C$ U)R!\XF"9$,!TC-;I
MY*RN4P']7$SALK19ZYRU$ARTP"\B2 ^^3*^R3&EF<&VBG_ LS.#P_=MZ06)U
M$_ADK3>0V5WS\7ZVYF+9)T *ED.D#DSVI2912/#HW4)D">G/Q(50);C81DPK
MQ>:#861S1/1Q"FL'=+<%L[Z)E%)6*2@"P4M9>NA8,#$B5I+.A*%8B*[2/&LG
M1</"[WAE;T?/D9(?NO[B94"O)W:+='5!FO(H<@A 70PEM,<@7"D)T=MD/9$L
M1O68I[;MP4TH_UA==3T);M!BC"7U[R]2F+B+[ML']_N: ><#EU0+L,0P##:R
M H2_!Y<PVJ"4):K-7IK??/:P13@5E'^D^(;7_W_.QO.%F^"SKJZ9"I<Y]0R8
M+3W]F,(M-.-WUG TD4YR?W^4T@[MWW_RL+<G*^C^*-$-K_F_N])?I9NLB?=1
M4!G+Q?1@%/I/3(!1QD,P61%.B#/,[J7WN\\=M@M$!:T?(;:AM_A7;A*[23=;
MDQ[1US%(/G!3A@ X4I+KS(-BFD2D7VJQ7Y7EW><.V^&A@L:/$-OPJ_SGQ?GW
M:[ ZKF2TZ)HP9]$UX;*,ZPD$=,KH]E(>1-AO9[_]U&$;,E30]\$B&WI]?T8G
M-"S6A$M#4Z;(>1:IC*F3"HRU$A)U1*>2R;Z?*=NAZ]M/W4O7^AGI^F"1#:WK
M]XOS-+L2R-5>1(WR,4:01$40.J#GF1"UA+)@>3"2[%DVO^7A>VG>/"/-'RO
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M.U0,6W_0QO9XN%H:P-3A@KMA>QH_3-ST5W>1UDLTR\QB=!YR+MUA;$G_Z.C
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M:BC;-G^RDO+JNX+K7Y0OWLW37__M_P-02P,$%     @ N(FI3+Q F^&F"
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MTX5J%.BID4HOZ(%M )%QS(UA[('LY$D@('@_X*"?%;(/F(5DH#'9P/](DHM
MP_[(.*AO@TJ6^/8DX^ 9ESH[[<QTI[4[V&GML((]$4"GH94#S+&TQT,"GS/
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MVG./Q$S9\JNB#[Y!NB*!>A!K,L/ZQ2'?UF^=YI_N_5;[INWQ_P%02P,$%
M  @ N(FI3.=9*E#>"   YD4  !4   !Q,3(P,3@M97AH:6)I=#,Q,BYH=&WM
M7&UO&CL6_KZ_PI=HJT3B_:5-((V4$*(BM4DWI>K>3U=F;,"*9SS7]D#87[_G
MV#.$!)+ IMU"0J429L8^?OQR'C_GS S'?YQ?M7M_?NV0D0TE^?K]['.W37*%
M4NE'K5TJG??.R:?>E\^D7BQ72$_3R @K5$1EJ=2YS)'<R-JX62I-)I/BI%94
M>ECJ79?05+TDE3*\R"S+G1SC&?CDE)W\X_B/0H&<JR )>61)H#FUG)'$B&A(
M?C!N;DBAD)9JJWBJQ7!D2;5<.20_E+X18^JO6V$E/\GL')?\\7')-7+<5VQZ
M<LS$F CV,2?^*O]5 1@E..'/&CN5_&-NQ-%ZL]Z(;6LBF!TU*^7R/ULY5^CD
M>* B"[8TU/1?O8$%,U)$O)#:JE3!@.6WMD"E&$9-AQ\MHH6L0I\&-T.MDH@5
M B65;NIA?[_::.2S_Z1<+!^T_+6]LOO70@.% 0V%G#9[(N2&7/()N58AC?PU
M(_[#H0/0%W<X\8 ^0-4%@&.NK0BH3$'VE;4J!)2=VY'H"TMJE6+6YZW 7;T_
M0RO.30 KA^M62/501 6KXN81@$@/O>TFPMJ6V6MWKGO=BV[[M->]NB17%Z3]
MJ=NY(!?=R]/+=O?T,YR"JYVMFMGKE\SLMDS<U^_7W[Z?7O9([XI\Z[1Q^M[M
M5=Z76[5RE5QMU7Q=O(7YZGWJD&^GUV>GEYUOA:M_?^[\24[;/?2X:KF\5=.U
M!G%N&DVNW,=NGGP1P8AR2<Y4%'&=)P$6'4R)'5'[.^9K9>SO]AJ'K4?G**:,
M@6XJ2#X .X?+#&_MK/T>!;+&Q" _;S3$+AG1,2>:CP6?@,:V(V'(A=(AJ90+
M_R)J0-I)V.=:THB1KR.J0QKPQ)DRI!L%15A\1V]S\54W>F)WGO%BB+5ZZXP:
M< H5D7!*;B(UD9P->=Y[B>:QTI8P!<U%"L)4:(B*B-!H2I+(ZH1#GR!P=3$L
M.!(E(1QI0249T !.::)"B*.L\N46"D0\X,90/<4B(;WAT.Z<30/G&("!)J4+
M@*$-+! (#0$O%(N@.B!A7)/)"#8W8A+\N*L_X9JG1K #H3 2(F,,LB?"CJ"#
M)N:! XAV8X"F&'031@P&I3^='P9' V[(WB07U';N]DO=C9.!B&!!HV_<+> \
MP5U)P64]=UU$ ]B_*.:@X'L@$P8VP4GF5FL>'$QH.24QK'%T3W1;*>_\+UWZ
MYD'3X.+,);?R6"*14 "<3H%GN.:,PQ-0,R(#J28F\TC-A\)83:$ABB<];D"9
MGW,LDX%90/O&?:N^\ZT70NS=6X/O]@ZKE0\MDSI.&N8@ZZO!0,"A6YU=0C5W
M?@#K6O0EQ_5*.#A?7PHSPN)8+(0=#W<]/&;"!%*9!.KA7JB5] X1:Q5P!J<-
MV8?USS@XE%_DG5L(N:(A)Z>PS5PG$DI4:K10:>SS U>UTF#^R!\*S !$WA'1
M/L&]:,X_O;\@EI4;&MQK:  -83\?>BV40)V\1J35J+\J)]RG!QN]Q+? "[<
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MY:TL-[GV[Y*DG_X74-QOL9S\%U!+ P04    " "XB:E,9G+KCJT%  #+*P
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M,#$X,#,S,2YH=&U02P$"% ,4    " "XB:E,,,^'CI8(  "H3@  $0
M        @ %/#P$ 8W!I>"TR,#$X,#,S,2YX<V102P$"% ,4    " "XB:E,
MK=HV_>T4  "HR@  %0              @ $4& $ 8W!I>"TR,#$X,#,S,5]C
M86PN>&UL4$L! A0#%     @ N(FI3!2?/"6['0  > D! !4
M ( !-"T! &-P:7@M,C Q.# S,S%?9&5F+GAM;%!+ 0(4 Q0    ( +B)J4R4
M7UH0HU\  $/H P 5              "  2)+ 0!C<&EX+3(P,3@P,S,Q7VQA
M8BYX;6Q02P$"% ,4    " "XB:E,TRP3I9XW  !'8@( %0
M@ 'XJ@$ 8W!I>"TR,#$X,#,S,5]P<F4N>&UL4$L! A0#%     @ N(FI3+Q
MF^&F"   Q#L  !4              ( !R>(! '$Q,C Q."UE>&AI8FET,S$Q
M+FAT;5!+ 0(4 Q0    ( +B)J4SG62I0W@@  .9%   5              "
M :+K 0!Q,3(P,3@M97AH:6)I=#,Q,BYH=&U02P$"% ,4    " "XB:E,9G+K
MCJT%  #+*P  %0              @ &S] $ <3$R,#$X+65X:&EB:70S,C$N
9:'1M4$L%!@     )  D 4P(  )/Z 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
